SBB, Interim Report January – June 2019: Net income after tax for the period amounted to SEK 933m

SAMHÄLLSBYGGNADSBOLAGET I NORDEN AB (PUBL): Interim Report January – June 2019 in brief: · Rental income increased with 12 % to SEK 893m (800). · The net operating income increased with 11 % to SEK 560m (505). · Cash flow from operating activities before changes of working capital increased with 56 % to SEK 244m (156). · Profit before tax increased with 54 % to SEK 1,060m (688), of which: · Income from property management increased with 40 % to SEK 254m (182). The management result includes costs for early redemption of loans and other non-recurring financing costs of SEK -123m. · Unrealized changes in the value of properties excluding building rights are included with SEK 1,161m (452). · Unrealized changes in value as a result of building rights are included with SEK 40m (54). · Realized value changes relating to properties are included with SEK -307m (-4). · Unrealized changes in value of derivatives are included with SEK -88m (4). · Profit for the period increased with 80 % to SEK 933m (518), after deductions for deferred tax of SEK -90m (-156) and current tax of SEK -37m (-14), corresponding to earnings per ordinary share of class A and B of SEK 1.01 (0.73) before dilution. · The value of the property portfolio increased by SEK 5.1bn during the period to SEK 30.3bn (25,2). · Long-term net asset value (EPRA NAV) increased to SEK 9,593m (7,831), corresponding to SEK 12.69 (10.61) per share, an increase with 20%. · SBB’s average interest rate on a 12-months rolling basis has decreased from 2.93 percent to 1.96 percent. THE SECOND QUARTER IN BRIEF · Rental income increased to SEK 464m (410). · Net operating income increased to SEK 320m (272) · Operating profit increased to SEK 148m (109). · Cash flow from operations before changes in working capital amounted to SEK 147m (116). · Net income after tax for the period amounted to SEK 717m (405), corresponding to earnings per share of SEK 0.73 (0.56) before dilution. ”SBB's stable cash flows are only marginally affected by the business cycle and external factors. We deliver strong earnings capacity from the property management and continue to see great opportunities to deliver profit from three value-creating areas - renovations/investments in our properties, development of building rights and transactions. We deliver strong profit before tax amounted to SEK 933m, and we deliver the strong 20% yearly increase in NAV. As previously communicated, we are continuing work to prepare SBB for a listing on Nasdaq Stockholm’s Main List. SBB is on a strong growth path, having announced ten acquisitions with a total value of SEK8.9bn in 2019. As we continue to see opportunities to grow, we may also evaluate the possibility of raising capital in connection with the listing on the Main List in order to further strengthen our capacity to fund growth in compliance with our recently achieved investment grade credit rating.” Ilija BatljanCEO and Founder Attachment: Interim Report January - June 2019 

Orexo signs license and supply agreement with Mundipharma for Zubsolv® in Australia and New Zealand

Uppsala, Sweden – July 10, 2019: Orexo AB (publ.), the fully integrated specialty pharmaceutical company addressing opioid addiction and pain, today announces the company has signed an agreement granting Mundipharma Pty Limited (Mundipharma Australia) the exclusive rights to commercialize Orexo’s lead product, Zubsolv®, for the treatment of opioid dependence, in Australia and New Zealand. As Mundipharma Australia has supported Orexo to obtain marketing authorization for Zubsolv in Australia it has been a natural step to continue the collaboration. Under the terms of the agreement, Orexo will be responsible for product supply and Mundipharma Australia will take responsibility for commercialization of Zubsolv in Australia and New Zealand. Orexo will receive royalties on future net sales and the launch is expected to take place in the first half of 2020. In Australia, an estimated 735,000 people used opioids for non-medical purposes in 2016-2017,[1] and more than 50,000 people received pharmacotherapy treatment for opioid dependence in 2018.[2] There were about 17,000 hospitalizations with a diagnosis of opioid dependence in 2016-2017,[3] and 1,045 opioid-induced deaths among Australians aged 15-64 years in 2016.[4] Zubsolv is used for the treatment of opioid dependence as part of a comprehensive treatment plan including counselling and psychosocial support. It is commercialized by Orexo in the US, the largest market for buprenorphine/naloxone products. Zubsolv is also approved in Europe where partnering discussions are on-going. “We have worked closely with Mundipharma in Australia for the last year to prepare for the launch of Zubsolv in Australia, and I am pleased we have reached an agreement to continue this partnership. In recent months, we have also been working intensively to establish a streamlined supply chain for Zubsolv outside the US to enable access to this new efficient treatment option. Mundipharma Australia has been a good partner in the approval process and we are confident that their experience and infrastructure will create a strong foundation for the successful launch of Zubsolv, providing important treatment options for patients where they are needed most.” said Nikolaj Sørensen, President and CEO of Orexo AB. “Mundipharma has worked closely with clinicians across Australia for more than 20 years and these connections have helped highlight the growing need for treatments that help reduce harms associated with opioid misuse and abuse,” said Jane Orr, Managing Director of Mundipharma Australia and New Zealand. “Earlier this year we began providing the potentially life-saving opioid overdose reversal nasal spray, Nyxoid®, so I’m proud that we can also now help Australians access this important treatment for opioid dependence,” continued Jane Orr. For further information, please contact Orexo AB (publ.)        Nikolaj Sørensen, President and CEO             Tel: +46 (0)18 780 88 00                                  E-mail: ir@orexo.com                                      or Lena Wange, IR and Communications Manager Tel: +46 (0)18 780 88 00 E-mail: ir@orexo.com Mundipharma Pty Limited Rob Bates, Communications Manager Tel: +61 422 196 238 E-mail: rob.bates@mundipharma.com.au About OrexoOrexo develops improved pharmaceuticals based on innovative drug delivery technologies. The focus is primarily on opioid addiction and pain but the aim is to address therapeutic areas where our competence and technologies can create value. The products are commercialized by Orexo in the US or via partners worldwide. The main market today is the American market for buprenorphine/naloxone products, where Orexo sells the product Zubsolv®. Total net sales for 2018 amounted to SEK 783.1 million and the number of employees was 129. Orexo is listed on the Nasdaq Stockholm Mid Cap (ORX) and is available as ADRs on OTCQX (ORXOY) in the US. The head office, where research and development is also performed, is situated in Uppsala, Sweden. For more information about Orexo please visit, www.orexo.com. You can also follow Orexo on Twitter, @orexoabpubl, LinkedIn and YouTube. About Mundipharma Pty LimitedMundipharma Australia is a member of a global network of independent associated companies which are engaged in research, development, production and marketing of prescription medicines and consumer healthcare products. Established as a leader in the development and provision of medicines for pain, we have expanded our portfolio to include treatments for cancer, glaucoma, asthma, burns, wounds, skin irritations and the common cold. The information was submitted for publication at 8.00 am CET on July 10, 2019. ---------------------------------------------------------------------- [1] Opioid harm in Australia and comparisons between Australia and Canada. Australian Government, Australian Institute of Health and Welfare. https://www.aihw.gov.au/getmedia/605a6cf8-6e53-488e-ac6e-925e9086df33/aihw-hse-210.pdf.aspx?inline=true [2] National Opioid Pharmacotherapy Statistics Annual Data collection (NOPSAD) 2018, AIHW. https://www.aihw.gov.au/reports/alcohol-other-drug-treatment-services/nopsad-2018/contents/introduction  [3] Opioid harm in Australia and comparisons between Australia and Canada. Australian Government, Australian Institute of Health and Welfare. https://www.aihw.gov.au/getmedia/605a6cf8-6e53-488e-ac6e-925e9086df33/aihw-hse-210.pdf.aspx?inline=true  [4] Opioid-, amphetamine-, and cocaine-induced deaths in Australia: August 2018. National Drug and Alcohol Research Centre.https://ndarc.med.unsw.edu.au/sites/default/files/newsevents/events/Drug%20Induced%20Deaths_August%202018_Drug%20Trends%20Bulletin.pdf.

Itiviti continues to deliver on commitment to strengthen support and experience for migrating SSEOMS clients

Greg joins Itiviti following 11 years within Bloomberg’s Sell Side Execution Order Management (SSEOMS) team, supporting, implementing and building relationships with clients across EMEA. “For more than a decade, I have enjoyed building strong partnerships with clients and helping them reach their goals, and I feel fortunate to now be able to join Itiviti and continue my journey,” said Greg Cooper. “Itiviti’s innovative OMS solution for low-touch and high-touch provides migrating SSEOMS clients with not just a replacement solution but a global, cross-asset product suite that is uniquely positioned to integrate with multiple external parties minimizing disruption.” “I’m delighted to have Greg on board, his experience with SSEOMS means the clients we are currently migrating can rest assured they are in safe hands, said Lee Griggs, President EMEA North, Itiviti. “We have huge expansion plans for Itiviti, and Greg’s contribution will be instrumental in helping us achieve our growth plans within EMEA.” “We are very much committed to delivering on our promise to continue investing in our best-in-class OMS solution as a viable alternative to SSEOMS, and to also invest in hiring the best talent,” said Rob Mackay, CEO, Itiviti. “It gives me great pleasure to welcome Greg to the EMEA team, I am confident that his vast experience and knowledge will prove to be invaluable and help Itiviti to ensure we deliver consistent high-quality service to our client base.” For further information, please contact: Lee Griggs, President EMEA North, Itiviti, Tel: +44 0207 9420958, Email: lee.griggs@itiviti.com Amal Ahmed, Head of Marketing & Communications, EMEA, Itiviti, Tel: +44 0207 9420950, Email: amal.ahmed@itiviti.com  About Itiviti Itiviti enables financial institutions worldwide to transform their trading and capture tomorrow. With innovative technology, deep expertise and a dedication to service, we help customers seize market opportunities and guide them through regulatory change.  Top-tier banks, brokers, trading firms and institutional investors rely on Itiviti’s solutions to service their clients, connect to markets, trade smarter in all asset classes by consolidating trading platforms and leverage automation to move faster.  A global technology and service provider, we offer the most innovative, consistent and reliable connectivity and trading solutions available.  With presence in all major financial centers and serving around 2,000 clients in over 50 countries, Itiviti delivers on a global scale.  For more information, please visit www.itiviti.com. Itiviti is owned by Nordic Capital.

Gabather AB expands intellectual property portfolio related to the clinical candidate GT-002

Gabather AB is pleased to announce a further advance in its intellectual property portfolio.  Gabather’s international Patent Cooperation Treaty (PCT) patent application, submitted in December 2017, related to the improved synthesis process for the large-scale manufacture of triazoloquinazolinones, including its GT-002 clinical drug candidate as WO 2019/123011. The application will next enter the PCT National Phases undergoing examination in individual countries in the EU as well as the USA, India, Japan and China . The filing of PCT national phase patent applications is due by July 2020. “The improved synthesis process for large-scale manufacturing allows a more efficient and high yield production of GT-002 and related compounds, which is important when producing large quantities of drug product for future clinical trials and furthermore it gives Gabather, if approved, extended patent protection and exclusivity for this compound series on the market”, says CEO Michael-Robin Witt Gabather AB Michael-Robin Witt, CEO E-mail: mrw@gabather.com Phone nr: 0736872839 About Gabather AB (publ) Gabather was founded in 2014, based on 10 years research at Lund University and Research Institute of Biological Psychiatry in Roskilde, to develop new drug candidates for the treatment of CNS diseases. Gabather was founded by Forskarpatent I Syd AB and inventors Olov Sterner and Mogens Nielsen, with the purpose of commercializing Sterner’s and Nielsen’s inventions. Sterner has worked with medicinal chemistry for 40 years, and Nielsen has worked in neuroscience for 45 years. Gabather is listed on Nasdaq First North and Certified Advisor is Erik Penser Bank (+46 (0) 8-463 83 00) or certifiedadviser@penser.se. Forward-looking statement This press release contains forward-looking statements that constitute subjective estimates and forecasts about the future. Assessments about the future are only valid on the date they are made and are, by their nature, similar to research and development work in the biotech field, associated with risk and uncertainty. In light of this, actual outcomes may differ substantially from what is described in this press release.

NOTE expands within medtech

Laerdal Medical A/S becomes a new customer to NOTE. Both industralisation services and volume manufacturing of electronics will take place at NOTE’s plant in China. Laerdal Medical is a world leading provider of training, educational and therapy products for lifesaving and emergency medical care. The head office is located in Stavanger, Norway. The number of employees amounts to approximately 1,400. The company cooperates with a large number of global companies and organisations. Laerdal Medical's stated goal is to save 500,000 lives a year by providing better equipment and training solutions.  “It is gratifying that our methodical investment in the medtech area is gaining new ground. We have high expectations that the cooperation with Laerdal can be developed into one of our largest businesses in this area,” says Johannes Lind-Widestam, NOTE’s CEO and President. “We are pleased to see the co-operation move towards a valuable partnership and grow with time. NOTE, with its customer focus and capabilities, has managed to exhibit their strength and we’re hoping for a valuable partner in the near future,” says Deepak Gajjala, Global Category Manager at Laerdal Medical A/S. For more information, please contact:Johannes Lind-Widestam, CEO and President, tel. +46 (0)70 541 7222  Henrik Nygren, CFO, tel. +46 (0)70 977 0686 About NOTENOTE is one of northern Europe’s leading EMS partners, producing PCBAs, subassemblies and box build products. NOTE’s offering covers the complete product lifecycle, from design to after-sales. NOTE has a presence in Sweden, Finland, the UK, Estonia and China. Net sales in the last 12 months were SEK 1,476 million; the group has approximately 1,050 employees. NOTE is listed on Nasdaq Stockholm. For more information, please go to www.note.eu. The information was submitted for publication at 08:30 a.m. CET on 10 July 2019.

Bulten’s Q2 report 2019

SECOND QUARTER   · Net sales amounted to SEK 781 (810) million, a decrease of -3.5% on the same period last year. · Operating earnings (EBIT) totaled SEK 21 (57) million, equating to an operating margin of 2.7% (7.1). · Operating earnings (EBIT) adjusted for relocation costs in China totaled SEK 27 (57) million, equating to an adjusted operating margin of 3.4% (7.1). · Earnings after tax amounted to SEK 14 (40) million. · Order bookings totaled SEK 752 (855) million, a decrease of -12.0% on the same period last year. · Cash flow from operating activities totaled SEK 52 (54) million. · Earnings per share were SEK 0.71 (1.99) JANUARY – JUNE · Net sales amounted to SEK 1,591 (1,663) million, a decrease of -4.3% on the same period last year. · Operating earnings (EBIT) totaled SEK 79 (124) million, equating to an operating margin of 4.9% (7.4). · Operating earnings (EBIT) adjusted for relocation costs in China totaled SEK 86 (124) million, equating to an adjusted operating margin of 5.4% (7.4). · Earnings after tax amounted to SEK 58 (88) million. · Order bookings totaled SEK 1,485 (1,634) million, a decrease of -9.1% on the same period last year. · Cash flow from operating activities totaled SEK -5 (80) million. · Earnings per share were SEK 2.83 (4.42). · Net debt amounted to SEK 595 (118) million. Net debt (excluding financial leasing) totaled SEK 347 (80) million. · The equity/assets ratio was 54.8% (66.0) at the end of the period. The equity/assets ratio (excluding financial leasing) totaled SEK 59.4% (66.0). SIGNIFICANT EVENTS AFTER THE END OF THE REPORTING PERIOD · Bulten have announced that earnings for the second quarter was negatively affected by approximately SEK 25 million due to a lower production rate in order to adjust the stock level. CEO’S COMMENTS “The second quarter saw a continuation of the decline on the car market which began in the second half of 2018, and the market situation is reflected in Bulten’s lower volumes. Net sales decreased by -3.5%. Earnings was affected negatively by a lower rate of production in order to balance inventory levels to demand, but also due to lower sales, primarily toward the end of the quarter. The lower production rate has brought the reduction in inventories according to plan, but also resulted in a lower utilization of the production units’ capacity and thus under-absorption of fixed costs. The ambition of adapting inventory levels was previously communicated in connection with the Q1 report. The under-absorption had a negative impact on earnings of approximately SEK 25 million during the second quarter. We are not satisfied with the development during the quarter, but the adjustment of production rate was necessary in the prevailing market climate. At present, demand remains lower than last year, and volumes related to new contracts have ramped up more slowly than anticipated. With this in mind, the production rate will remain lower at the start of Q3. A review of the company’s costs has been initiated for adaptation to the current market situation. As previously announced, Bulten has contracts in place worth just over half a billion SEK a year at full production in 2021. During the first half-year, we have also won several smaller contracts with a total annual value of approximately SEK 20 million, in addition to the previously already announced of approximately SEK 130 million.” Anders Nyström, President and CEO Investors, analysts and media are invited to participate in the teleconference on July 10 at 11:00 CET. The report will be presented by Anders Nyström, President and CEO and Helena Wennerström, Executive Vice President and CFO via audiocast. The presentation will be held in English and can be followed live via the link: https://tv.streamfabriken.com/bulten-q2-2019. It will also be possible to take part of the audiocast afterwards at the same address or at www.bulten.com/ir. To participate in the teleconference, please call 5 minutes before the opening: SE: +46856642695UK: +443333009262US: +18335268347 For further information, please contact: Anders Nyström, President and CEOTel: + 46 31-734 59 00 Kamilla Oresvärd, Senior Vice President Corporate CommunicationsTel: +46 70-520 59 17, e-mail: kamilla.oresvard@bulten.com This information is information that Bulten AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact person set out above, at 08:30 CET on July 10, 2019. Bulten is one of the leading suppliers of fasteners to the international automotive industry. The company’s product range includes everything from customer-specific standard products to customized special fasteners. The company also provides technical development, line-feeding, logistics, material and production expertise. Bulten offers a Full Service Provider concept or parts thereof. The company was founded in 1873, has some 1,400 employees in eight countries and head office in Gothenburg. The share (BULTEN) is listed on Nasdaq Stockholm. Read more at www.bulten.com.

Finnair continues to grow its Asian traffic: Busan in Korea as a new destination in summer 2020

Finnair continues to grow its Asian operations and adds Busan in South Korea as a new destination in summer 2020. Finnair will be the first and only airline connecting Busan to Europe with a non-stop flight.    In summer season 2020, Finnair will operate from Helsinki to Busan three times a week, on Mondays, Wednesdays and Fridays, starting on March 30th, 2020 (subject to regulatory approvals) with its modern Airbus A350 aircraft, with flights connecting smoothly to and from Finnair’s vast network of European destinations.  The addition of Busan into Finnair’s network connects over 100 European destinations with 20 destinations in Asia.   “We are excited to be the first European airline operating to Busan, which is a wonderful addition to our Asian network,” says Ole Orvér, Chief Commercial Officer, Finnair. “Korea is one of our top markets globally, and we have been operating to Seoul for 11 years. We are delighted to be able to offer a new destination to our customers in Korea and to continue growing sustainably in Asia.”   Busan is South Korea’s second largest city with 3.5 million inhabitants. It is located on the south-eastern tip of the Korean Peninsula and is known for its beautiful scenery that combines mountains, rivers and the sea. It offers excellent beaches and great hiking trails in a temperate climate.     Finnair specialises in connecting Europe and Asia via the short Northern route through Helsinki, Finland, with timetables designed to support smooth transfers and short travel times.  

Apetit to divest its fresh cut products business operations

Apetit Plc has signed an agreement on selling its fresh cut products business operations to the Swedish company Greenfood AB. Greenfood AB is an importer, distributor and processor of fruit and vegetables as well as a leading healthy fresh food actor that operates in the Nordic countries and Western Europe. In Finland, Greenfood AB owns Salico Oy, Satotukku Oy, Picadeli Oy and Snackpoint Oy. Salico is one of the leading Finnish suppliers of fresh cut fruit and vegetable products to food service, retail and fast food chains. The arrangement will be carried out as a business transfer that covers Apetit’s plant property in Kivikko in Helsinki, including machinery and equipment. The employees of Apetit’s fresh cut products business operations will transfer to Salico Oy, Greenfood AB’s Finnish subsidiary, as existing employees. The parties are not disclosing the transaction price. Apetit will recognise a non-recurring sales gain of around EUR 2 million after taxes for the corporate transaction in the second half of 2019. More detailed information will be available once the arrangement has been completed. Apetit’s net sales from fresh cut products business operations totalled EUR 23.2 million in 2018 and it has 120 employees. Apetit will report its fresh cut products business operations under discontinued operations in its half-year financial report on 16 August 2019. The corporate transaction is expected to have a positive effect on Apetit’s full-year operational EBIT. Juha Vanhainen, CEO of Apetit Plc: “Apetit has recently made significant investments in improving the efficiency and, consequently, the profitability of its fresh cut products business operations. However, there is considerable competition in the fresh cut products market in Finland, and we have been unable to make these business operations profitable sufficiently quickly. Due to this, we have decided to sell our fresh cut products business operations to a strong international operator with the capacity to further develop these operations on a larger scale. The transaction is expected to improve Apetit’s profitability.” David von Laskowski, CEO, Greenfood AB: “The acquisition of Apetit’s fresh cut products business operations offers us an opportunity to grow in Finland. We believe that, combined with our international expertise, this business transfer will create significant added value for the fresh cut products business operations, as well as strengthening their cost-competitiveness in particular.” In order to be completed, the transaction requires the approval of the competition authorities. The transaction is expected to be completed in the second half of 2019. Apetit PlcFor more information, please contact: Juha Vanhainen, CEO, Apetit Plc, tel. +358 10 402 2100 David von Laskowski, CEO, Greenfood, tel. +46 70 290 63 13 Apetit is number one in vegetables. It is a food industry company firmly rooted in Finnish primary production. We create well-being with vegetables by offering healthy and tasty food solutions that make daily life easier. We also produce high-quality vegetable oils and rapeseed expellers for feeding stuff, and trade grain on the international markets. Apetit seeks to lead the way in vegetable-based food solutions. Apetit Plc's shares are listed on Nasdaq Helsinki. In 2018, the company's net sales were EUR 283 million. Read more at apetit.fi . About Greenfood AbWe just love healthy food. Making it tastier. Easier. Better. And more accessible. Passion is what’s made us at Greenfood one of the Nordic region’s leading groups in healthy food, with a history that stretches back 50 years. In 2018 our sales totalled approx. SEK 4.7 billion, and we have just over 1,300 employees. We pursue a broad range of activities, and with our four business areas we cater for the entire grocery chain – from growing, processing and delivery to the moment the consumer puts the fork in their mouth. Greenfood’s business areas are: Picadeli, Food Solutions, Fresh Cut and Fresh Produce. The Group’s brands include: Picadeli, Green Deli, Wrapson, Daily Greens, SallaCarte. Read more at www.greenfood.se.

Pricer Improves Operating Result in Second Quarter of 2019

Pricer, supplier of systems and solutions for in-store digitization, has maintained a high activity of small and medium-sized deliveries during the second quarter of the year. Revenues in the second quarter are estimated to amount to approximately SEK 271 million, which corresponds to a growth of 22% compared with the second quarter of 2018. Sales growth, combined with a high gross margin as a result of a favorable product and contract mix, as well as positive currency effects due to the weakening of the Swedish krona against the Euro and the US dollar, is expected to result in a significant improvement in operating profit. The operating profit for the second quarter of 2019, which has not yet been finally determined, is estimated to amount to approximately SEK 34 million corresponding to 12.5% in operating margin, compared with SEK 20.1 million for the corresponding period of last year. This corresponds to an increase in operating profit of 69%. The order intake for the second quarter of 2019 amounted to SEK 230 million, which is considerably lower than the record high order intake of SEK 520 million reported for the second quarter of 2018, containing more than SEK 300 million from a single large customer in North America. The order backlog at the end of the second quarter of 2019 amounted to SEK 131 million, compared with SEK 445 million in the corresponding time of last year and SEK 169 million at the end of the first quarter of 2019. Like what was commented in the first quarter report, the demand and market activity for Pricer’s systems remain unchanged at a high level. In addition to what is stated above, Pricer will not comment on the development of the business before the interim report for the second quarter is published, which will be in accordance with the financial calendar on July 18, 2019 at 13:00.  For further information, please contact:Helena Holmgren, President and CEO, +46 (0)702 870 068Susanne Andersson, CFO, +46 (0)730 668 904Mail: ir@pricer.com This information is information that Pricer AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 10:00 CET on July 10, 2019. Every care has been taken in the translation of this document. In the event of discrepancies, the Swedish original will supersede the English translation.Pricer, founded in 1991 in Uppsala, Sweden, is the global leader in providing in-store shelf-edge digital solutions that enhance both store performance and the shopping experience. Pricer AB (publ) is quoted on the Small Cap list of Nasdaq Stockholm. For further information, please visit www.pricer.com. 

Risk Intelligence issues warrants to employees

The Board of Directors has decided to issue 130.110 warrants to employees and by that continuing the current warrant program approved at the Annual General Meeting in 2018. The current warrant program in brief: Until 1 July 2020, the Board has the right to issue a total of 595,080 warrants. The allocation of the warrant program is approximately 40 per cent of warrants for employees and approximately 60 per cent for Company management.  Each warrant will provide the holder with the right to subscribe for one new share in the Company at a subscription rate of DKK 6.25. The warrants program is dedicated for allocation to Company management and employees, whereby they may be offered the opportunity of participating in a value growth in Company shares. This is expected to lead to an increase in interest in Company development - such as the pricing trends in Company shares price - and that continued business loyalty will be stimulated in the coming years. In addition, the warrants program strengthens future options for the Company in terms of new employees. For further information about Risk Intelligence, please contact:  Hans Tino Hansen, CEOJens Krøis, CFO Telephone: +45 7026 6230E-mail: investor@riskintelligence.eu  Web page and social media:  Web page: www.riskintelligence.euTwitter: www.twitter.com/riskstaffLinkedIn: www.linkedin.com/company/risk-intelligenceFacebook: www.facebook.com/riskstaff 

Brighter carries out a directed share issue of SEK 10.8 M through set-off and cash.

Brighter’s Board of Directors has, with authorization from the Annual General Meeting on May 9, 2019, decided to offer lenders to the company to set off previously raised loans by issuing new shares. The share issue totalling SEK 10.8 million will be made through set-off of loans of SEK 2.8 million and cash payment of SEK 8.0 million. The cash amount received will then be fully utilized to repay additional loans. The purpose of the share issue and the reason for the deviation from the shareholders' preferential rights is to strengthen the company's balance sheet in a time and capital efficient manner. Terms: 10% discount on the lowest VWAP during the last 15 (fifteen) trading days. The subscription price is SEK 8.92. The number of shares in the company increases by 1,212,873, to a total of 85,036,043. The share capital increases by SEK 60,643.65 to SEK 4,251,802.15.  About Brighter AB (publ). Brighter is a Swedish-based company that, from a unique IP portfolio, creates smart solutions for one of healthcare’s biggest challenges: changing patient behavior. Chronic diseases such as diabetes are rapidly increasing, and account for an increasing share of healthcare costs globally. Brighter's Business Model and Multi-Sided Market Platform - The Benefit Loop®- is based on the fact that many special interests create value for each other. By increasing access to valid health data, Brighter creates value for all stakeholders in the care chain: patients and their close associates, healthcare providers, research institutes, the pharmaceutical industry, and society as a whole. Brighter is certified under ISO 13485. In 2019 the company won the Swecare Rising Stars Award. https://brighter.se/   The Company's shares are listed on NASDAQOMX First North/BRIG . Visit our website and subscribe to press releases: www.brighter.se  Follow us on:   www.introduce.se Certified Adviser Brighter’s Certified Adviser on Nasdaq OMX First North is Eminova Fondkommission AB, +46 (0)8 – 684 211 00, info@eminova.se, www.eminova.se. For further information, please contact: Henrik Norström, CEO  Phone: +46 733 4030 45    Email:henrik.norstrom@brighter.se This information is information that Brighter AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 11:05 CET on July 10, 2019.

Saab Signs Framework Agreement for AT4 and Carl-Gustaf Ammunition with the United States Government

The recently signed framework agreement allows the customer to place orders for Saab’s AT4 disposable weapon system and ammunition for the Carl-Gustaf® recoilless rifle. A first purchase order of USD 83 million (approximately SEK 771 million) was released at the signing of the agreement. “This framework agreement further strengthens our relationship with the U.S. Armed Forces, who have been users of our ground combat systems for decades. We see these continued investments as a clear proof that the customer values the flexibility and effectiveness of our systems,” says Görgen Johansson, head of Saab business area Dynamics. The order was booked in Q2 2019.Both Saab’s AT4 and Carl-Gustaf (designated MAAWS in the U.S.) have long track records in the U.S. Since 1987, Saab has delivered more than 600,000 AT4s, both directly and under license, to U.S. forces. The Carl-Gustaf system has been a program of record in the U.S. since 2013 and in 2018 it was announced that U.S. Army will acquire the latest version of the system – the Carl-Gustaf M4 (designated M3E1 in the U.S.). For further information, please contact: Saab Press Centre, +46 (0)734 180 018, presscentre@saabgroup.com www.saabgroup.com  www.saabgroup.com/YouTube  Follow us on twitter: @saab  Saab serves the global market with world-leading products, services and solutions within military defence and civil security. Saab has operations and employees on all continents around the world. Through innovative, collaborative and pragmatic thinking, Saab develops, adopts and improves new technology to meet customers’ changing needs. 

Pricer Receives an Order for Full Chain Roll-out with Italian Grocery Chain Tosano

Tosano, an Italian grocery chain with 15 large format stores, has placed an order to equip all its stores with Pricer’s digital price label system. Tosano will integrate Pricer’s advanced digital solutions, such as dynamic product positioning and InstantFlash functionality, for a new application aimed at optimizing the logistics flow from the external warehouse to the store shelf.In addition, Pricer and Tosano will engage in a strategic partnership to integrate Pricer’s shelf-mounted camera into the solution with the intention to further improve efficiency of several in-store processes based on data analytics.The value of the order is approximately SEK 60 million and is included in Pricer’s order intake for the third quarter of 2019. Deliveries are expected to be completed before the end of 2019.      For further information, please contact:Michael Cacciatore, Country Manager Pricer Italy +39 347 2505228Helena Holmgren, President and CEO, +46 702 870 068Susanne Andersson, CFO, +46 730 668 904info@pricer.com    This information is information that Pricer AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 15:30 CET on July 10, 2019.Every care has been taken in the translation of this document. In the event of discrepancies, the Swedish original will supersede the English translation.      About PricerPricer AB, founded in Sweden in 1991, listed on the NASDAQ Stockholm, is a global leader in providing in-store digital shelf-edge solutions that enhance both store performance and the shopping experience. The increasingly feature-rich Pricer platform is fast, robust, interconnectable and scalable. For further information, please visit www.pricer.com

Invitation to Press and Analyst Meeting for Presentation of Saab’s Interim Report January-June 2019

Date:          Friday, 19 July at 11.30 (CET). Address:    Saab, Olof Palmes Gata 17, 5th floor, Stockholm, Sweden The report is published at 07.30 a.m. (CET) the same day.  You are welcome to participate on site at Saab, watch the live webcast or dial in to the conference call. It is possible to post questions also over the web and conference call.  Live webcast: http://saab-interimreport.creo.se/190719 Conference call: Please, dial in using one  of the numbers below. Sweden:                                            +46 8 566 42705 United Kingdom:            +44 3333009031 United States:                +1 8338230590 The interim report, the presentation material and the webcast will be available on http://www.saabgroup.com/investor-relations. R.S.V.P.  E-mail: marie.bergstrom@saabgroup.com Tel: +46 8 463 02 45 For further information, please contact: Saab Press Centre, +46 (0)734 180 018 presscentre@saabgroup.com  Saab Investor Relations Ann-Sofi Jönsson, +46 (0) 734 187 214 www.saabgroup.com www.saabgroup.com/YouTube Follow us on twitter: @saab   Saab serves the global market with world-leading products, services and solutions within military defence and civil security. Saab has operations and employees on all continents around the world. Through innovative, collaborative and pragmatic thinking, Saab develops, adopts and improves new technology to meet customers’ changing needs. 

Vattenfall wins tender for Dutch offshore wind power

Magnus Hall, CEO of Vattenfall, comments: "This is excellent news for Vattenfall, our partners and the Dutch energy transition. It means a significant step for Vattenfall in view of our ambition to make fossil-free living possible within one generation and to grow in renewable energy production. The Netherlands is an important market for us and this will be one of our biggest offshore projects. We are looking forward to contribute with this project to the transformation of the Dutch energy system.” “Winning the bid for Hollandse Kust Zuid 3&4 is a result of our continuous efforts along our entire value chain and the solid track record and portfolio approach of our company. Adding to that, working collaboratively with our partners in the supply chain has enabled us to hand in a state-of-the-art proposal for this project. We can bundle now the projects Hollandse Kust Zuid 1&2 and 3&4 which is a great advantage leading to further optimization and synergies”, says Gunnar Groebler, Senior Vice President and Head of Business Area Wind of Vattenfall. Offshore construction is scheduled to take place in 2022. According to the tender rules, Hollandse Kust Zuid 3&4 needs to be fully operational within 5 years after permit have become irrevocable. In total, HKZ 1 - 4 will produce renewable energy to up to 3 million Dutch homes. For more information, please contact:Vattenfall Press Office + 45 8 739 50 10 press@vattenfall.com   Vattenfall is a leading European energy company, that for more than 100 years has electrified industries, supplied energy to people’s homes and modernised our way of living through innovation and cooperation. We now want to make fossil-free living possible within one generation. Therefore, we are driving the transition to a more sustainable energy system through growth in renewable production and climate smart energy solutions for our customers. We employ approximately 20,000 people and have operations mainly in Sweden, Germany, the Netherlands, Denmark and the UK. Vattenfall is owned by the Swedish state. For more information: www.corporate.vattenfall.com

Publishing of YIT Corporation's Half-year report for January-June 2019 on July 25, 2019

Publishing of YIT Corporation's Half-year report for January-June 2019 on July 25, 2019 YIT Corporation's Half-year report for January-June 2019 will be published on Thursday, July 25, 2019 at approximately 8:00 a.m. Finnish time (EET, approximately 6:00 a.m. GMT). The stock exchange release and the presentation materials in Finnish and in English will be published at that time on the company's website at www.yitgroup.com/investors. News conference for investors and media YIT will arrange a news conference on Thursday, July 25, 2019 at 10:00 a.m. Finnish time (EET, at 8:00 a.m. GMT) at YIT's head office, Panuntie 11, 00620 Helsinki, Finland. The event is in English and targeted for analysts, portfolio managers and the media. Welcome! Webcast The news conference and presentation by the President and CEO of YIT Corporation Kari Kauniskangas can also be followed through a live webcast at www.yitgroup.com/webcast. The live webcast starts at 10:00 a.m. (EET) and a recording of the webcast will be available at the same address later that day. Conference call The news conference can be participated also through a conference call. Conference call participants are requested to dial in at least five minutes prior to the start of the conference, at 9:55 a.m. (EET). Conference call numbers are: Participants from Finland +46 (0)8 5033 6574 Participants from Sweden +46 (0)8 5033 6574 Participants from Norway +47 2100 2610 Participants from UK and outside of Nordic countries +44 (0)330 336 9105 The participants will be asked to provide the following confirmation code: 8263077. During the webcast and conference call, all questions should be presented in English. At the end of the event, the media has the opportunity to ask questions also in Finnish. For further information, please contact: Tiina Kuusisaari, Manager, Investor Relations, YIT Corporation, tel. +358 40 5288 154, tiina.kuusisaari@yit.fi   YIT CORPORATION Hanna JaakkolaVice President, Investor Relations Distribution: Nasdaq Helsinki, major media, www.yitgroup.com YIT is the largest Finnish and significant North European construction company. We develop and build apartments and living services, business premises and entire areas. We are also specialised in demanding infrastructure construction and paving. Together with our customers, our nearly 10,000 professionals are creating more functional, more attractive and more sustainable cities and environments. We work in 11 countries: Finland, Russia, Scandinavia, the Baltic States, the Czech Republic, Slovakia and Poland. The new YIT was born when over 100-year-old YIT Corporation and Lemminkäinen Corporation merged on February 1, 2018. Our pro forma revenue for 2018 was approximately EUR 3.8 billion. YIT Corporation's share is listed on Nasdaq Helsinki Oy. www.yitgroup.com 

Instalco acquires ventilation company in Gävle

Milen Ventilation AB was established in 2014 and the company specialises in ventilation and climate solutions in connection with new construction and renovations. They have 17 employees and annual sales of approximately SEK 70 million. “Although Milen Ventilation is a relatively new company, its employees have extensive experience and expertise in their industry. The acquisition significantly expands the geographic scope of our operations. Milen is a very well-run company with competence and expertise that is an excellent fit with the other ventilation companies in the Instalco group,” says Johan Larsson, Business Area Manager for Instalco North. Milen offers a full range of services and solutions with all steps of the installation process, from advice and project planning to optimisation and service. Its main customers are construction companies and property owners. Milen has solid experience from working in collaboration projects to create further customer value, and can also ensure installation of cooling, heating and control connected to the ventilation. “We look forward to develop our operations based on the business opportunities that are created when we become part of Instalco. We are confident that we will be able to contribute with our capabilities to Instalco while also taking advantage of Instalco’s network and expertise,” says Niklas Ulin, CEO at Milen. Instalco has acquired 100 percent of the shares in Milen Ventilation AB as of 10 July 2019. For more informationFredrik Trahn, Head of Communications and IRphone +46 70 913 67 96, e-mail fredrik.trahn@instalco.se Instalco is one of the leading installation companies in the Nordic region, active in the areas of heating, plumbing, electricity, cooling and industrial solutions. We work closely with customers, offering all the advantages of a local company, along with efficient collaboration and leadership. The operations are conducted through approximately 60 leading and highly specialised local companies, with the support of a small central organisation. Instalco is listed at Nasdaq Stockholm under the ticker INSTAL. For further information, visit www.instalco.se.

BioArctic and Eisai to present BAN2401 at the Alzheimer's Association International Conference 2019

Stockholm, Sweden, July 11, 2019 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that presentations related to BAN2401 will be given at the Alzheimer’s Association International Conference® 2019 (AAIC®) to be held July 14-18 in Los Angeles, USA. In addition to the presentations, BioArctic’s partner Eisai will sponsor an interactive satellite symposium focusing on the rationale and opportunities for drug development in preclinical Alzheimer’s disease – clinically normal people with increased cerebral amyloid deposition who are at risk for developing Alzheimer’s disease. The symposium will take place Tuesday, July 16. Presentations related to BAN2401 during AAIC® 2019: +------------+-----------------------------------------+-----------------------+|Presentation|Topic |Date and Time ||ID | |(Pacific Daylight Time)|+------------+-----------------------------------------+-----------------------+|Abstract ID:|BAN2401 binding to soluble aggregated |Wednesday, July 17 ||35340 |amyloid-beta species |1:00 – 2:00 PM ||Poster P4 |Presenter: Dr. Lars Lannfelt, Uppsala | ||-704 |University and BioArctic | |+------------+-----------------------------------------+-----------------------+|Abstract ID:|Population |Wednesday, July 17 ||35653 |Pharmacokinetic/Pharmacodynamic Analyses |1:00 – 2:00 PM ||Poster P4 |of BAN2401 In Patients with Early | ||-657 |Alzheimer’s Disease: Correlation of | || |BAN2401 Exposure, PET Standard Uptake | || |Value Ratio, and Cognitive Outcomes | |+------------+-----------------------------------------+-----------------------+|Abstract ID:|BAN2401 In Early Alzheimer's Disease: |Wednesday, July 17 ||35585 |Neurodegeneration Biomarker Analysis From|2:00 – 2:15 PM ||Oral |Randomized Phase 2 Study | ||presentation| | ||DT-01-01 | | |+------------+-----------------------------------------+-----------------------+ This release discusses investigational uses of an agent in development and is not intended to convey conclusions about efficacy or safety. There is no guarantee that any investigational uses of such product will successfully complete clinical development or gain health authority approval. For more information, please contact: Gunilla Osswald, PhD, CEO, BioArctic ABE-mail: gunilla.osswald@bioarctic.seTelephone: + 46 8 695 69 30 This information was submitted for publication at 07:30 a.m. CET on July 11, 2019. Notes to editors About BAN2401 BAN2401 is a humanized monoclonal antibody that is the result of a strategic research alliance between BioArctic and Eisai. BAN2401 has a unique binding profile and selectively binds to and eliminates soluble, toxic amyloid-beta aggregates (protofibrils) that are thought to contribute to the neurodegenerative process in Alzheimer’s disease. As such, BAN2401 has the potential to have an effect on the disease pathology and to slow down the progression of the disease. Eisai obtained the global rights to study, develop, manufacture and market BAN2401 for the treatment of Alzheimer’s disease pursuant to an agreement concluded with BioArctic in December 2007. In March 2014, Eisai and Biogen entered into a joint development and commercialization agreement for BAN2401. Currently, a global confirmatory Phase 3 clinical study (Clarity AD) of BAN2401 in patients with early Alzheimer´s disease is underway. According to Eisai, the final readout of the primary endpoint of the study is targeted for 2022. About the collaboration between BioArctic and Eisai Since 2005, BioArctic has long-term collaboration with Eisai regarding the development and commercialization of drugs for the treatment of Alzheimer's disease. The most important agreements are the development and commercialization agreement on the BAN2401 antibody, which was signed in December 2007, and the development and commercialization agreement on the antibody BAN2401 back-up for Alzheimer's disease, which was signed in May 2015. Eisai is responsible for the clinical development, application for market approval and commercialization of the products for Alzheimer’s disease. BioArctic has no development costs for BAN2401 in Alzheimer’s disease. About BioArctic AB BioArctic AB (publ) is a Swedish research-based biopharma company focusing on disease-modifying treatments and reliable biomarkers and diagnostics for neurodegenerative diseases, such as Alzheimer’s disease and Parkinson’s disease. The company also develops a potential treatment for Complete Spinal Cord Injury. BioArctic focuses on innovative treatments in areas with high unmet medical needs. The company was founded in 2003 based on innovative research from Uppsala University, Sweden. Collaborations with universities are of great importance to the company together with its strategically important global partners in the Alzheimer (Eisai) and Parkinson (AbbVie) projects. The project portfolio is a combination of fully funded projects run in partnership with global pharmaceutical companies and innovative in-house projects with significant market- and out-licensing potential. BioArctic’s B-share is listed on Nasdaq Stockholm Mid Cap (ticker: BIOA B). For more information about BioArctic, please visit www.bioarctic.com . About Eisai Co., Ltd. Eisai Co., Ltd. is a leading global research and development-based pharmaceutical company headquartered in Japan. Eisai defines their corporate mission as “giving first thought to patients and their families and to increasing the benefits health care provides,” which Eisai calls their human health care (hhc) philosophy. With approximately 10,000 employees working across the global network of R&D facilities, manufacturing sites and marketing subsidiaries, Eisai strives to realize their hhc philosophy by delivering innovative products to address unmet medical needs, with a particular focus in the strategic areas of Neurology and Oncology. Eisai has been working to establish a social environment that involves patients in each community in cooperation with various stakeholders including the government, healthcare professionals and care workers, and is estimated to have held over ten thousand dementia awareness events worldwide. As a pioneer in the field of dementia treatment, Eisai is striving to not only develop next generation treatments but also to develop diagnosis methods and provide solutions. For more information about Eisai Co., Ltd., please visit www.eisai.com.

Arjo acquires equity stake in Atlas Lift Tech – a Silicon Valley tech-company offering patient handling solutions and real-time efficiency analytics

Today, Arjo has acquired substantial equity in Atlas Lift Tech, thereby gaining a seat on its Board of Directors. Atlas, a Silicon Valley-based company, transforms the way in which care delivery organizations deploy and manage comprehensive mobility programs through their innovative Lift Coach Model and Mobility Tracking Software Platform. Atlas’ Lift Coaches integrate themselves into each healthcare facility and empower care providers through bedside training methods, thereby reducing injuries and mitigating risks, while boosting overall morale. Atlas’ proprietary software system, LiftTracker, is embedded into each facility to provide real-time task tracking and scheduling. Together, the LiftTracker software and data collection devices provide Big Data insights, leading to better patient handling processes and improved clinical outcomes. Patient mobilization and repositioning has been demonstrated as a safe and feasible manner of improving clinical outcomes for patients and financial benefits to healthcare providers. Reduced mobility can lead to a long line of negative side effects for patients, including lost muscle strength, pressure injuries, infection and an increased risk of falls, as well as despondency and depression. “By combining our offering and Atlas’ solutions, we will help our customers address challenges of mobility in an effective manner, while providing data and evidence for improved clinical outcomes. This collaboration gives us a strong platform to offer a unique end-to-end solution, with the mutual goal of reducing caregiver injuries and improving patient care, while creating efficiencies for healthcare facilities. Further, we gain access to Atlas’ strong Silicon Valley network to help drive innovations and new practices within patient handling and mobilization,” says Joacim Lindoff, President & CEO of Arjo. The improper mobilization of patients can come at a cost for healthcare professionals. A significant cause of missed work days in hospital workers is related to overexertion or related movements, including lifting, bending and reaching.* These movements are often performed during patient lifts and transfers, and can cause long-term health issues for care professionals and significant inefficiencies for care facilities. Established in 2009, Atlas is a dynamic company with a solid growth trajectory. During the third quarter of 2018, Arjo and Atlas began exploring the possibilities of gaining market share in the US through the mutual goal of improving clinical outcomes through mobilization. The investment and commercial collaboration is expected to have a positive impact on Arjo’s net sales, gross margin and earnings per share already in 2019, delivered by an increased growth within the Patient Handling portfolio. There is a performance-based option for Arjo to acquire additional equity in Atlas. “Arjo is a trusted partner with a strong reputation worldwide, and like Atlas, shares the goal of optimizing the care experience for patients and caregivers. Together with Arjo’s market leading equipment and clinical expertise, and Atlas’ operational precision and innovative technology, we can now develop the next generation Mobility Program. We will assist clients and care staff to attain proven and effective practices, while improving patient safety. This will give a platform to produce a thriving and sustainable culture of safety, where customers will not have to choose between caregiver and patient safety,” adds Eric Race, President & Founder of Atlas. The transaction is subject to customary closing conditions. *OSHA, 2011 About Atlas Founded in 2009, Atlas Lift Tech is transforming the way care delivery organizations nationwide deploy and manage safe patient handling and mobility (SPHM) programs. Atlas provides proven and effective practices that reduce caregiver injury, promote patient safety, and produce a thriving and sustainable culture of safety. Working together with a facility's interdisciplinary team, Atlas identifies opportunities for integration of an SPHM program customized to the unique requirements of each facility. www.atlaslifttech.com. For further information, please contact: Kornelia Rasmussen, Marketing Communications & Public RelationsTel: +46 (0)10 335 4810Email: kornelia.rasmussen@arjo.com Saloni Deva, Corporate Communications & Investor RelationsTel: +46 (0)10 335 4867Email: saloni.deva@arjo.com Jenna Lindgren, Head of Sales & Marketing at Atlas Lift TechTel: 925 271 9020Email: jlindgren@atlaslifttech.com This information is information that Arjo AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 07:45 CET on July 11 2019. About Arjo At Arjo, we are committed to improving the everyday lives of people affected by reduced mobility and age-related health challenges. With products and solutions that ensure ergonomic patient handling, personal hygiene, disinfection, diagnostics, and the effective prevention of pressure injuries and venous thromboembolism, we help professionals across care environments to continually raise the standard of safe and dignified care. Arjo has approximately 6,000 employees worldwide and customers in over 100 countries. In 2018, Arjo sales amounted to approximately SEK 8.2 billion. Arjo is listed on Nasdaq Stockholm and its head office is located in Malmö, Sweden. Everything we do, we do with people in mind. www.arjo.com.

Interim Report January – June 2019

Summary of key events for the second quarter 2019 · BioArctic received MEUR 15 milestone payment from Eisai for start of BAN2401 confirmatory Phase 3 study in early Alzheimer’s disease · Alzheimer’s Clinical Trials Consortium and Eisai announced that BAN2401 will be evaluated in a clinical study for prevention of Alzheimer’s disease · Ewa Björling was elected new member of the board at the Annual General Meeting · The Annual General Meeting approved the introduction of an employee warrant program 2019/2028 for the company’s management, researchers and other staff Key events after the period  · There are no key events to report after the period   Financial summary for the first half of 2019 · Net revenues for the period increased with MSEK 130.1 to MSEK 234.7 (104.6) as a result of the received milestone payment from Eisai · Operating profit amounted to MSEK 144.1 (25.3) and the operating margin was 61.4 percent (24.2) for the period · Profit for the period amounted to MSEK 113.9 (20.5) and earnings per share were SEK 1.29 (0.23) · Cash flow from operating activities amounted to MSEK 430.8 (-79.3) for the period Financial summary +---------------------------+------+------+------+-------------+-------------+|MSEK  | Apr| Apr| Jan|Jan-Jun 2018 |Jan-Dec 2018 || | -Jun| -Jun| -Jun| | || | 2019 | 2018 | 2019 | | |+---------------------------+------+------+------+-------------+-------------+|Net revenues  |171.3 | 52.3 |234.7 | 104.6 | 714.0 |+---------------------------+------+------+------+-------------+-------------+|Other operating income  | -0.7 | 3.6 | 6.2 | 15.0 | 16.3 |+---------------------------+------+------+------+-------------+-------------+|Operating profit  |126.8 | 6.4 |144.1 | 25.3 | 488.8 |+---------------------------+------+------+------+-------------+-------------+|Operating margin, %  | 74.0 | 12.3 | 61.4 | 24.2 | 68.5 |+---------------------------+------+------+------+-------------+-------------+|Profit for the period  |100.3 | 5.1 |113.9 | 20.5 | 381.6 |+---------------------------+------+------+------+-------------+-------------+|Earnings per share, SEK [1]| 1.14 | 0.06 | 1.29 | 0.23 | 4.33 |+---------------------------+------+------+------+-------------+-------------+|Equity per share, SEK [1] |11.35 | 7.46 |11.35 | 7.46 | 11.56 |+---------------------------+------+------+------+-------------+-------------+|Cash flow from operating | 97.2 |-37.3 |430.8 | -79.3 | -200.1 ||activities  | | | | | |+---------------------------+------+------+------+-------------+-------------+|Cash flow from operating | 1.10 |-0.42 | 4.89 | -0.90 | -2.27 ||activities per share, SEK | | | | | ||[1] | | | | | |+---------------------------+------+------+------+-------------+-------------+|Equity/assets ratio, %   | 78.4 | 61.7 | 78.4 | 61.7 | 73.1 |+---------------------------+------+------+------+-------------+-------------+|Return on equity, %  | 9.9 | 0.8 | 11.3 | 3.2 | 46.1 |+---------------------------+------+------+------+-------------+-------------+|Share price at the end of |74.40 |21.80 | 74.40| 21.80| 82.00||the period | | | | | |+---------------------------+------+------+------+-------------+-------------+ [1] The allocation of the employee warrants program has not yet been concluded as of June 30, 2019; thus, there is no dilutive effect   CEO commentsIn the first half of 2019, BioArctic made significant progress in that all three clinical projects advanced to the next phase in their respective development program and all of our research projects continued to generate results. All in all, this means that we have had a very successful first half of the year. The global, confirmatory Phase 3 study (Clarity AD) has been started with the drug candidate BAN2401, a potential disease modifying treatment for early Alzheimer’s disease. In May, the first patient was dosed which triggered a milestone payment of MEUR 15 to BioArctic from our partner Eisai. This large Phase 3 study, which is intended to support a regulatory filing, is based on the positive results from the Phase 2b study. According to Eisai, the final readout of the primary endpoint of the study is targeted for 2022. The Phase 2b study with BAN2401 was the first study in late clinical phase to have successfully demonstrated potential disease modifying effects on both clinical function and clearance of amyloid beta in the brain. Further, the Phase 2b study also demonstrated effects on neurodegenerative biomarkers. These consistent results strengthen BioArctic’s belief that BAN2401’s unique binding profile is important and differentiates it from other antibodies.  For the participants in the Phase 2b study, an open-label extension study is ongoing with continued BAN2401 treatment with the highest dose and without placebo control.  BAN2401 has also recently been selected by the Alzheimer’s Clinical Trials Consortium (ACTC) to be evaluated in a clinical trial aimed at prevention of Alzheimer’s disease (the A45 study). According to ACTC and Eisai, the trial will be starting in early 2020. We are pleased to note Eisai’s strong commitment to the continued clinical development of BAN2401 in Alzheimer’s disease. In the Parkinson’s program, our partner AbbVie started the Phase 1 study with the drug candidate ABBV-0805. AbbVie is responsible for running the clinical program and its financing. Within the framework of the collaboration, BioArctic continues to conduct two additional projects in research stages with antibodies targeting alpha-synuclein for treatment of Parkinson’s disease. Also, the Alzheimer projects as well as the projects on diagnostics and technologies in research phase have continued to develop well. In collaboration with Uppsala University, BioArctic develops a technology platform that facilitates the passage of antibodies across the blood-brain barrier. This innovative technology could potentially be used to treat various diseases of the brain. We have recently recruited an internationally renowned scientist to further strengthen the company’s capabilities and competence in the neuroscience therapeutic area, antibody engineering and blood-brain barrier technology.  The product candidate SC0806 for complete spinal cord injury has advanced into Phase 2 in the ongoing Phase 1/2 study. An interim analysis of the first panel concerning efficacy and safety is planned for the first half of 2020, at the latest. An important step to attract and retain competence in the company is the new employee warrant program which currently is being implemented. I am proud of our successes and to lead this innovative company with the aim to improve the quality of life for patients with central nervous systems disorders. Gunilla OsswaldCEO, BioArctic AB ContactsFor further information, please contact:Gunilla Osswald, CEO, gunilla.osswald@bioarctic.se, telephone + 46 (0)8 695 69 30Jan Mattsson, CFO, jan.mattsson@bioarctic.se, telephone + 46 (0)703 52 27 72 PresentationBioArctic invites to an audiocast with teleconference (in English) for investors, analysts and media today, July 11, at 09:30 – 10:30 a.m. CET. CEO Gunilla Osswald and CFO Jan Mattsson will present BioArctic, comment on the Interim Report and answer questions. Webcast: https://tv.streamfabriken.com/bioarctic-q2-2019   To participate in the conference call, please call:Sweden +46 8 505 583 66 46Denmark +45 781 501 08Germany +49 692 222 203 80Netherlands +31 207 219 495Norway +47 235 002 36Switzerland +41 225 805 977UK +44 333 300 9274USA +1 844 625 1570 About BioArcticBioArctic AB (publ) is a research-based biopharmaceutical company focusing on disease modifying treatments and diagnostics for neurodegenerative diseases, such as Alzheimer’s disease and Parkinson’s disease. The company also develops a treatment for complete spinal cord injury. The company focuses on new types of treatments in areas with high unmet medical needs. BioArctic was founded in 2003 based on innovative research from Uppsala University, Sweden. The company has cutting-edge scientific competence and experience in developing drugs from idea to market. Collaborations with universities are of great importance to the company together with the strategically important global partners in the Alzheimer and Parkinson projects. BioArctic conducts its own clinical development in the field of complete spinal cord injury. Through long-term collaboration agreements with global pharmaceutical companies, BioArctic has demonstrated high skills and great ability to deliver innovative pharmaceutical projects. In Alzheimer's disease, BioArctic has collaborated with Eisai since 2005. The company has entered into three research agreements and two license agreements relating to the antibodies BAN2401 and BAN2401 back-up. The total aggregated value of these agreements may amount to MEUR 218 and, in addition, payments of royalty. So far, MEUR 62 has been received. In Parkinson's disease, BioArctic has collaborated with AbbVie since 2016, when a research collaboration agreement was entered including i.a. the antibody BAN0805. The total aggregated value of the agreement may amount to MUSD 755 and, in addition, payments of royalty. So far, MUSD 130 has been received. The project portfolio consists of fully funded projects run in partnership with global pharmaceutical companies and innovative in-house projects with significant market and out-licensing potential.BioArctic’s B-share is listed on Nasdaq Stockholm Mid Cap (ticker: BIOA B). This information is information that BioArctic AB (publ) is obliged to disclose pursuant to the EU Market Abuse Regulation and the Swedish Securities Market Act (Swe. VpmL). The information was submitted for publication, through the agency of the contact persons above, at 08:00 a.m. CET on July 11, 2019.  

Orexo Interim Report Q2 2019

Improving all fundamentals Q2 2019 highlights · Total net revenues of SEK 201.2 million (199.7), up 0.8 percent and 19.1 percent when excluding ex-US milestone payment of SEK 30.8 million in Q2 2018 · Zubsolv® US net revenues of SEK 184.4 million (158.4), up 16.4 percent in SEK and 6.7 percent in local currency · EBITDA of SEK 60.4 million (50.6), up 19.4 percent · US EBIT of SEK 87.5 million (55.5), up 57.6 percent · Cash flow from operating activities of SEK 46.1 million (39.0), building a cash balance of · SEK 697.0 million (494.8) · Net earnings of SEK 54.6 million (50.1), up 9.0 percent Important events after the end of the period · Signed license and supply agreement for Zubsolv in Australia and New Zealand with Mundipharma Pty Ltd. · SEK 32.5 million (10 percent) of the total corporate bond loan will be prepaid in August 2019 SEK m, unless 2019  2018  2019 2018 12 mth 12 mthotherwise stated  Apr Apr Jan-Jun  Jan-Jun  Jul 2018- Jul 2017- -Jun  -Jun  Jun 2019  Jun 2018 Net revenues  201.2  199.7  375.5  339.4  819.2  696.7 whereof Zubsolv® US 184.4  158.4  346.1  289.5  678.2  537.1 net revenues Cost of goods sold  -31.3  -37.6  -56.6  -86.0  -142.4  -168.4 Operating expenses  -117.1  -116.7  -265.1  -229.9  -550.8  -433.7  EBIT  52.8  45.4  53.8  23.5  126.0  94.5 EBIT margin, %  26.2  22.7  14.3  6.9  15.4  13.6 US EBIT  87.5  55.5  159.4  80.8  276.7  132.4 US EBIT margin, %  47.4  35.0  46.1  27.9  40.8  24.6 EBITDA  60.4  50.6  72.3  33.7  155.0  115.2 Earnings per share, 1.54  1.45  1.93  0.70  5.1  2.29 before dilution,SEK Earnings per share, 1.51  1.45  1.90  0.70  5.0  2.28 after dilution, SEK Cash flow from 46.1  39.0  97.1  144.9  193.3  214.6 operatingactivities Cash and cash 697.0  494.8  697.0  494.8  697.0  494.8 equivalents  Unless otherwise stated in this report, all data refers to the Group, and numbers relate to the actual quarter while numbers in parentheses relate to the corresponding period in 2018. Strong fundamentals fueling business development and pipeline progress Following a strong first quarter, I am pleased to report that the second quarter has continued on the same positive trajectory. Zubsolv® remains the core driver of Orexo’s strong financial performance and record-high profitability. Zubsolv continues to demonstrate resilience to increased competition and with greater profit contribution from our US operations, we remain focused on expanding our pipeline and product portfolio with new assets. Strengthened financial performance – EBITDA reached SEK 60.4 millionThe second quarter of 2019 marks the first quarter in many years where our legal expenses are immaterial, and where the full impact of revenue growth and efficiency improvements are reflected in the financial health of the business. The second quarter has been the strongest financial period for the company to date, when excluding milestone payments. Isolating the financial performance of US operations, the EBIT margin reached 47 percent and contributed to our overall profitability with SEK 87.5 million (USD 9.2 million), a significant improvement of 58 percent in SEK from last year. With a cash position of SEK 697 million, our main focus is to expand our pipeline and to identify commercially attractive assets to drive future growth. Business development gaining tractionToday, Orexo is in a strong position to engage in partnering and new business activities, thanks to our commercial platform in the US, a profitable business with strong patent protection for Zubsolv, and a solid cash position. We are actively engaged in new business and partnering discussions to ensure the longer-term growth of the business and we are an increasingly attractive partner in the opioid addiction market and its adjacents treatment areas. We are currently in negotiations for the rights to new and existing products. Assuming the negotiations materialize, we would expect to present our first agreement in the second half of 2019. Development programs making good progressOur three most advanced internal projects continue to progress as planned. The next significant milestone will be the phase I study of OX338, a sublingual formulation with ketorolac for the treatment of pain, planned for Q4 this year. For OX338, OX124 and OX125 we feel confident in the clinical development risk profile of these programs and continue to work towards realizing their commercial potential. From an external development perspective, we are also pleased to see our partner, Gesynta Pharma AB, progress OX-MPI (microvascular disease) into a phase I clinical trial. Market Dynamics – Market access is keyThe current trend in the addiction market is for payers to provide more product choice to patients. This would benefit Orexo in fast-growing public markets where Zubsolv currently has fewer reimbursement agreements. However, it also poses a risk in the form of greater competition when it comes to signing and keeping exclusive contracts for Zubsolv. We expect United Health Group will start reimbursing generic products later this year, but will also maintain Zubsolv in the current position as a preferred formula with unrestricted reimbursement. We have recently seen a similar change with Humana, where we lost some percentage points in market share, but our sales volumes have remained resilient and we have seen the Zubsolv demand increase by 3 percent since last quarter, despite increased generic competition. This demonstrates our competitive edge when patients and clinicians are aware of the benefits of Zubsolv over generic products. Summary and outlook2019 is on track to be Orexo’s strongest year to date, both financially and operationally. Zubsolv remains a key driver of growth for the business, while management intend to build on the progress made to ensure the longer-term health of the company. To this end we will continue to expand our pipeline and product portfolio to offer best in class treatment options where they are needed most. Uppsala, Sweden, July 11, 2019 Nikolaj SørensenPresident and CEO For further information, please contactNikolaj Sørensen, CEO and President, Joseph DeFeo, EVP and CFO or Lena Wange, IR & Communications ManagerTel: +46 18 780 88 00, +1 855 982 7658 Email: ir@orexo.com PresentationAt 2.00 pm CET, the same day as the announcement of the report, Orexo invites analysts, investors and media to attend an audiocast with a web presentation where Nikolaj Sørensen, CEO, and Joseph DeFeo, CFO, will present the report. After the presentation a Q&A will be held. Questions can also be sent in advance to ir@orexo.com, no later than 11.00 am CET. Please view the instructions below on how to participate.Internet: https://tv.streamfabriken.com/orexo-q2-2019Telephone: SE: +46 8 50 55 8350 UK: +44 33 33 00 9031 US: +1 83 35 26 8380The presentation material will be available on Orexo´s website prior to the audiocast.  This information is information that Orexo AB (publ.) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 8.00 am CET on July 11, 2019.

Alligator Bioscience AB (publ) Interim report January-June 2019

Significant events April-June• Janssen presented data from the clinical Phase I study with ADC-1013 indicates good safety and shows initial signs of clinical effect.• Study design and progress for the ongoing ATOR-1015 Phase I study showcased at ASCO.• Clinical trial authorization (CTA) application submitted to initiate a ATOR-1017 Phase I study.• New preclinical data presented at scientific conferences:- ATOR-1015:s tumor-localizing properties, shown with live-imaging technique, presented at PEGS (The Essential Protein Engineering Summit).- ALG.APV-527 data, showing a favorable preclinical safety profile, presented at AACR (American Association for Cancer Research).- ATOR-1144 demonstrates potential to activate both the innate and the adaptive immune system with a direct anti-tumor effect. Data presented at AACR. Financial informationApril-June 2019• Net sales, SEK 0.0 million (0.4)• Total operating costs SEK -50.6 million (-39.9)• Operating result, SEK -50.5 million (-39.1)• Earnings per share before and after dilution, SEK -0.69 (-0.53)• Cash flow for the period, SEK -44.9 million (-31.1)• Cash, cash equivalents, incl securities, SEK 358.2 million (518.4) January-June 2019• Net sales, SEK 0.1 million (1.2)• Total operating costs SEK -97.3 million (-84.9)• Operating result, SEK -96.7 million (-83.1)• Earnings per share before and after dilution, SEK -1.31 (-1.12)• Cash flow for the period, SEK -79.2 million (-30.3) "The results that Janssen presented at ASCO show that ADC-1013 can be administered in considerably higher doses than any of the other CD40 antibodies in clinical development. […] The study also shows early signs of clinical efficacy”, CEO Per Norlén comments. Read the complete report in the pdf below. For further information, please contact:Per Norlén, CEO, per.norlen@alligatorbioscience.com, 046-540 82 00Per-Olof Schrewelius, CFO, per-olof.schrewelius@alligatorbioscience.com, 046-540 82 03Cecilia Hofvander, Director IR & Communications, cecilia.hofvander@alligatorbioscience.com, 046-540 82 06 This information is such information as Alligator Bioscience AB (publ) is obliged to make public pursuant to the Swedish Securities Markets Act. The information was submitted for publication, through the agency of the contact persons set out above, at 8:00 a.m. CEST on July 11, 2019. Alligator Bioscience AB (publ) 556597-8201Medicon Village, Scheelevägen 2, 223 81 Lund, SwedenPhone +46 46 540 82 00. http://www.alligatorbioscience.com About Alligator BioscienceAlligator Bioscience AB is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs. Alligator’s growing pipeline includes five lead clinical and preclinical drug candidates: ADC-1013, ATOR-1015, ATOR-1017, ALG.APV-527 and ATOR-1144. Alligator’s shares are listed on Nasdaq Stockholm (ATORX). The Company is headquartered in Lund, Sweden, and has approximately 55 employees. For more information, please visit http://www.alligatorbioscience.com. ADC-1013 (JNJ-7107) is licensed to Janssen Biotech, Inc. for global development and commercialization.

Citycon H1/2019: Stable overall performance

-Solid first half of the year-Growth in tenant sales and footfall-Net rental income and EPRA earnings continued to grow-Occupancy remained at a high level; positive leasing spread continued-Two shopping centres successfully divested during Q2/2019-Outlook specified after stable half-year performance and completed disposals APRIL—JUNE 2019 - Net rental income was EUR 56.1 million (Q2/2018: 54.3). Development project in Mölndal coming online increased net rental income by EUR 1.5 million, which was offset by planned divestments in 2018 and Q2/2019, impacting net rental income by EUR 1.1 million. Weaker currencies had an impact of EUR -0.6 million. Adoption of IFRS 16 standard increased net rental income in Q2/2019 by EUR 1.8 million in total.- EPRA Earnings excluding the one-time expenses related to organizational changes increased to EUR 39.2 million or EUR 0.220 per share. Reported EPRA Earnings increased to EUR 38.7 million (36.4) as result of higher net rental income, lower net financial expenses and the adoption of IFRS 16 standard. EPRA Earnings per share (basic) was EUR 0.217 (0.205), impact from weaker currencies was EUR -0.002 per share.- IFRS-based earnings per share was EUR 0.04 (0.00) as a result of higher net rental income and higher other operating income and expenses.- The reporting period includes the adoption of IFRS 16 from 1.1.2019 onwards. Please see Note 2 for more information. JANUARY—JUNE 2019- Net rental income was EUR 109.7 million (H1/2018: 107.6). Completed (re)development projects increased NRI by EUR 2.6 million, while divestments decreased net rental income by EUR 2.9 million and weaker SEK and NOK by EUR 1.2 million. Adoption of IFRS 16 standard increased net rental income in H1/2019 by EUR 3.5 million in total.- EPRA Earnings excluding the one-time expenses related to organizational changes increased to EUR 76.1 million or EUR 0.427 per share. Reported EPRA Earnings was EUR 74.5 million (72.5) due to higher net rental income and lower net financial expenses. EPRA Earnings per share (basic) was EUR 0.418 (0.407), negative impact from weaker currencies was EUR 0.006.- IFRS-based earnings per share was EUR 0.12 (0.11) as a result of higher net rental income, lower net financial expenses and higher other operating income and expenses.- The reporting period includes the adoption of IFRS 16 from 1.1.2019 onwards. Please see Note 2 for more information.   KEY FIGURES +------------------+----+-------+-------+------+----------------------+| | |Q2/2019|Q2/2018|% 1) |Comparable change % 3)|+------------------+----+-------+-------+------+----------------------+|Net rental income |MEUR|56.1 |54.3 |3.3 % |4.4 % |+------------------+----+-------+-------+------+----------------------+|Direct Operating |MEUR|50.7 |48.4 |4.9 % |6.0 % ||profit 2) | | | | | |+------------------+----+-------+-------+------+----------------------+|IFRS Earnings per |EUR |0.04 |0.00 |- |- ||share   (basic) 4)| | | | | |+------------------+----+-------+-------+------+----------------------+|Fair value of |MEUR|4,149.8|4,140.8|0.2 % |- ||investment   | | | | | ||properties | | | | | |+------------------+----+-------+-------+------+----------------------+|Loan to Value |% |48.9 |47.0 |4.1 % |- ||(LTV) 2) | | | | | |+------------------+----+-------+-------+------+----------------------+| | | | | | |+------------------+----+-------+-------+------+----------------------+|EPRA based key | |Q2/2019|Q2/2018|% 1) |Comparable change % 3)||figures 2) | | | | | |+------------------+----+-------+-------+------+----------------------+|EPRA Earnings |MEUR|38.7 |36.4 |6.1 % |7.7 % |+------------------+----+-------+-------+------+----------------------+|EPRA Earnings per |EUR |0.217 |0.205 |6.1 % |7.7 % ||share   (basic) 4)| | | | | |+------------------+----+-------+-------+------+----------------------+|EPRA NAV per share|EUR |12.77 |13.42 |-4.9 %|- ||4) | | | | | |+------------------+----+-------+-------+------+----------------------+   +------------------+----+--------+--------+----+-----------------------+--------+| | |Q1 |Q1 |% 1)|Comparable change % 3) |2018    || | |-Q2/2019|-Q2/2018| | | || | | | | | | |+------------------+----+--------+--------+----+-----------------------+--------+|Net rental income |MEUR|109.7 |107.6 |2.0 |3.1 % |214.9 || | | | |% | | |+------------------+----+--------+--------+----+-----------------------+--------+|Direct Operating |MEUR|98.4 |95.8 |2.7 |3.9 % |187.6 ||profit 2) | | | |% | | |+------------------+----+--------+--------+----+-----------------------+--------+|IFRS Earnings per |EUR |0.12 |0.11 |7.5 |12.3 % |0.09 ||share   (basic) 4)| | | |% | | |+------------------+----+--------+--------+----+-----------------------+--------+|Fair value of |MEUR|4,149.8 |4,140.8 |0.2 |- |4,131.3 ||investment   | | | |% | | ||properties | | | | | | |+------------------+----+--------+--------+----+-----------------------+--------+|Loan to Value |% |48.9 |47.0 |4.1 |- |48.7 ||(LTV) 2) | | | |% | | |+------------------+----+--------+--------+----+-----------------------+--------+| | | | | | | |+------------------+----+--------+--------+----+-----------------------+--------+|EPRA based key | |Q1 |Q1 |% 1)|Comparable change % 3) |2018    ||figures 2) | |-Q2/2019|-Q2/2018| | | || | | | | | | |+------------------+----+--------+--------+----+-----------------------+--------+|EPRA Earnings |MEUR|74.5 |72.5 |2.7 |4.4 % |143.5 || | | | |% | | |+------------------+----+--------+--------+----+-----------------------+--------+|EPRA Earnings per |EUR |0.418 |0.407 |2.7 |4.4 % |0.806 ||share   (basic) 4)| | | |% | | |+------------------+----+--------+--------+----+-----------------------+--------+|EPRA NAV per share|EUR |12.77 |13.42 |-4.9|- |12.95 ||4) | | | |% | | |+------------------+----+--------+--------+----+-----------------------+--------+ 1)       Change from previous year. Change-% is calculated from exact figures.2)       Citycon presents alternative performance measures according to the European Securities and Markets Authority (ESMA) new guidelines. More information is presented in Basis of Preparation and Accounting Policies in the notes to the accounts.3)       Change from previous year (comparable exchange rates). Change-% is calculated from exact figures.4)       Key ratios have been adjusted in the comparison periods to reflect the new number of shares after the reversed share split executed in March 2019. CEO F. SCOTT BALL: "Citycon’s operational performance remained solid and the total net rental income grew to EUR 109.7 million during the first half of 2019. Like-for-like net rental income grew over 2018 and we were pleased to see a stable like-for-like development in Finland after many subdued years. EPRA earnings continued to grow and the EPRA EPS reached EUR 0.418 during January-June 2019. The occupancy rate also remained stable at the high level of 95.6%. We continued to take steps to further strengthen our asset management during January-June 2019. We introduced a new organization in the first quarter of the year and the onboarding continued during the second quarter. This new organization provides consistency across the countries and enables us to intensify our asset management efforts. I am also pleased that we strengthened our team with several key recruitments during the quarter, including Erik Lennhammar, who will join our Corporate Management Committee in August 2019 as the new Chief Development Officer. He will be a great addition to our team thanks to his broad background in asset management and property development in various sectors. Together with the strengthened development team, we will begin to exploit the various densification opportunities within our portfolio. Citycon once again received recognition for the Iso Omena shopping centre during the second quarter. In April, this project was awarded the best large shopping centre expansion project in Europe by the International Council of Shopping Centres and in June, it was awarded the best shopping centre in the Nordics by the Nordic Council of Shopping Centres. Iso Omena is the prototype of the type of asset we want to own in the future. Further, these recognitions are a great acknowledgement of our strategy and of our development capabilities. In particular, the service square in Iso Omena, which combines a range of the City of Espoo’s municipal services from a library to medical services, has received praise from visitors and also several global acknowledgements. In May, we announced that a similar service square concept will be launched later this year in our shopping centre Trio in Lahti, Finland. The service square will be a great addition to the shopping centre and we are confident it will drive further footfall to the centre. It is also a great example of our intensified focus on asset management. We continued to take action to strengthen our balance sheet during January-June 2019. During the second quarter of the year, we sold two shopping centres in Finland for EUR 77 million. The disposal price was in line with the assets’ latest IFRS fair value, which demonstrates that there is investor demand for good retail assets and is a further confirmation of the stable value of our assets. In addition, we agreed to sell another land plot adjacent to our Columbus shopping centre in Helsinki, Finland during the quarter with the buyer intending to build 900 residential units which will further strengthen our shopping centre. We will continue to recycle capital going forward as our vision is to focus on multi-functional properties that are connected to public transportation in growing urban areas. We have a very stable business model with the clear majority of our leases linked to indexation. In addition, our diversified tenant mix with a relatively low share of fashion tenants, has helped us weather the headwinds the retail sector is facing. After six months of solid performance and completed disposals of two shopping centres, we have specified our guidance. We now expect EPRA EPS to be in the range of EUR 0.785-0.850 for the full year 2019.“ OUTLOOK 2019 SPECIFIED Citycon forecasts the 2019 EPRA Earnings per share (basic) to be EUR 0.785–0.850. Furthermore, the Direct operating profit is expected to be in the range of EUR 189–200 million and EPRA Earnings in the range of EUR 140–151 million. +---------------------------------+---+-----------+-----------+| | | |Previously |+---------------------------------+---+-----------+-----------+|EPRA Earnings   per share (basic)|EUR|0.785–0.850|0.775–0.875|+---------------------------------+---+-----------+-----------+|Direct operating   profit |Me |189–200 |188–206 |+---------------------------------+---+-----------+-----------+|EPRA Earnings |Me |140–151 |138–156 |+---------------------------------+---+-----------+-----------+ These estimates are based on the existing property portfolio as well as on the prevailing level of inflation, the EUR–SEK and EUR–NOK exchange rates, and current interest rates. Premises taken offline for planned or ongoing (re)development projects reduce net rental income during the year. AUDIOCAST Citycon's investor, analyst and press conference call and live audiocast will be arranged on Thursday 11 July 2019 at 10 am EEST. The audiocast can be participated by calling in and followed live on the following website: https://citycon.videosync.fi/2019-q2-results   Conference call numbers are:Participants from Europe +44 333 300 08 04Participants from the US + 185 585 706 86PIN: 48783109# For more investor information, please visit the company’s website at www.citycon.com.Helsinki, 10 July 2019Citycon OyjBoard of DirectorsFor further information, please contact:Eero SihvonenExecutive VP and CFOTel. +358 50 557 9137eero.sihvonen@citycon.com Mikko PohjalaIR and Communications DirectorTel. +358 40 838 0709mikko.pohjala@citycon.com Citycon is a leading owner, manager and developer of urban, grocery-anchored shopping centres in the Nordic region, managing assets that total almost EUR 4.5 billion. Citycon is No. 1 shopping centre owner in Finland and among the market leaders in Norway, Sweden and Estonia. Citycon has also established a foothold in Denmark.Citycon has investment-grade credit ratings from Moody's (Baa3) and Standard & Poor's (BBB-). Citycon Oyj’s share is listed in Nasdaq Helsinki.www.citycon.com 

First Person Lightning Roulette and Dream Catcher join Evolution’s RNG games range

Both of these First Person games are RNG-based versions of acclaimed and award-winning Evolution live games. The live dealer version of Evolution’s Lightning Roulette won three Game of the Year awards in 2018. The company’s Dream Catcher game, a spinning money wheel with a live presenter, was named Digital Product of the Year in the Global Gaming Awards at G2E Las Vegas 2017. Now the new First Person versions of both games are available to online casino operators looking to add something distinctly different to their RNG games line-ups. In First Person Lightning Roulette the game action centres on a super-realistic animated Roulette table in an electrifying setting with lightning effects. In every game round, one to five randomly generated Lucky Numbers are struck by lightning and have random prize multipliers of between 50x and 500x applied. First Person Dream Catcher, meanwhile, is an extremely easy to play game based on the large, vertical, multi-segment spinning wheels as seen in land-based casinos. Players simply bet on the number segment on which they think the wheel will stop. Adding to the excitement are the 2x and 7x prize multiplier segments on the wheel. A key feature in both games is the unique ‘Go Live’ button, present in the User Interface of every Evolution First Person game. One touch of the button and the player is transported from the First Person game through an in-game portal to the live version of the game. That transition is made as seamless as possible as the First Person and live versions of each game have the same rules and easy-to-use Evolution UI. Todd Haushalter, Chief Product Officer at Evolution, commented, “Our First Person Gaming range continues to leverage the latest technology to help our licensees build player loyalty across their entire online casino games offering.” He added: “All Evolution First Person titles are great games in their own right with superior animation and gameplay. But with the ‘Go Live’ button these games go far beyond conventional RNG games. That button is a way of very easily taking players into the hugely entertaining world of Evolution Live Casino, a world that offers so much more than classic Live Casino table games.”

Eyeonid Group AB (publ) signs an exclusive cooperation agreement whit Sinew Software Systems Pvt Ltd regarding their Password Manager, Enpass

As part of being able to offer the most complete and best service offering to our partners in what is called ID-security, Eyeonid have been evaluating several password managers for its customer friendliness as well as the technology behind to find and add such a module into Eyeonids customer offering. The Enpass Product is in fact more than a regular password manager where you as a user in a safe and secure way can add your passwords. In fact, it’s a secure vault where you can store sensitive digital PII data as well as other sensitive digital data such as passwords, credit card information, passport information, digital documents etc. In addition to storing sensitive digital data the Product contains several well developed and smart additional features. The Product also meet the strict requirements by Eyeonid on compliance, highly innovative features as well as required security methodology. Important note is that the Product application as well as all data being added by the user is saved and stored locally on your computer, tablet, smartwatch or mobile phone and not in the cloud. The cooperation- and distribution agreement consists of: ·  Eyeonid have the right to offer and distribute the Product as a non White-Label and White-Label Product to partners globally. ·   Eyeonid have the exclusive right on the European market to offer and distribute the Product as a non White-Label and White-Label Product to partners. ·  The EyeOnPASS (password check) service shall be implemented in the Product to partners of Eyeonid. ·  The Parties looks at the possibilities of integrating EyeOnPASS in the Product for all of Enpass users and were a PoC (Proof of Concept) have verified that the EyeOnPASS service generates a higher result of hits than the current solution (the database of leaked password in EyeOnPASS is bigger). ·  As part of the cooperation the Parties will jointly work to assess the opportunities of integrating other ID- and security related features from the parties in its respective product offerings. The financial terms of the cooperation agreement are built on Revenue Share models, meaning that the Parties will receive a revenue share of either the revenue paid by the Eyeonid partner or the revenue generated directly from an end user. The terms of the main agreement are two years and will be prolonged with an additional one year a sender if not terminated by either party. For each new Eyeonid partner a customer addendum will be added to the main agreement. The customer addendums agreement period overrules the main agreement and outlive the main agreement if main agreement is terminated before a customer addendum period has come to an end. Eyeonid is entitled to revenue share over 3 years on revenue generated from previous Eyeonid partner users who after the service period with the partner have decided to continue to buy the Product directly from Enpass. The parties will now implement the integration between the parties’ systems alongside that Enpass prepares for a major release of the Product during late fall, that also entails a changed offering model of its Product. The planed “go live” dates are set year end 2019 for the non White-Label offering and by the latest February 2020 for the first White Label launch. ” After some time now, we have seen a success for our product Enpass in the market, that has shown a steady growth of new users, we see this new cooperation as yet another important step to a faster advance our position in the market. Beside the fact that the agreement can generate a large number of new users, the agreement will also enable new integration and innovations between the companies that are equally interesting. We look forward to an exciting cooperation and a long-term business relationship”, says Hemant Kumar, CEO Sinew Sofware Systems Pvt Ltd. ”It feels very good to have closed this agreement. For me EyeOnID is an innovation company working with our own developed solutions as well as with partners and together we build new smart future proof and business relevant solutions for the market. The cooperation with Enpass is a very good example how we drive this kind of innovation work. The agreement signed today is also the foundation for further possibilities to offer EyeonID’s services through Enpass globally. Furthermore, this will open up for new offerings and packaging towards new target groups with in primarily the B2B market for business customers. We have now come to the phase were we really offer a true end-to-end solution for our partners. Within our industry we have not yet identified anyone else with the capacity or capability to provide the same. Our offer today reaches from proactive ID-monitoring, where we can monitor over 100 connected PII (Personally Identifiable Information) assets (E-mail, Passwords, Credit card numbers, Personal ID numbers, IP-addresses, Phone numbers etc etc.), several ”360 Moules”, Password Vault, insurance, assistance services as well as payment solutions. All this packaged under white label via API or a cloud-based Portal where EyeOnID as the enabler offer partners a connection to all services. The team led by Daniel Söderberg, as RnD responsible, have ensured that we have reached a very strong solution and commercial agreement and I’m very proud over the job delivered, Patrik Ugander, CEO Eyeonid Group AB (publ). For any further information, please contact:   Patrik Ugander, CEO Eyeonid Group AB (publ)Phone: +46 705 440 168Mail: patrik.ugander@eyeonid.com  Eyeonid was founded in 2014 and has since its inception developed a technically complex and advanced platform for proactive ID protection services. The company's service monitors and alerts customers when sensitive, private and corporate digital information, such as login credentials, credit card numbers and social security numbers, are found at unauthorized sites on the internet, whereupon the customer can act and protect himself.   This information is information that Eyeonid Group AB (publ) is obliged to disclose under the EU Market Abuse Regulation. The information was provided, through the contact of the above contact person, for publication on July 11, 2019.  

BillerudKorsnäs first to produce paper battery on a paper machine

In collaboration with researchers at Uppsala University, basic research has been developed to be able to use ordinary paper fibers for the manufacturing of batteries.The first production has now been carried out on a paper machine. This has been done at the dedicated pilot machine FEX at RISE, Research Institutes of Sweden. It is an important step forward that confirms the possibility of industrial production of the electrode material.-This is a big step for us, seeing a concept born in test tubes now running on a big paper machine, says Maria Strømme, Professor of Nano-technology at the Department of Engineering Sciences, Nanotechnology and Functional Materials at Uppsala University.The battery material is now ready for commercial testing. BillerudKorsnäs continues to work on identifying possible partners in energy storage and other electrochemical applications. The next step is further product development in-house and with partners, for production on an industrial scale.- We are really happy to be part of the project. It has been an interesting challenge for us that shows the value of the pilot machine in scaling up bio-based concepts, says Konstantin Sundin, Vice President Papermaking and Packaging at RISE.- Confirming run-ability on a paper machine is an important milestone for production of the forest based Paper Battery electrode. The pilot production confirms that we can produce the material really effectively and in big scale, says Lars Sandberg, Innovation Leader at BillerudKorsnäs.There are several potential applications of the paper battery. One is within Internet of Packaging, that is, digitization of packaging. Intelligent and active packaging provides sustainable solutions that create and protect products and also offers new experiences for consumers. Another application is large-scale and cost-effective energy storage in the smart grids field.       For further information, please contact:Lars Sandberg, Innovation Leader BillerudKorsnäs, +46 (0) 706 44 17 39 lars.sandberg@billerudkorsnas.comAnna Helsén, Head of Press, +46 (0) 70 698 48 58 anna.helsen@billerudkorsnas.com          (anna.helsen@billerudkorsnas.com)BillerudKorsnäs provides packaging materials and solutions that challenge conventional packaging for a sustainable future. We are a world-leading provider of primary fibre based packaging materials and have customers in over 100 countries. The company has 8 production units in Sweden, Finland and the UK and about 4500 employees in over 13 countries. BillerudKorsnäs has an annual turnover of about SEK 24 billion and is listed on Nasdaq Stockholm. www.billerudkorsnas.com

Bioservo has entered distribution agreement for selling the all-new Ironhand® in France

Bioservo Technologies AB (publ) (Nasdaq First North: BIOS) has entered an exclusive distribution agreement for selling the all-new Ironhand® with GOBIO, a brand of EUROPE TECHNOLOGIES Group, for the French market. Within EUROPE TECHNOLOGIES, GOBIO has a management team and sales forces in place that have already gained experience in successfully selling exoskeletons for industrial applications and are well connected with relevant customers in France that fit the Bioservo commercialization strategy. Petter Bäckgren, CEO Bioservo, commented: "We gladly welcome GOBIO to our broad set up in France as we are establishing distribution networks throughout Europe and the US. We now enter into agreements with experienced organizations that with the help of their vast networks will be great partners when marketing the all-new Ironhand® on their respective markets.” Patrick Cheppe, CEO EUROPE TECHNOLOGIES, commented: “As a recognized leader of exoskeletons promotion and distribution in France for a broad set of industry segments, we are carefully selecting the best and most mature product solutions in order to provide our end-customers with a broad portfolio. We are proud to become a strong partner of Bioservo as we are convinced of the added value and benefits of the all-new Ironhand®. Bioservo has previously entered an exclusive agreement in France with Loxam for renting out the all-new Ironhand®. This rental scheme was launched primarily to Eiffage and will be available throughout France for other companies from all industries and sectors. Discussions are ongoing with distributors for additional markets and additional agreements are expected during 2019. About Ironhand®Bioservo’s soft robotic muscle strengthening system Ironhand® comprises a lightweight glove with a portable power pack worn like a backpack. Ironhand® can add up to 80 N to the wearer’s grip within milliseconds. In addition to that, it is equipped with smart data capabilities which makes it possible to digitalize ergonomic risk assessment as well as provide an adaptive performance to the operator over time. At the same time as it supports the wearer, it collects and analyzes data making it possible to evaluate and identify grip intense use cases that run a high ergonomic risk. The wearer is in full control of the system which helps to create a healthy and sustainable work environment. About GOBIOGOBIO is a trademark of the EUROPE TECHNOLOGIES group based in Nantes (France). GOBIO distributes a complete range of exoskeletons and produces its own zero gravity arms. Its solutions are aimed at the manufacturing, mechanical, agri-food, transport, infrastructure, public works, and logistics industries. The brand has among its customers well-known references such as RENAULT, ST MICHEL, VINCI, DECATHLON, etc.WEBSITE:  www.gobio-robot.com  About EUROPE TECHNOLOGIESCreated in 1992, EUROPE TECHNOLOGIES is private company today composed of nearly 350 employees for a turnover of 63M €. Dedicated to the manufacturing industry (aerospace, naval, defense, automotive, agri-food, etc.) the group offers, through its subsidiaries, the industrialization and manufacture of metal and composite parts, the design and production of robotic cells and customized machines integrating its own processes (parts finishing, cutting, welding, etc.) and finally international MRO services. Located in France with multiple facilities, EUROPE TECHNOLOGIES also has a subsidiary in the USA (Alabama) and a subsidiary in CHINA (Hangzhou). The French subsidiaries of the group are: GEBE2 PRODUCTIQUE - ORATECH INNOVATION – SERVISOUD - SONATS and SONIMAT.WEBSITE: www.europetechnologies.com About Bioservo TechnologiesBioservo Technologies (publ) is a technology and development company that combines medical science with modern robotics. The company holds a leading global position within soft exoskeleton technology – wearable non-invasive devices – for people in need of extra power to optimise the body’s endurance and performance, or for people with reduced muscle strength. After many years of research and development, Bioservo Technologies is now focused on a commercialisation of the company’s products and patented technologies. The gloves are well-suited to medical rehabilitation, and to preventive use in a variety of industrial applications. The company has signed strategic cooperation agreements with several multinational companies within e.g. the automotive, aviation as well as the construction and infrastructure industry. Bioservo Technologies was founded in 2006 through a collaboration between researchers at the Royal Institute of Technology and doctors at Karolinska University Hospital in Stockholm. Bioservo Technologies is a Swedish public limited company with its headquarters and operations based in Kista, north of Stockholm. FNCA Sweden AB, +46(0)8-528 00399, info@fnca.se, is the company’s Certified Adviser on Nasdaq First North. To learn more, please visit www.bioservo.com. For more information, please contact: Petter BäckgrenCEOTel.: +46 (0)8 21 17 10petter.backgren@bioservo.com Anett Grusser-PetterssonInternational Business DevelopmentTel.: +46 (0)8 21 17 10anett.pettersson@bioservo.com

TagMaster owned Balogh receives a further order on their new SIL 4 product platform

Press release, Stockholm, July 11, 2019 TagMaster, the leading supplier of advanced sensor systems for Smart Cities within Traffic and Rail, has, through its subsdiary Balogh SA, received an order for an American metro project. Balogh is one of the real pioneers in the RFID technology and was founded in 1958. Balogh today has offices for development and production in Paris, in Toulouse and in Normandie and works within the two RFID segments Rail and Access/Security (Traffic). The order comprises the new product range of MOS200/OMS201 (SIL4) products that have been finalized since TagMaster acquire the company. SIL4 (Safety Integrity Level) is the highest level of risk reduction that can be obtained through a Safety Instrumented Function/System. Prior to this order Balogh have also begin deliveries of this product range to another American project and recently to a European project. This second American order gives a strong reference for future orders. The products will be delivered during first half of 2020 and the total order value is approximately € 300 000.The customer is a one of the major global actors in signaling systems. ”TagMaster has earlier expressed its enthusiasm for the Balogh acquisition and this orders confirms that our ambition that, together with Balogh, become a stronger supplier within Rail solutions is materializing. We together have a wider product offering and we will together become one of the leading actors in train signaling” says Jonas Svensson, CEO, TagMaster. For further information please contact: Jonas Svensson, CEO, +46 8-6321950, jonas.svensson@tagmaster.com   This information is information that TagMaster AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 9.00 CET on July 11, 2019.  About TagMaster TagMaster is an application driven technology company that designs and markets advanced sensor systems and solutions based on radio and vision technology (RFID, Radar and ANPR) for demanding environments. Business areas include Traffic Solutions and Rail Solutions sold under the brands TagMaster, CitySync, Balogh, CA Traffic, Magsys, Hikob and Sensys Networks with innovative mobility solutions in order to increase efficiency, security, convenience and to decrease environmental impact within Smart Cities. TagMaster has dedicated agencies in the US and in China and exports mainly to Europe, The Middle East, Asia and North America via a global network of partners and systems integrators. TagMaster was founded in 1994 and has its headquarters in Stockholm. TagMaster is a public company and its shares are traded on First North stock exchange in Stockholm, Sweden. TagMasters certified advisor is Erik Penser Bank phone +4684638300, E-mail: certifiedadviser@penser.se www.tagmaster.com  

Trelleborg acquires engineering group and becomes a system provider for the fast-growing LNG transfer segment

Trelleborg has, through its Trelleborg Industrial Solutions business area, signed an agreement and finalized the acquisition of the engineering group Signum Technology Ltd. The group delivers safety critical solutions for flow control for the oil, gas and petrochemicals industries, such as marine breakaway couplings and LNG transfer systems. The acquisition complements and extends Trelleborg’s product portfolio and strengthens Trelleborg as a system provider, primarily to the fast-growing LNG transfer market segment. The group is headquartered in Wiltshire, England, with manufacturing in the U.K., and service centers globally. Sales totaled approximately SEK 410 M in 2018. This bolt-on acquisition is part of Trelleborg’s strategy to strengthen its positions in attractive market segments. “We are very pleased to announce the acquisition of Signum. Combined, we are creating a very attractive offering of integrated packages and safety critical systems for both LNG ship-to-ship and ship-to-shore transfer in demanding industries. Signum has a reputation for quality and innovation, very much like Trelleborg. This acquisition will also further strengthen our geographic coverage notably in the aftermarket and service business, hence a really good fit for us in many aspects,” says Jean-Paul Mindermann, President of the Trelleborg Industrial Solutions business area. The transaction will be consolidated as of July 10, 2019. 

Nordstjernan’s subsidiary Etac invests in HoverTech, a US patient handling company

Nordstjernan’s wholly-owned subsidiary Etac has made an investment in 70 percent of the shares in the US company HoverTech International (“HoverTech”). The investment strengthens Etac’s global position and will create a strong platform for further growth in Europe, the US and important export markets. Etac is a global supplier of mobility equipment and solutions used in home care, long term care and acute care. Etac’s sales in 2018 amounted to approximately SEK 1,750 million and the company has just over 900 employees. Etac’s products include manual wheelchairs, patient handling equipment, bathing and toileting aids, pressure care products as well as a specialized range of mobility equipment for children and adolescents. The head office is located in Sweden with manufacturing and R&D units in Europe and North America. HoverTech is a US leader in air-assisted patient handling technologies, focusing on devices for lateral transfer and repositioning. The company’s sales in 2018 totalled approximately USD 100 million. The company is owned by its founder Dave Davis and family, and is based in Allentown, Pennsylvania. “The investment in HoverTech represents an acceleration of Etac’s growth and is in line with Nordstjernan’s ambition to create and further develop qualitative companies in healthcare and medtech. As a result of the acquisition, Etac is aspiring to become Nordstjernan’s largest single holding”, says Nordstjernan’s CEO Peter Hofvenstam. “The investment in HoverTech is a game-changer for Etac. It represents much greater exposure toward the US and creates a platform to accelerate growth in the region. The substantial cross sales potential strengthens Etac’s global position as a supplier of patient handling equipment”, says Etac’s chairman Nora Larssen. “We are very pleased to have Etac and thereby Nordstjernan as the majority shareholder in HoverTech. Nordstjernan and Etac have a long term growth oriented focus which is a great fit with HoverTech. Together with Etac we look forward to continue our growth journey and expand internationally and take HoverTech to the next level”, says Dave Davis, founder and CEO of HoverTech. Nordstjernan has in recent years actively invested in the care, healthcare and medtech sector, and today holdings within this sector account for almost 20 percent of Nordstjernan’s net asset value. Nordstjernan has a long tradition as an active shareholder in listed and private companies. Nordstjernan was founded in 1890 and the company’s major shareholders are the Axel and Margaret Ax:son Johnson Foundations. The shares in HoverTech have been transferred to Etac as of June 26. The parties have agreed not to disclose the terms of the transaction.   Peter HofvenstamPresident and CEONordstjernan AB   Questions will be answered by: Peter Hofvenstam, CEO, NordstjernanE-mail: peter.hofvenstam@nordstjernan.se Stefan Stern, Head of Communications, NordstjernanTelephone: +46 70 636 74 17E-mail: stefan.stern@nordstjernan.se   (stefan.stern@nordstjernan.se) Nordstjernan is a family-controlled investment company whose business concept is to be an active owner that creates long-term value growth. More information about Nordstjernan can be found on www.nordstjernan.se.

Climeon one of 100 innovations with greatest potential to reduce carbon dioxide emissions

In 2015, more than 190 countries agreed to adopt Agenda 2030, the most ambitious agreement for sustainable development that world leaders have ever made. With these global goals, the world's leaders have committed to achieving three things by 2030; to abolish extreme poverty, to reduce inequalities and injustices in the world and to solve the climate crisis. Solving the climate crisis requires new innovations within sustainable energy and therefore, Mission Innovation was launched to dramatically accelerate global innovation within clean energy. Mission Innovation consists of 24 countries and the European Commission, on behalf of the European Union, seeking to dramatically accelerate global clean energy innovation. The countries partaking in Mission Innovation represent 60% of the world’s population, 70% of GDP, and 80% of government investment in clean energy research.  Mission Innovation is also the initiator of the 1.5°C Compatible Solutions Framework which aims to help public and private investors find the technologies that have the greatest potential to tackle climate change and limit the global temperature increase to 1.5 degrees Celsius, in alignment with the Paris Agreement and the IPCC 1.5 C special report. At the ministerial gathering, Mission Innovation 4, in Vancouver in May 2019, the 1.5°C Compatible Solutions Framework was presented together with the 100 innovative solution providers with the greatest potential to reduce carbon dioxide emissions. One of the solutions was Climeon’s Heat Power technology that converts waste heat and geothermal heat into clean electricity. - Climeon was founded out of a drive to fight climate change, so to be elected as one of the solutions that can help the world reach the crucial 1.5°C target feels fantastic, says Thomas Öström, CEO of Climeon. - We are proud to be selected as part of the 1.5°C Compatible Solutions Framework and have the potential of our technology recognized by Mission Innovation. This also shows that international policy makers believe that Climeon has the potential to significantly contribute to reducing carbon dioxide emissions and fighting climate change, says Thomas Öström, CEO of Climeon. The 100 solutions will each have the potential to reduce carbon dioxide emissions by 10 million CO2e, or more, by 2030, or be of strategic importance. Read more about Mission Innovation and the 1.5°C Compatible Solutions Framework on https://www.misolutionframework.net.  For additional information, please contact:  Thomas Öström, CEO of Climeon+46 70 894 96 05Thomas.ostrom@climeon.com Charlotte Becker, Head of Investor Relations & PR+46 730 37 07 07charlotte.becker@climeon.com About Climeon AB (publ)Climeon is a Swedish product company within energy technology. The company’s unique technology for geothermal heat power - Heat Power - makes a large untapped energy resource available and provides sustainable electricity around the clock all year round. Heat Power is a cheap and renewable energy source with the potential of replacing much of the energy that comes from coal, nuclear, oil and gas, today. Climeon aims to become a global leader and the world's number one climate solver. The B share is listed on Nasdaq First North Premier. Certified Adviser is FNCA Sweden AB, +46(0)8-528 00 399, info@fnca.se. 

STENOCARE receives new information from CannTrust that causes immediate quarantine on sales of products from current inventory

Early this morning, STENOCARE received new and more detailed information from CannTrust which indicates that most, yet not all, of the CannTrust products that STENOCARE has in inventory and that STENOCARE has supplied to the Danish market since June 10, 2019 were cultivated in the production rooms at CannTrust that were not approved at the time of production (between October 2018 and March 2019). As a result of the new information, all products delivered from STENOCARE relating to the batches in question will be put in quarantine, which means that they will be isolated and blocked from being sold until the Canadian health authorities, Health Canada and the Danish Medicines Agency have concluded in the matter. The most likely consequences from this new situation is that there will be a temporary shortage of medical cannabis products to the Danish market. This will have negative financial consequences to STENOCARE irrespective of the fact that CannTrust is contractually committed to deliver fully licensed and approved products to STENOCARE. This matter relates to a total of 5 batches, of which STENOCARE was first informed of one, that were produced during the period from October 2018 and March 2019 in 5 new production rooms at CannTrust that were not yet approved by the Canadian authorities. All products delivered by CannTrust before and after are unrelated to this matter and CannTrust has been producing fully approved products from all of its facilities since April 2019. It is important to stress, that all products supplied from CannTrust have been tested for all the required quality standards, and independent third party Lab analysis has documented this prior to receiving the products into the STENOCARE warehouse in Denmark. Irrespective of that, STENOCARE considers this matter with utmost severity and is in close dialogue with the Danish Medicines Agency to secure that all necessary actions are taken. This information is information that STENOCARE A/S is obliged to publish in accordance with the EU Market Abuse Regulation. The information was provided by the contact person above for publication on July 11, 2019.

Press release: Nel launches the A1000 electrolyzer

Nel Hydrogen Electrolyser, a subsidiary of Nel ASA, today officially launched the A1000 alkaline electrolyzer “After working with large-scale solutions for our alkaline electrolyzers, we have now designed a new medium scale, 2 ton/day solution. It is a pleasure to now officially include this product in our electrolyzer offering,” says Anders Søreng, CTO of Nel. The A1000 builds on the industry leading A-Range atmospheric alkaline platform, and comes in the size range of 600 to 970 Nm3/hr, allowing for flexible scale-up according to customer demand. “We are paying close attention to our customer needs, and are already experiencing significant interest for this solution in the market. With the A1000, we are offering the same robustness and reliability of our conventional A-Range units, but with a lower cost for medium-scale needs," says Luc Graré, VP Sales and Marketing in Nel. Visit our website for specifications of the A1000.   For more information about Nel alkaline electrolyzers, please contact Luc Graré, VP Sales and Marketing, lugra(at)nelhydrogen.com, +32 479981755 ENDS About Nel ASA | www.nelhydrogen.com     Nel is a global, dedicated hydrogen company, delivering optimal solutions to produce, store and distribute hydrogen from renewable energy. We serve industries, energy and gas companies with leading hydrogen technology. Since its origins in 1927, Nel has a proud history of development and continual improvement of hydrogen plants. Our hydrogen solutions cover the entire value chain from hydrogen production technologies to manufacturing of hydrogen fueling stations, providing all fuel cell electric vehicles with the same fast fueling and long range as conventional vehicles today.

CELLINK has been granted a patent for "Clean chamber technology for 3D Printers and Bioprinters" from the Korean Intellectual Property Office

CELLINK has been granted a patent for a unique technology enabling bioprinting in a clean environment. The patent protection applies to the Korean market, the company also conducts the process of expanding patent protection in additional countries. The patent protection from the Korean Intellectual Property Office shows uniqueness and height of innovation. This technology is used in CELLINK’s flagship bioprinter the BIO X and the INKREDIBLE+ to enable true desktop printing and ensuring sterility during the printing process. “We are extremely excited to have another granted patent for our revolutionary technology platform. As a globally recognized leader in the field, it is essential for us to protect our technologies so that we can continue to offer the most innovative solutions to our customers and collaborators around the world. The Clean Chamber Technology is a unique, value adding feature that ensures that the printing environment inside the Bioprinter is kept sterile so that the user can reduce the risk of contaminations and protect the precious cells during the printing process.”- Erik Gatenholm, CEO The granted patent strengthens the company's protection for intellectual properties and is in line with the company's strategy to protect core technologies within the field. The company is in a phase where great focus is on the development of innovative solutions to enable printing of various tissues and organs. For further information, please contact: Erik Gatenholm, CEO                                                                       Gusten Danielsson, CFO Phone: EU +46 73 267 00 00                                                          Phone: +46 70 991 86 04US +1 (650) 515 5566                                                                     US +1 (857) 332 2138  Email: eg@cellink.com                                                                     Email: gd@cellink.com Important information This information is such information as CELLINK AB is required to disclose under the EU Market Abuse Regulation. The information was submitted for publication on July 11, 2019 at. 11:50 CET. About CELLINK CELLINK  is the leading 3D bioprinter provider and the first bioink company in the world. We focus on developing and commercializing bioprinting technologies to allow researchers to print human organs and tissues for pharmaceutical and cosmetic applications. Founded in 2016 and active in more than 50 countries, CELLINK is changing the future of medicine as we know it. Visit www.cellink.com to learn more. CELLINK is listed on Nasdaq First North under CLNK. Erik Penser Bank AB is the company’s certified adviser, available by phone at +46 846 383 00 and by email at certifiedadviser@penser.se. at: certifiedadviser@penser.se.

Invitation to Kongsberg Automotive's Q2 2019 Earnings Call

Kongsberg Automotive ASA will release its second quarter 2019 results on Friday July 26th 2019 at 07:30 am CET. The company will host an earnings conference call for investors, analysts and media at 09:00 CET, on July 26th, which will include a review of the Q2 2019 presentation. After the review, listeners can ask questions to the presenters.   The Q2 earnings conference call will be available via web and audio, and to access the audio webcast please select one of the options below: 1. Web access: Link: https://globalmeet.webcasts.com/starthere.jsp?ei=1231903&tp_key=fb96795a80 2. Audio only access: (apply confirmation code: 319050) Austria, Vienna +43 (0)1 9289 266Canada, Toronto +1 647 484 0477China 4001 209101Denmark, Copenhagen +45 35 15 80 49Germany, Frankfurt +49 (0)69 2222 13420Germany, Munich +49 (0)89 20303 5709India, Delhi +91 (0)11 7127 9040Ireland, Dublin +353 (0)1 246 5638Japan, Tokyo +81 (0)3 4563 4401Mexico, Mexico City +52 55 4164 4815Netherlands, Amsterdam +31 (0) 20 721 9251Norway, Oslo +47 2100 2610Poland, Warsaw +48 (0)22 206 9996Russian Federation, Moscow +7 495 213 1767Singapore, Singapore +65 6320 9025Slovakia, Bratislava +421 (0) 2 5011 2130Spain, Madrid +34 91 114 7293Sweden, Stockholm +46 (0)8 5033 6574Switzerland, Geneva +41 (0)22 567 5729Switzerland, Zurich +41 (0)44 580 7206United Kingdom, Local +44 (0)330 336 9105United States, Los Angeles +1 323-794-2597Other Locations +44 (0)330 336 9105

Redsense Medical comments on the Trump initiative - potential impact on Redsense's business

President Trump will outline proposals to keep people with kidney disease off dialysis longer and to make treatment less expensive, to encourage more live donation of kidneys and livers, and to force the 58 non-profits that collect transplant organs to improve their performance, people briefed on the plan said. The President also will try to reduce the discarding of less-than-perfect organs by transplant surgeons. ‘At Redsense Medical, we are committed to creating sustainable and long-term value for all our stakeholders. Sharing of organs is becoming an important way to help patients, implementing the actual organ donation effectively is a challenging process for all involved. To improve patient safety is our priority and by this initiative, we see potential impact of expanding our presence in the US.’ says Patrik Byhmer CEO of Redsense Medical. Jane Hurst, Clinical Director, Redsense Medical, US continues, ‘In the executive order, The Center for Medicare and Medicaid Innovation has been instructed to experiment with new approaches to provider payment. By focusing on a more comprehensive approach to kidney health, the administration may actually improve care at every stage.’ https://www.stripes.com/news/us/trump-to-order-overhaul-of-organ-transplant-kidney-dialysis-systems  https://www.vox.com/future-perfect/2019/7/10/20687507/triump-kidney-disease-transplant 

Nordic Nanovector completes patient enrolment into Phase 1 trial of Betalutin® in diffuse large B-cell lymphoma (DLBCL)

Oslo, Norway, 11 July 2019 Nordic Nanovector ASA (OSE: NANO) announces that the final patient has been enrolled in the LYMRIT 37-05 clinical trial of Betalutin® (177Lu-satetraxetan-lilotomab) in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) not eligible for stem cell transplantation. The LYMRIT 37-05 study is a Phase 1 open-label, single-arm, dose-escalation study designed to assess the safety, tolerability, pharmacokinetic profile and preliminary anti-tumour activity of a single administration of Betalutin®. Patients were enrolled at clinical trial sites in the US and Europe. More information on this study can be found at www.clinicaltrials.gov (NCT02658968). Preliminary results are expected in the second half of 2019. DLBCL is an aggressive form of non-Hodgkin’s Lymphoma (NHL) that accounts for up to 43% of all NHL cases, making it the most common form of the disease. Approximately 40% of DLBCL patients relapse after first-line combination treatment with rituximab and chemotherapy and only 30-40% of relapsed patients respond with subsequent high-dose chemotherapy followed by Stem Cell Transplantation (ref. 1 below). There are currently very few therapeutic options for patients not eligible for SCT, which makes relapsed DLBCL a serious unmet medical need. The number of diagnosed cases of DLBCL in the US and Europe in 2016 was 26,500 and 17,200, respectively. These numbers are expected to reach 31,500 (US) and 19,000 (Europe) by 2024 (ref. 2 below). Lisa Rojkjaer, Chief Medical Officer at Nordic Nanovector, said: “We are delighted to have reached this important milestone and look forward to the preliminary results during the second half of the year. Planning is underway for an expansion cohort to further assess safety and efficacy in this challenging to treat patient population. We expect more patients to be enrolled when the best dose is selected from the first part of the study.” References 1. L.S. Raut and P. P. Chakrabarti: Management of relapsed-refractory diffuse large B cell lymphoma (2014) South Asian J. Cancer 3(1): 66–70 2. Non-Hodgkin’s Lymphoma (2015) Decision Resources For further information, please contact: IR enquiries Malene Brondberg, VP Investor Relations and Corporate Communications Cell: +44 7561 431 762 Email: ir@nordicnanovector.com International Media Enquiries Mark Swallow/David Dible (Citigate Dewe Rogerson) Tel: +44 207 638 9571 Email: nordicnanovector@citigatedewerogerson.com About Nordic Nanovector Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs and advance cancer care. The Company aspires to become a leader in the development of targeted therapies for haematological cancers. Nordic Nanovector's lead clinical-stage candidate is Betalutin®, a novel CD37-targeting radioimmunotherapy designed to advance the treatment of non-Hodgkin's lymphoma (NHL). NHL is an indication with substantial unmet medical need, representing a growing market forecast to be worth nearly USD 29 billion by 2026. Nordic Nanovector intends to retain marketing rights and to actively participate in the commercialisation of Betalutin® in core markets. Further information can be found at www.nordicnanovector.com Forward-looking statements This press release contains certain forward-looking statements. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances, since they relate to events and depend on circumstances that will occur in the future and which, by their nature, will have an impact on Nordic Nanovector's business, financial condition and results of operations. The terms "anticipates", "assumes", "believes", "can", "could", "estimates", "expects", "forecasts", "intends", "may", "might", "plans", "should", "projects", "targets", "will", "would" or, in each case, their negative, or other variations or comparable terminology are used to identify forward-looking statements. These forward-looking statements are not historic facts. There are a number of factors that could cause actual results and developments to differ materially from those expressed or implied in the forward-looking statements. Factors that could cause these differences include, but are not limited to, risks associated with implementation of Nordic Nanovector's strategy, risks and uncertainties associated with the development and/or approval of Nordic Nanovector's product candidates, ongoing and future clinical trials and expected trial results, the ability to commercialise Betalutin®, technology changes and new products in Nordic Nanovector's potential market and industry, Nordic Nanovector's freedom to operate (competitors patents) in respect of the products it develops, the ability to develop new products and enhance existing products, the impact of competition, changes in general economy and industry conditions, and legislative, regulatory and political factors. No assurance can be given that such expectations will prove to have been correct. Nordic Nanovector disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. This information is subject to a duty of disclosure pursuant to Section 5-12 of the Securities Trading Act.

University Hospital Tübingen delivers 1,000th fraction with its Elekta Unity MR-Linac

TÜBINGEN, Germany – Less than one year after installing its Elekta Unity magnetic resonance radiation therapy (MR/RT) system, the team of clinicians at University Hospital Tübingen in Germany have delivered their 1,000th radiation therapy fraction to a patient receiving treatment for prostate cancer. Many radiation therapy regimens divide the total radiation dose into two or more smaller doses, known as fractions, which are delivered in separate treatment sessions. The 1,000th fraction represents the 1,000th treatment session delivered with Elekta Unity. “Achievement of this milestone by University Hospital Tübingen in such a short time demonstrates that Unity can be efficiently used to personalize treatments for many patients,” said Richard Hausmann, CEO at Elekta. “Importantly, these fractions have been used to treat nine different cancer indications, demonstrating the broad therapeutic potential of the system. We are proud to continue collaborating with clinicians and researchers to further enable precision radiation medicine.” Elekta Unity combines two technologies: a state-of-the-art 1.5T MRI scanner and a best-in-class 7 MV linear accelerator, driven by breakthrough real-time adaptive radiotherapy software. It provides the ability to reshape the dose based on daily changes in shape, size and position of the tumor and surrounding healthy anatomy, as visualized with MRI, and then enables accurate dose delivery with real-time visualization of the tumor.  “At University Hospital Tübingen, we recognized that integrating online, real-time diagnostic quality MR images with linac-based radiation delivery was essential to advancing radiotherapy,” said Professor Dr. Daniel Zips, Medical Director, of University Hospital Tübingen’s Comprehensive Cancer Clinic. “The excellent imaging quality of Elekta Unity has enabled us to adapt each patient’s treatment in real time, which allows already today optimal sparing of normal tissues and potentially in the future to individualize the dose to the tumor. The ability to visualize and adapt what we treat makes Elekta Unity an important new treatment option for a wide variety of cancer indications, including hard-to-treat cancers and complex anatomies previously considered not optimal for radiation therapy.” In addition to University Hospital Tübingen, nine other leading cancer centers with Unity are treating patients with similar success. To learn more, visit elekta.com/Unity . Elekta Unity has CE mark and 510(k) clearance but is not available in all markets. # # #

Results on the IMMray™ PanCan-d optimization study to be presented at PancreasFest 2019

LUND, SWEDEN - Immunovia AB (publ) (“Immunovia”) today announced that, following the breakthrough news that was announced in June (link to PR ), the additional, more detailed data of the optimization study will be presented at the PancreasFest 2019, July 24-26 in Pittsburgh, US. PancreasFest 2019 is a major annual meeting of pancreas physicians and translational researchers. The results demonstrated that the IMMray™ PanCan-d signature together with CA19-9 generated ROC AUC-values of 0.97, 0.98 and 0.96 when differentiating PDAC vs. non-PDAC symptomatic individuals, healthy controls and type II diabetes, respectively. Similar results were achieved for all stages of PDAC. “We are very pleased with these outstanding results which we believe will be welcomed by clinicians as well. They show conclusively that IMMray™ PanCan-d, has the capacity to differentiate between symptomatic, non-PDAC individuals, including type II diabetes, and all different stages of PDAC. These findings have significant clinical implications for individuals attending primary and secondary care units with non-specific but concerning symptoms where PDAC may be suspected,” commented Mats Grahn, CEO Immunovia. “Being first in the world to show such result give us increased confidence as we work towards launching the first reliable blood-based test for early detection of PDAC and further applying the platform technology to other indications.” The study collected and tested 937 patient samples from 150 PDAC (stage I-IV), 570 non-PDAC symptomatic individuals and 217 healthy individuals using IMMray™ PanCan–d in combination with CA19-9 ELISA assay. To minimize confounding, pre-analytical variables, all patient samples were collected and processed using the same standard operating procedures, stored at -80°C and tested within a year after collection. Data analysis was performed using Immunovia software algorithms and accuracies, SVM ROC AUC-values, were determined for the different groups. For more information, please contact: Julie Silber Investor Relations Director, Immunovia Tel.: +46-79-3486277 Email: julie.silber@immunovia.com (mats.grahn@immunovia.com) This is information that Immunovia is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 15:40 p.m. (CET) on July 11, 2019. About ImmunoviaImmunovia AB was founded in 2007 by investigators from the Department of Immunotechnology at Lund University and CREATE Health, the Center for Translational Cancer Research in Lund, Sweden. Immunovia’s strategy is to decipher the wealth of information in blood and translate it into clinically useful tools to diagnose complex diseases such as cancer, earlier and more accurately than previously possible. Immunovia´s core technology platform, IMMray™, is based on antibody biomarker microarray analysis. The company is now performing clinical validation studies for the commercialization of IMMray™ PanCan-d that could be the first blood-based test for early diagnosis of pancreatic cancer. In the beginning of 2016, the company started a program focused on autoimmune diseases diagnosis, prognosis and therapy monitoring. (Source: www.immunovia.com) Immunovia’s shares (IMMNOV) are listed on Nasdaq Stockholm. For more information, please visit www.immunovia.com. About Pancreatic Cancer   Pancreatic Cancer is one of the most deadly and difficult to detect cancers, as the signs and symptoms are diffuse and similar to other diseases. There are more than 40,000 deaths and over 50,000 new cases diagnosed each year in the U.S. alone, and the five-year survival rate for pancreatic cancer is currently 5-9 %. It is predicted to overtake colorectal cancer to become the second leading cause of cancer death by 2020. However, because resection is more successful in stage I/II, early diagnosis can significantly improve pancreatic cancer patients’ 5-year survival rates from 5-9 % to up to 49%. ###

Catena invests an additional SEK 150 million at Sunnanå Logistics Position

11 July 2019, 4:00 p.m. CET  The fifth facility to be established by Catena in Sunnanå is an air cargo warehouse of a total 10,162 square metres. A ten-year lease agreement with an annual rent of approximately SEK 10.5 million has been signed with DHL Express, the world's leading supplier of international express deliveries.   “DHL Express’ choice of the Sunnanå Logistics Position, which is part of Greater Copenhagen, for its handling of air cargo confirms the excellent location of the site for transports both within Sweden and abroad,” says Jörgen Eriksson, Regional Manager at Catena.  “We look forward to the collaboration with Catena and the new facility will allow us to establish the conditions needed to continue exceeding our customers’ rigorous demands of service quality in the best way possible,” says Henrik Jensen, Operations Director at DHL Express Sweden.  DHL is scheduled to move in during the autumn of 2020. The new building will be adjacent to the DHL terminal that was the first facility established by Catena in the area, since which facilities in the area have also been leased to Chefs Culinar, Svensk Cater, DS Smith and Lekia. For further information, please contact: Benny Thögersen, CEO                                       Tel. +46 706-60 83 50                                          benny.thogersen@catenafastigheter.se Jörgen Eriksson, Regional Manager, MalmöTel. +46 730-70 22 24                                          jorgen.eriksson@catenafastigheter.se

Aker BP second quarter and first half year 2019 report

The company’s net production in the second quarter was 127.3 (158.7) thousand barrels of oil equivalents per day (“mboepd”). The decrease was primarily driven by planned maintenance. Net sold volume was 140.7 (162.0) mboepd. The company maintains its full-year production estimate of 155-160 mboepd. Average realised liquids price was USD 69.3 (63.9) per barrel, while the realised price for natural gas averaged USD 0.16 (0.24) per standard cubic metre (“scm”). Production costs for the oil and gas sold in the quarter amounted to USD 198 (200) million. Production cost per produced barrel oil equivalents (“boe”) increased to USD 15.4 (13.4) driven by the lower volume and high maintenance activity. The company expects lower production cost per boe in the second half of 2019, and maintains its guidance of around USD 12.5 per boe on average for the full year. Exploration expenses amounted to USD 60 (90) million. Total cash spend on exploration was USD 119 (159) million. The company completed four exploration wells in the quarter, of which the Froskelår NE well was classified as a discovery. The Liatårnet well has been completed as a discovery after the end of the quarter. The company has also added two new wells to the 2019 exploration program and has consequently increased its expected exploration spend for the year to around USD 550 (500) million. Depreciation was USD 168 (183) million, equivalent to USD 14.5 (12.8) per boe. Profit before taxes amounted to USD 268 (249) million. Tax expense was USD 206 (239) million, representing an effective tax rate of 77 (96) per cent. Net profit was USD 62 (10) million. Investments in fixed assets amounted to USD 414 (364) million in the second quarter. All field development projects, including Johan Sverdrup, Valhall Flank West and Ærfugl progressed according to plan. Abandonment expenditures were USD 40 (21) million, driven by removal of the Valhall QP and plugging of two wells at the abandoned Jette field. The company successfully put in place a new capital structure in the second quarter. The previous USD 4 billion secured bank facility was replaced with a new USD 4 billion senior unsecured facility at lower cost and extended maturity. The company also issued a new USD 750 million bond. Net interest-bearing debt was USD 2.9 (2.5) billion at the end of the quarter, including USD 0.4 billion in lease debt. Total available liquidity at the end of the quarter was USD 3.3 (3.0) billion. In May, the company paid a quarterly dividend of USD 0.5207 (NOK 4.52) per share. The Board has resolved to pay a quarterly dividend of USD 187.5 million (USD 0.5207 per share) in August 2019. The Board expects an additional quarterly dividend of USD 187.5 million to be paid in the fourth quarter, implying total annual dividends of USD 750 million. The Board’s ambition is to increase the annual dividends by USD 100 million per year until 2023. AkerBP Q2 2019  2019-Q2 presentation  Presentation, webcast and conference call details The full report and presentation are attached and can also be found on www.akerbp.com.  A live webcast will be available on our website from 08:30 (CEST).  To access the conference call, please contact the conference call operator at the telephone numbers listed below. Please call in 5 minutes prior to the scheduled start time and provide the confirmation code 28 333 53 or ask for the Aker BP Second Quarter 2019 Presentation. +--------------+-------------------+|Location |Phone Number |+--------------+-------------------+|Norway |+47 2350 0296 |+--------------+-------------------+|United Kingdom|+44 (0)330 336 9411|+--------------+-------------------+

Q-FREE - SECOND QUARTER AND FIRST HALF 2019 RESULTS

The second quarter of 2019 represented a significant rebound from Q1-19. Revenues were up 12% and EBITDA was up 167% quarter on quarter. Order intake was solid despite the absence of major new contracts, and the order backlog remains at a very high level. Highlights for Q2-19 include: * 251 MNOK in revenues, up 11% YoY driven by the tolling and urban business areas * 23 MNOK in EBITDA (9% margin), a significant increase from 9 MNOK in Q1-19, but down from 31 MNOK in Q2-18 * 209 MNOK in order intake including several high-margin ALPR/ANPR contracts * 1 120 MNOK in order backlog, up 6% YoY * 45 MNOK in net proceeds paid to increase shareholding in Intelight Inc. from 53% to 75% * 55 MNOK MLFF tolling contract in Australia signed in early July after closing of Q2-19 Highlights for H1-19 include: * 474 MNOK in revenues, up 10% from H1-18 * 31 MNOK in EBITDA (7% margin), down from 47 MNOK in H1-18 due to mix effects and lower than normal tolling project margins * 507 MNOK in order intake, up 11% YoY - We are pleased to see that we, as promised, delivered stronger results in the second quarter than in the first quarter of 2019. Based on the current order backlog and contract pipeline Q-Free believes that performance in the second half of 2019 will be better than in the first half. Moreover, with the expected signing of new contracts with attractive margins in the coming months, Q-Free will benefit from operational leverage and build a very strong foundation for 2020, comments President & CEO in Q-Free, Håkon Volldal. The live broadcast, starting at 9 AM CET, can be followed on https://www.q-free.com/investor_relations/web-cast/ A recorded version will be available after the webcast has been concluded. Enclosures: Q2-19 report, Q2-19 presentation For further information, please contact: President & CEO, Håkon Volldal: +47 977 19 973 CFO, Tor Eirik Knutsen: +47 950 50 062 About Q-Free Q-Free is a leading global supplier of ITS (Intelligent Transportation Systems) products and solutions. The company has approximately 390 employees, offices in 17 countries, and a presence on all continents. Headquartered in Trondheim, Norway, Q-Free is listed on the Oslo Stock Exchange under the ticker QFR. www.q-free.comTwitter: @QFreeASA

Atea reports financial results for Q2 2019

Financial highlights are as follows: ·  Revenue: NOK 9.5 billion (NOK 9.1 billion) ·  EBIT: NOK 145 million (NOK 127 million) ·  Net profit: NOK 97 million (NOK 84 million) ·  Cash flow from operations: NOK 873 million (NOK -302 million) Atea’s revenue in Q2 2019 was NOK 9,487 million, an increase of 4.3% from last year. Adjusted for acquisitions, Atea’s pro forma revenue growth was 4.0%. Revenue growth was driven by strong sales of software, which increased by 18.4% from last year. EBIT in Q2 2019 increased by 14.3% to NOK 145 million, based on higher revenue and lower operating expenses compared with last year. Profit before tax was NOK 124 million, compared with NOK 109 million last year. Net profit after tax grew by 15.6% to NOK 97 million. “Atea increased revenue and EBIT across all markets in the second quarter of 2019. We also won several large frame agreements during the quarter. Our company is well-positioned for continued growth as a leading European reseller, system integrator and managed service provider within IT infrastructure,” commented Atea CEO Steinar Sønsteby. Atea expects the market for IT infrastructure to continue to grow, as organizations invest in new IT solutions to enhance productivity and redefine how they provide goods and services. This adoption of new technologies is creating greater complexity for IT departments, and driving increased demand for specialist competence in IT infrastructure and system integration. This trend strongly benefits Atea, as a system integrator with expertise across multiple product platforms. The interim report and presentation are available at https://www.atea.com/investors/financial-reports/A webcast of management’s presentation of the financial results is available at https://www.atea.com/investors/financial-reports/2019/webcast-q2-19/   The Stock Exchange Announcement is available at https://www.atea.com/about-atea/news/ For further information, please contact: Steinar Sønsteby, CEO Atea ASA, mobile (+47) 930 55 655 Robert Giori, CFO Atea ASA, mobile (+47) 934 09 188 About Atea Atea is the leading supplier of IT infrastructure and system integration in the Nordic and Baltic regions with 7,400 employees. Atea is present in 87 cities in Norway, Sweden, Denmark, Finland, Lithuania, Latvia and Estonia. Atea delivers IT products from leading vendors and assists its customers with specialist competencies within IT infrastructure services. Atea had revenue of approximately NOK 35 billion in 2018 and is listed on Oslo Stock Exchange https://www.atea.com 

Clinicians and cancer patients to benefit from advanced image guided radiation therapy solutions agreement between Elekta and C-RAD

STOCKHOLM, July 12, 2019 – Elekta (EKTA-B.ST) and C-RAD announced today that the companies have signed a sales and distribution agreement. C-RAD is a Swedish company specializing in positioning and surface scanning products. C-RAD offers surface image guided radiation therapy (SIGRT) technology with its Catalyst HD™ system, a solution used in stereotactic radiosurgery (SRS), stereotactic body radiotherapy (SBRT) and motion management. C-RAD has worked with Elekta for several years to provide its SIGRT technology to new and existing customers worldwide. C-RAD simplifies patient setup and provides comprehensive SIGRT for all patient positioning and motion management. The Catalyst system, which integrates with Elekta linacs, provides gross patient positioning and postural positioning along with respiratory motion management. It extends the value of Elekta’s Versa HD™ high definition dynamic radiosurgery (HDRS) solution through complementary capabilities and technologies. Maurits Wolleswinkel, President Linac Solutions at Elekta, said: “Our priority is always to provide a high level of patient safety and comfort while ensuring an efficient and seamless workflow for clinicians with the greatest degree of confidence. This collaboration with C-RAD supports Elekta’s linear accelerators – in particular, Versa HD – to meet the growing demand for SIGRT.” Tim Thurn, CEO of C-RAD, added: “SIGRT is on its way to become part of the standard of care in advanced radiation therapy. With our cutting-edge solutions and strong alliances, we have the opportunity to empower even more cancer centers, and ultimately their patients, to benefit from our technology.” This sales and distribution agreement is scheduled to start in North America and Mexico on July 12, 2019 and eventually expand to other markets. # # # For further information, please contact:Oskar Bosson, Global EVP Corporate Communications and Investor RelationsTel: +46 70 410 7180, e-mail: Oskar.Bosson@elekta.comTime zone: CET: Central European Time  Raven Canzeri, Global Public Relations ManagerTel: +1 770 670 2524, e-mail: raven.canzeri@elekta.comTime zone: EST: Eastern Standard Time  About ElektaFor almost five decades, Elekta has been a leader in precision radiation medicine. Our nearly 4,000 employees worldwide are committed to ensuring everyone in the world with cancer has access to – and benefits from – more precise, personalized radiotherapy treatments. Headquartered in Stockholm, Sweden, Elekta is listed on NASDAQ Stockholm Exchange. Visit elekta.com  or follow @Elekta  on Twitter. About C-RADC-RAD develops innovative solutions for use in advanced radiation therapy. The C-RAD group offers products and solutions for patient positioning, tumor localization and radiation treatment systems. All product development is conducted in three fully owned subsidiaries: C-RAD Positioning AB, C-RAD Imaging AB and C-RAD Innovation AB, all of which are located in Uppsala, Sweden. C-RAD has established three companies for direct sales: C-RAD Inc. in the US, C-RAD GmbH in Germany and C-RAD WOFE in China. Cyrpa International SPRL, a Franco-Belgian laser company, is a wholly owned subsidiary whose operations are integrated. C-RAD AB is listed on NASDAQ Stockholm. For more information on C-RAD, please visit http://www.c-rad.com

HISTORIC PMA APPROVAL AND PROGRESS IN THE R&D PORTFOLIO

SECOND QUARTER 2019 (APRIL - JUNE) · Net sales of non-durable goods in the quarter amounted to SEK 50.5 (42.2) million, corresponding to an increase of 20 percent in SEK and 13 percent in local currency. Total net sales (incl. durable goods) in the quarter amounted to SEK 56.4 (46.1) million, corresponding to an increase of 22 percent in SEK and 15 percent in local currency.  · Sales from warm perfusion represented 45 percent (43) of sales of non-durable goods.  · Operating income before depreciation and amortization (EBITDA) adjusted for costs for a share-based bonus program for employees outside Sweden amounted to SEK 12.1 million (10.9), corresponding to an EBITDA margin of 21 percent (24). Reported EBITDA amounted to SEK 8.1 (8.1) million, corresponding to an EBITDA margin of 14 percent (18).   · Operating income adjusted for the share-based bonus program was SEK 5.9 million (6.8). Reported operating income amounted to SEK 1.9 (4.0) million, after amortization and depreciation of SEK 6.1 (4.1) million.   · Net income amounted to SEK 2.2 (3.9) million, resulting in earnings per share of SEK 0.08 SEK (0.15).  · Cash flow from operating activities during the quarter amounted to SEK 21.0 (13.1) million. Cash flow from investing activities amounted to SEK -27.8 (-19.2) million.  · XVIVO has received Premarket approval (PMA) from the FDA for STEEN Solution™ and XPS™. The PMA approval was the first of its kind in the world.  · At ISHLT (International Society for Heart and Lung Transplantation), the positive results from the first six heart transplant patients from the study at Lund University Hospital were presented.  · The Swedish MPA has given approval to begin clinical studies with the company's new products for heart preservation.  · SEK 27 million shares was issued because of warrants being exercised. · Canada new country with XPS™.  THE PERIOD 2019 (JANUARY - JUNE) · Net sales of non-durable goods in the period amounted to SEK 97.3 (80.1) million, corresponding to an increase of 21 percent in SEK and 13 percent in local currency. Total net sales (incl. durable goods) in the period amounted to SEK 104.1 (88.6) million, corresponding to an increase of 18 percent in SEK and 9 percent in local currency.  · Sales from warm perfusion represented 44 percent (39) of sales of non-durable goods.  · Operating income before depreciation and amortization (EBITDA) adjusted for costs for a share-based bonus program for employees outside Sweden amounted to SEK 20.8 million (18.0), corresponding to an EBITDA margin of 20 percent (20). Reported EBITDA amounted to SEK 11.3 (15.2) million, corresponding to an EBITDA margin of 11 percent (17).   · Operating income adjusted for the share-based bonus program was SEK 9.6 million (9.9). Reported operating income amounted to SEK 0.1 (7.1) million, after amortization and depreciation of SEK 11.2 (8.1) million.   · Net income amounted to SEK 1.9 (7.7) million, resulting in earnings per share of SEK 0.07 (0.29).   · Cash flow from operating activities for the period amounted to SEK 21.2 (22.3) million. Cash flow from investing activities amounted to SEK -39.5 (-30.0) million. · Reimbursement for the entire EVLP process obtained in France.   · 2 XPS™ were delivered during the period. At the end of the quarter 48 hospitals had access to either XPS™ or LS™.  CONFERENCE CALL CEO Magnus Nilsson will present the report in a conference call at 2 p.m. CET on Friday, July 12, 2019. Telephone UK: +44 333 300 0804 or USA: +1 631 913 1422. PIN: 15013516# July 12, 2019GothenburgXVIVO Perfusion AB (publ)Magnus Nilsson, CEO 

Interim report January – June 2019

Quote from Therese Hillman, Group CEO“The weak development in the Nordic countries continued in the second quarter, particularly in Sweden, where we have seen fewer players and lower ARPU since the new regulation was introduced at the beginning of the year. Looking ahead, we continue to invest in increased game production, a technical platform featuring more functionality, and Live Casino, in order to defend, and over the longer term increase our market shares in all our markets.” Second quarter 2019 · Revenues for the second quarter amounted to SEK 419 (437) million · EBITDA was SEK 201 (202) million, corresponding to a margin of 48.0 (46.3)%  · Operating profit (EBIT) was SEK 130 (149) million, corresponding to a margin of 31.0 (34.0)% · Net profit was SEK 120 (139) million · Earnings per share was SEK 0.50 (0.58) before and after dilution · 8 (8) new customer agreements were signed, and 10 (7) new customers’ casinos launched First half-year 2019 · Revenues for the first half-year amounted to SEK 837 (867) million · EBITDA amounted to SEK 397 (384) million, a margin of 47.5 (44.3) % · Operating profit (EBIT) amounted to SEK 256 (283) million, a margin of 30.6 (32.6)% · Profit after tax of SEK 240 (285) million · Earnings per share of SEK 1.00 (1.19) before and after dilution · 16 (14) new customer agreements signed, and 19 (15) new customers’ casinos launched Important events in the second quarter · 7 (5) slot games were released, of which Narcos was the most successful · Customer agreement signed with Draftkings in New Jersey, USA · Games launched with the state-owned gambling operator Veikkaus in Finland · UK subsidiary established · A commercial decision was taken not to prolong the license in British Columbia (Canada) · One million shares were repurchased by the company Comments by Therese Hillman, Group CEO Continued weak development in Sweden and rest of the NordicsIn the second quarter, NetEnt’s total revenues decreased by 4.1 percent (-6.6 percent in euro) compared to the corresponding period last year. The development resembled that of the first quarter, with weakness in the Nordic countries and primarily in Sweden, driven by fewer players and lower ARPU since the new regulation was introduced at the beginning of the year. We are present in 23 regulated markets, which accounted for 49 percent of total revenues in the quarter. Outside of Sweden revenues from those markets grew by 1.7 percent in euro during the period, with growth coming mainly from the US (New Jersey), Eastern Europe, Spain and Portugal.We signed eight new customer agreements and launched ten new customers during the quarter. Among the newly launched customers is the Finnish state-owned gambling operator Veikkaus, where our games have been well received since they were launched at the end of June.We signed an agreement with DraftKings in New Jersey, which is a market where we continue to see solid growth. We now look forward to our launch in Pennsylvania as the market opens next week, having signed yet another customer, Rush Street, after the end of the quarter. High activity and strengthened presence in the UKSo far this year, we have released twelve new games and we stick to our plan to launch a total of 30-35 new games for 2019, which is a significant increase compared to last year’s 20 new games. During the second quarter, we released seven new slot games: Dead or Alive 2, Wild Worlds, Narcos, Arcane Reel Chaos, Cash-o-Matic, Twin Happiness and Happy Panda. Narcos has been our best revenue-generating game in 2019 and Dead or Alive 2 has also performed well across our entire customer network.The EBIT margin was 31.0 (34.0) percent in the second quarter. Operating profit was affected by legal costs as NetEnt took action to defend the IP rights of one of its most important games. In May, the dispute was contractually settled to our advantage. NetEnt’s transformation process has continued and the result for the quarter also include severance pay to senior executives that have left the company. During the quarter, we also recruited senior business area directors from the industry and established a UK subsidiary, to strengthen our presence in Europe’s largest and most important gambling market. Investing in long-term growthNow we take the next step in developing our technical platform as we are creating an open platform with new types of functionality and aggregation of third-party content for operators, services that will be launched on a broader scale during 2020.The transformation of Live Casino continues at full speed and we added several new functions during the quarter to make our product more competitive. The customer response is positive, and we expect growth in the coming quarters from this segment, but it will take a few more quarters before we can see more meaningful revenues. The industry is going through significant changes, and we see opportunities to strengthen our position in all our markets. Through our strategy to invest in increased game production, a technical platform featuring more functionality, and Live Casino – supported by our brand, global distribution and customer relations – we have the right basis to defend, and over the longer term increase our market shares. Presentation of reportOn Friday, July 12th, 2019, at 9.00 a.m. the report will be presented by CEO Therese Hillman live via a telephone conference and webcast. The audiocast can be followed in real-time on NetEnt’s website, the link is: https://tv.streamfabriken.com/netent-q2-2019 For additional information please contact:Therese HillmanGroup CEOPhone: +46 8 5785 4500therese.hillman@netent.com This information is information that NetEnt AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact person set out above, at 7:30 CET on July 12th, 2019. About NetEntNetEnt AB (publ) is a leading digital entertainment company, providing premium gaming solutions to the world’s most successful online casino operators. Since its inception in 1996, NetEnt has been a true pioneer in driving the market with thrilling games powered by a cutting-edge platform. NetEnt is committed to helping customers stay ahead of the competition, is listed on Nasdaq Stockholm (NET–B) and employs around 900 people in Malta, Stockholm, Gothenburg, Gibraltar, Kiev, Krakow and New Jersey. For more information, please visit www.netent.com.

STOREBRAND ASA: Q2 interim result 2019 – Group result of NOK 578 million and NOK 1,311 million year to date

·  Group result of NOK 578 million for the second quarter and NOK 1,311 million year to date ·  Solvency II 167%  ·  Strong customer returns generated NOK 166 million in earned, but not booked performance related profit as of half year  - Storebrand presents a satisfying underlying result adjusted for restructuring costs and performance related costs. Sales are good, and we have won many new customers both in Norway and Sweden. We are looking forward to welcoming them later this year, Odd Arild Grefstad, CEO of Storebrand Group said.  The underlying operating profit is satisfying, but is influenced by restructuring costs and accrual of performance based costs.  The operating profit for the second quarter was NOK 474 million, down from NOK 645 million in the second quarter 2018. The good performance of the Skagen funds increased the performance related costs with NOK 44 million in the quarter, while the related profit can only be booked by the end of the full year. Restructuring costs, which will lead to reduced costs moving forward, influence the operating profit with NOK 45 million. An ordinary insurance result in the quarter generates a lower operating profit when compared to the extraordinary strong insurance results for the second quarter of 2018.  Storebrand enters the market for public occupational pension The pension system for public employees is about to be adjusted to better fit the pension reform that was introduced in 2010. The change will take effect from 2020. In the second quarter of 2019, Storebrand officially decided to return to this market to offer occupational pension solutions to municipalities. This market is currently only covered by own pension funds and Kommunal Landspensjonskasse (KLP), a mutual company.  Good sales in the quarter Storebrand look forward to welcoming Posten and its employees to Storebrand. Posten is the largest occupational pensions client to transfer to the Group to date with more than NOK 3 billion in assets and NOK 300 million in annual premiums. In Sweden, new sales continue at a high pace and are up 38 per cent compared to the same period last year.  Assets under management increases to NOK 752 billion  The financial markets continued the positive development in the second quarter, which contributed to an increase of assets under management from NOK 707 billion to NOK 752 billion, compared to second quarter 2018. Assets under management in the Unit Linked business increased by NOK 20 billion, equivalent to 11 per cent growth. Good performance, good sales and structural market growth drive the growth. Managed unit linked assets is now over NOK/SEK 100 billion in Norway and Sweden.  The insurance segment shows signs of growth, after a period of flat development. The annual portfolio premium grew 2 per cent compared to the same quarter last year. Within P&C Insurance, the portfolio premium increased by 6 per cent during the same period. Strong cost control and robust solvency The underlying Group cost control is strong, and Storebrand maintains the ambition of reducing costs between 2015 and 2020. Aligned with this ambition, the Group has implemented substantial restructuring activities during the second quarter, leading to a one-off cost of NOK 45 million. The Group solvency is robust. The solvency margin was estimated to 167 per cent at the end of Q2. The solvency is reduced by 6 percentage points this quarter, mainly due to a lower and more flat yield curve. KEY FIGURES IN THE QUARTER: (Q2-18 in brackets) ·  Solvency II 167% (167%) ·  Earnings per share adjusted for amortisation 1,21 (1,46) ·  Equity 32 242 (30 227) Activity related to the second quarter, 2019 07:30 CET: Release of stock exchange notification. Press release, quarterly report and analyst presentation will be at www.storebrand.no/ir. 10:00 CET: Combined press and analyst conference (in Norwegian) at Storebrand's head office, Lysaker Park. Main entrance: Professor Kohts vei 9, Lysaker. Web–TV: The presentation (in Norwegian) will be available on web-TV  (live and on demand). 14:00 CET: Analyst conference call  in English. To attend the conference call we kindly ask you to dial in 10 minutes before start by calling +44 (0) 20 3003 2666  for international participants or 21 56 33 18  from Norway. Passcode is Storebrand. For further inquiries, please contact: Group Head of Strategy, Finance and M&A Kjetil Ramberg Krøkje: kjetil.r.krokje@storebrand.no or (+47) 934 12 155 SVP Communications, Vibeke Hansen: vibeke.hansen@storebrand.no or (+47) 990 13 349 Storebrand's ambition is to be the best provider of saving for pensions. Storebrand will deliver sustainable solutions adapted to the customer's individual situation, so that each person receives a better pension in a more sustainable world. Storebrand has about 40.000 corporate customers and 2 million individual customers, and has its headquarter at Lysaker outside of Oslo, Norway. Storebrand manages more than NOK 750 bn and is Norway's largest private asset manager. We work hard to fulfil our vision: Recommended by our customers. Storebrand (STB) is listed on Oslo Stock Exchange. Visit us at www.storebrand.no and follow us on Twitter: @Storebrand_no This announcement is subject to information pursuant to the Securities Trading Act § 5-12

Interim report for Duni AB (publ) 1 January - 30 June 2019

1 April – 30 June · Net sales amounted to SEK 1,348 m (1,197), corresponding to a 12.6% increase in sales. Adjusted for exchange rate movements, net sales increased by 9.9%. · Earnings per share after dilution amounted to SEK 1.41 (1.39). · Gradually declining raw material prices combined with the implemented price increases contributes to a recovery of the margin. 1 January – 30 June · Net sales amounted to SEK 2,612 m (2,277), corresponding to a 14.7% increase in sales. Adjusted for exchange rate movements, net sales increased by 11.1%. · Earnings per share after dilution amounted to SEK 2.49 (2.61). · Positive contribution from price increases and BioPak in Australia, which was acquired in October 2018. · Continuing higher expenses for input materials and increased year-on-year expenses for logistics services. KEY FINANCIALS +--------------+-------+---------+-------+---------+-----------------+------------+|SEK m |3 month| 3 months|6 month| 6 months| 12 months | 12 months|| | s| Apr| s| Jan|Jul-Jun 2018/2019|Jan-Dec 2018|| | Apr|-Jun 2018| Jan|-Jun 2018| | || | -Jun| | -Jun| | | || | 2019| | 2019| | | |+--------------+-------+---------+-------+---------+-----------------+------------+|Net sales | 1,348| 1,197| 2,612| 2,277| 5,263| 4,927|+--------------+-------+---------+-------+---------+-----------------+------------+|Organic growth| -2.1%| 2.0%| -0.9%| 2.1%| 0.1%| 1.5%|+--------------+-------+---------+-------+---------+-----------------+------------+|Organic pro | 1.0%| 2.1%| 2.1%| 2.2%| 3.3%| 2.5%||forma growth1)| | | | | | |+--------------+-------+---------+-------+---------+-----------------+------------+|Operating | 111| 96| 203| 186| 447| 430||income2,3) | | | | | | |+--------------+-------+---------+-------+---------+-----------------+------------+|Operating | 8.2%| 8.0%| 7.8%| 8.2%| 8.5%| 8.7%||margin2,3) | | | | | | |+--------------+-------+---------+-------+---------+-----------------+------------+|Income after | 86| 87| 152| 165| 316| 328||financial | | | | | | ||items | | | | | | |+--------------+-------+---------+-------+---------+-----------------+------------+|Net income | 67| 66| 119| 125| 244| 249|+--------------+-------+---------+-------+---------+-----------------+------------+ 1) Currency-adjusted growth including acquired companies, which are compared with the previous year’s pro forma figures.2) For key financials, definitions and reconciliation of alternative key financials, see pages 26-27.3) For impact of the new leasing standard as of 1 January 2019, see Note 1. CEO’S COMMENTS “Sustainable packaging drives growthIn the second quarter, sales increased by 12.6% to SEK 1,348 m (1,197). Organic pro forma growth1) for the quarter amounted to 1.0%, despite fewer days of sales. Restrictions on the use of single-use products made of plastic are now in the pipeline in many countries. Duni is positive about these important activities for the environment and it is well in line with our new strategy where we increase our focus on sustainability and see a very positive growth in sustainable packaging. In addition to the positive sales development of sustainable packaging, we also see solid growth in premium napkins, while the table covers continue to develop negatively. The trend for our geographic growth areas has carried over from the previous quarter. This means that we are growing in most regions with particularly high growth in Australia, our second largest country in terms of sales. Margin program contributes to all-time-high income Operating income for the quarter was SEK 111 m (96), which is an all-time high for Q2. We are seeing positive effects from our margin program which included price increases, to compensate for the significant rise in pulp prices, as well as indirect expense savings. Nevertheless, we humbly note that we benefitted from important external factors such as falling pulp prices and the weakened Swedish krona in the quarter. However, increased freight prices had a negative impact on our income. Performance in our business areas Taking a look at our business areas, Meal Service and New Markets saw positive growth in both sales and income and Table Top’s performance was steady while Business Area Consumer continues to have a weak performance. Organic pro forma growth1) amounted to 6% in Meal Service and 14% in New Markets, but Consumer had a negative sales development of 15% at fixed exchange rates. Our price increases in 2018 resulted in a loss of some high volumes contracts within Consumer. To boost our future competitiveness in the business area, we are now engaging in activities aiming to raise efficiency in the value chain. Pulp prices continue to fall Pulp prices continued to decline in the second quarter. This should have a positive impact on income in the third quarter as well,” says Johan Sundelin, President and CEO, Duni. 1)Currency-adjusted growth including acquired companies, which are compared with the previous year’s pro forma figures. :: Additional information is provided by:Johan Sundelin, President and CEO, +46 40 10 62 00Mats Lindroth, CFO, +46 40 10 62 00Helena Haglund, Group Accounting Manager, +46 734 19 63 04 Duni AB (publ)Box 237SE-201 22 MalmöTel.: +46 40 10 62 00www.duni.com Business registration number: 556536-7488  :: Duni is a leading supplier of attractive and convenient products for table setting and take-away. The Duni brand name is sold in more than 40 markets and enjoys a number one position in Central and Northern Europe. Duni has around 2,400 employees in 24 countries, headquarters in Malmö, Sweden, and production units in Sweden, Germany, Poland, New Zealand and Thailand. Duni is listed on NASDAQ Stockholm under the ticker name “DUNI”. The ISIN code is SE0000616716. This information is information that Duni AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 07:45 CET on 12 July 2019. 

Interim Report January-June 2019

”We deliver stable earnings and growth, whilst the integration of Pöyry and the realisation of cost synergies are proceeding at a higher rate than foreseen. With a strengthened position we look forward to continued profitable growth in 2019,” said Jonas Gustavsson, President and CEO. Second quarter 2019 – Net sales amounted to SEK 5,393 million (3,608) – EBITA, excl. items affecting comparability, was SEK 481 million (366) – EBITA margin, excl. items affecting comparability, was 8.9 percent (10.2) – EBITA totalled SEK 405 million (366) – EBITA margin was 7.5 percent (10.2) – EBIT (operating profit) amounted to SEK 392 million (353) – Basic earnings per share: SEK 2.59 (3.35) January – June 2019 – Net sales amounted to SEK 9,782 million (7,023) – EBITA, excl. items affecting comparability, was SEK 870 million (691) – EBITA margin, excl. items affecting comparability, was 8.9 percent (9.8) – EBITA totalled SEK 732 million (691) – EBITA margin was 7.5 percent (9.8) – EBIT (operating profit) amounted to SEK 705 million (664) – Basic earnings per share: SEK 4.94 (6.29) COMMENTS BY THE CEO The first half of 2019 demonstrates a stable performance, with organic growth of 5.2 percent (4.5). Net sales in the second quarter totalled SEK 5,393 million (3,608). EBITA, excluding items affecting comparability, amounted to SEK 481 million (366) and corresponding EBITA margin to 8.9 percent (10.2). The integration of Pöyry is proceeding at high speed, while we are seeing persistently healthy demand for our services. Market trend The demand for sustainable solutions continued to be good with disruptive trends as strong drivers. The market for infrastructure continues to be favourable, and we can especially note a high demand for technical solutions in buildings. Demand in the industry sector remained stable, with 5G, electrification and automation as drivers. However, demand in the automotive industry is being impacted by cost savings and reprioritisation of R&D programmes, despite the fact that the industry is on the cusp of extensive technical changes. The process industries market remains strong, especially in Europe. In the energy market we see continued demand for large-scale energy projects in Southeast Asia, and at the same time demand for renewable energy is on the rise. There is also persistently high demand for advisory services due to major transformations within process industries and the energy sector. Integration of Pöyry and synergies With the acquisition of Pöyry, we are now forming a leading engineering, design and advisory company. Our operations have been integrated quickly, while maintaining a firm focus on our clients and we show organic growth in the quarter. The realisation of cost synergies is proceeding at a higher rate than foreseen. The annual run-rate savings after the second quarter amount to SEK 99 million. As previously announced, the cost synergies target is SEK 180 million and the majority is expected to be realised in 2019. The issue of new shares carried out in April was well received and oversubscribed. In June, ÅF Pöyry issued bonds totalling SEK 2 billion to replace existing financing in connection with the acquisition. Following the issue of new shares and implemented financing, net debt in relation to EBITDA is at 2.7 (adjusted for Pöyry’s EBITDA over the past 12 months), creating conditions for carrying out additional acquisitions in the second half of the year. Performance among the divisions The Infrastructure Division experienced a somewhat slow start to the year, but delivered a second quarter with stable growth. The profitability was negatively impacted by the slow down in architecture and weak development in Denmark. Strong demand for technical, low-carbon solutions for buildings continued to contribute to the division’s growth and profitability. The Industrial & Digital Solutions Division gave a stable performance in the second quarter despite demand in the automotive industry levelling off slightly. Demand for services in product development, electrification and automation remains good in all sectors. Business area Food & Pharma has performed well, and in the second quarter a new assignment was received from Arla Foods in Denmark for project planning of a new production facility. The Process Industries Division performed well in the quarter, with persistently high demand in the Nordics. During the quarter, the division received an assignment from Metsä Fibre for the design of a bioproduct mill, which is one of the largest investments in the Nordic paper and pulp industry. At the same time, there are good opportunities for growth in Latin America, the US and Russia, where major projects are entering the next phase. Digitalisation and sustainability continue to be the primary drivers. The Energy Division exhibited improved growth and profitability in the second quarter, with the division’s international delivery capabilities making a positive contribution. Meanwhile work is continuing on adapting the division’s structure to both market changes and in order to boost profitability. The required transition to sustainable, renewable energy production is gaining momentum and the division was awarded several assignments in the quarter within hydropower, waste management and nuclear decommissioning. The Management Consulting Division performed well in the quarter and the core markets remained stable. The key industry drivers are the solid transaction volume across the sectors, as well as the ongoing transition of the energy sector. Overall, the integration of Pöyry is successful and we have strenghtened our position in all divisions. The two right issues that have been carried out have strengthened our capital structure, and we are at the forefront in terms of realising cost synergies. With our new joint company and a market driven by megatrends such as digitalisation, urbanisation and climate change, we are ready to meet our clients’ needs and to continue pursuing profitable growth. This report has not been subjected to scrutiny by the company’s auditors. This information fulfils ÅF Pöyry AB’s (publ) disclosure requirements under the provisions of the EU’s Market Abuse Regulation and the Swedish Securities Markets Act. The information was submitted for publication through the agency of the contact person set out above at 08.00 CET on 12 July 2019. All assumptions about the future that are made in this report are based on the best information available to the company at the time the report was written. As is the case with all assessments of the future, such assumptions are subject to risks and uncertainties, which may mean that the actual outcome differs from the anticipated result. This is a translation of the Swedish original. The Swedish text is the binding version and shall prevail in the event of any discrepancies. The full report including tables (pdf) is available for download. Link to press-imageshttp://www.afconsult.com/en/newsroom/press-images--logo/ For further information, please contactJuuso Pajunen, CFO, +358 10 33 26 632

Castellum’s half-year report January-June 2019: Continued strong rental growth promotes 9% increase in income from property management

·  Income for the period January-June 2019 amounted to MSEK 2,871 (MSEK 2,740 corresponding period previous year). ·  Income from property management amounted to MSEK 1,543 (1,420), corresponding to SEK 5.65 (5.20) per share, an increase of 9%. ·  Changes in value on properties amounted to MSEK 1,882 (827) and on derivatives to MSEK – 297 (25). ·  Net income after tax for the period amounted to MSEK 2,586 (2,425), corresponding to SEK 9.47 (8.88) per share. ·  EPRA NAV amounted to SEK 184 (159) per share, an increase of 16%. ·  Net investments amounted to MSEK 186 (2,069) of which MSEK 2,770 (1,019) were acquisitions, MSEK 1,473 (1,437) new developments, extensions and redevelopments and MSEK 4,057 (387) sales. Property value amounted to SEK 91.4 billion by the end of the period.  ·  Net lease for the period amounted to MSEK 4 (128). “I am far more optimistic about market conditions today than I was back in January. We have noted numerous positive signals during the quarter, including rising rental levels in the metropolitan areas and a positive result for net leasing compared with the previous quarter.” says Henrik Saxborn, CEO, Castellum AB. “In addition to stronger results from our property management operations, the detailed development plans for three of our largest projects have been approved, which translates to a project volume of MSEK 3,000. In the current market, projects have a considerably higher yield than acquisitions, and now account for the lion’s share of Castellum’s investments, which is important for the next few years.” says Saxborn. Enclosure: Half-year report January-June 2019 This information is information that Castellum is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact persons set out below, at 8:00 a.m. CET on July 12, 2019. For further information contact:Henrik Saxborn, CEO, Castellum AB, + 46 (0)31-60 74 50Ulrika Danielsson, CFO, Castellum AB, +46 (0)706-47 12 61 Castellum is one of the largest listed real estate companies in Sweden. Property values amount to SEK 91.4 billion and holdings comprise office, warehousing/logistics and public sector properties, covering a total leasable area of 4.2 million square metres.The real estate portfolio is owned and managed under the Castellum brand through a decentralized organization with strong and clear local presence in 20 cities in Sweden and also in Copenhagen and Helsinki.In 2018, Castellum received two awards for sustainability efforts; designated Number One in the world by GRESB for the offices-and-logistics sector, as well as the Level Gold award for sustainability reporting from the EPRA (European Public Real Estate Association). In addition, Castellum is the only Nordic real-estate and construction company elected to the Dow Jones Sustainability Index (DJSI), joining a select group of companies in the world who perform best on sustainability issues. The Castellum share is listed on Nasdaq Stockholm Large Cap. For further information visit www.castellum.com.  

OptiGroup finalises the sale of its German paper distribution business

OptiGroup has today closed the sale of its German paper distribution business, Papyrus Deutschland GmbH & Co KG, to Investimentos, Participações e Gestão, S.A. (Inapa), which intends to combine the business with their German subsidiary, Papier Union GmbH. The transaction is in line with OptiGroup’s strategy to diversify into areas with higher growth. The effective date of the transaction will be July 31, 2019. OptiGroup’s President and CEO, Sören Gaardboe comments:“The sale of our German paper distribution business marks another concrete step in OptiGroup’s strategy to strengthen and proactively develop the business portfolio. In recent years, we have made several strategic acquisitions in the areas of personal protection equipment, cleaning & hygiene and packaging. The capital released through the sale will be used to further develop our portfolio of businesses, and accelerate the transformation journey towards sectors with higher growth”. Business Area Head Printing & Creative Solutions, Niklas Järbur comments:“The paper distribution market in Germany has been under severe pressure in recent years and it is necessary for traditional paper merchants to restructure and strengthen their platform and customer offering in order to compete successfully. We are convinced that the combination of Papier Union and Papyrus Deutschland will create a stronger platform for customers, suppliers and employees. Our Papyrus businesses outside Germany are unaffected by this transaction and Papyrus will continue to be a leading paper distributor to the printing industry with strong market positions in Benelux, Nordics, Switzerland and Eastern Europe”.

Divestment of Aleris

Patricia Industries, a part of Investor AB, has signed an agreement to divest Aleris to Triton at an enterprise value of SEK 2.8bn. Adjusted for net debt of approximately SEK 550m and estimated transaction costs of SEK 200m this equals an equity value of SEK 2bn. Doktor24 will remain within Patricia Industries and be included in Financial Investments. Aleris is a provider of specialty care, healthcare and diagnostics with a strong footprint across Scandinavia with high medical quality, customer satisfaction and strong offerings. Aleris serves 1.1 million patients and conducts 1 million radiological examinations annually. “During our ownership since 2010, Aleris has developed and strengthened its offering and achieved higher customer satisfaction. However, the financial performance has not been satisfactory. As owners we always strive to do what we deem is best for our companies and our shareholders. In late 2018, Aleris divested Aleris Care to Ambea, a new good owner of the business. Now the healthcare business is divested to Triton, which we see as a good owner that will continue to develop the offering to the patients and customers. Through this transaction we will free up resources for further development of our strong platforms within Patricia Industries”, says Johan Forssell, CEO of Investor. “As a focused healthcare company, Aleris has further developed its business, accelerated the restructuring of the Swedish operations and won new contracts. With Triton as an owner with broad industry experience, the company has a strong platform to continue to provide high-quality healthcare services with satisfied customers”, says Christian Cederholm, Co-Head, Patricia Industries. The transaction is subject to regulatory approvals and closing is expected during the third quarter 2019.

Report and presentation for the second quarter 2019

Financial and operating highlights 2Q19 (2Q18 in brackets): · Operating revenues were NOK 2 023 million (NOK 1 662 million) · EBITDA was NOK 511 million (NOK 350 million) · EBIT was NOK 271 million (NOK 95 million) · Net result after tax from continuing operations was NOK -11 million (NOK -26 million) Segment highlights 2Q19 (2Q18 in brackets): Renewable energy · EBITDA NOK 111 mill. (NOK 165 mill.) · Total generation down 3% · Year on year decreasing electricity prices in all markets Shipping / Offshore wind · EBITDA NOK 255 mill. (NOK 64 mill.) · Utilization for T&I and O&M vessels 99% (69%) · Contract pipeline for T&I and O&M in 2H 2019 covered by 34% firm contracts · GWS with growth and high activity, extra costs associated with entering new markets Cruise · EBITDA NOK 137 mill. (NOK 123 mill.) · Net ticket income per diems increased by 4% · Passenger days increased 3% · Higher operating costs due to fuel and sales incentives Financial information The Group of companies’ operating revenues in the quarter amounted to NOK 2 023 million (NOK 1 662 million). Renewable energy had operating revenues of NOK 234 million (NOK 291 million), Shipping / Offshore wind NOK 806 million (NOK 411 million), Cruise NOK 671 million (NOK 617 million). Other investments had operating revenues of NOK 311 million (NOK 343 million), of which NHST Media Group comprised NOK 301 million (NOK 332 million). EBITDA in the quarter was NOK 511 million (NOK 350 million). Renewable energy achieved EBITDA of NOK 111 million (NOK 165 million), Shipping/Offshore wind NOK 255 million (NOK 64 million), while Cruise had EBITDA of NOK 137 million (NOK 123 million). Within Other investments EBITDA was NOK 9 million(NOK -2 million), of which NHST contributed with NOK 33 million (NOK 24 million). Depreciation in the quarter was NOK 240 million (NOK 256 million). Renewable energy has reassessed the estimated lifetime for wind farms and thereby increased lifetime from 15 years to 20 years. This causes a reduced depreciation of NOK 59 million in the quarter, while Shipping / Offshore wind had NOK 40 million higher depreciation in this quarter compared to last year, mainly because of the acquisition of Blue Tern in 4Q18 and the charter of jack-up O&M vessel Jill. No impairment was recognized neither in 2Q19 nor 2Q18. EBIT in the quarter was NOK 271 million (NOK 95 million). Net financial items in the quarter were NOK - 256 million (NOK - 109 million). Net interest expenses were NOK 91 million (NOK 80 million). The increase is a consequence of new financing in FOCB Ltd. entered into in 2Q18 and the Blue Tern Ltd. acquisition in 4Q18. Net loss on foreign currency in the quarter was NOK -10 million (NOK -27 million). NOK 26 million was recognized as unrealized loss related to fair value adjustment of financial instruments (NOK 6 million), whereof the major part being interest hedging within Renewable energy. In the quarter a loss of NOK 120 million was recognized on financial assets. Other financial expenses amounted to NOK - 9 million (NOK -8 million). Net Result in the quarter from continuing operations was NOK -11 million (NOK – 26 million). Net result from discontinued operations in the quarter was 0 million (NOK -1 674 million). Net result for the period was thusNOK - 11 million (NOK -1 701 million), of which NOK - 9 million (NOK – 859 million) is attributable to the shareholders of the parent company. The non-controlling interests´ share of the net result in the quarter was NOK -2 million (NOK - 842 million). For the first half year, revenues were NOK 3 710 million (NOK 3 073 million) while EBITDA was NOK 762 million (NOK 542 million). Operating result (EBIT) was NOK 292 million (NOK 40 million). Net financial items were NOK - 471 million (NOK - 200 million). Net result after estimated tax from continuing operations was NOK - 211 million (NOK – 193 million), while net result from discontinued operations was NOK 0 million (NOK -2 011 million). For further information see note 8. Net result for the first half year was NOK - 211 million (NOK - 2 204 million), of which NOK - 210 million (NOK - 1 266 million) are attributable to the shareholders of the parent company. The non-controlling interests´ share of net result from continuing operations was NOK - 1 million (NOK - 938 million).

Interim report Q1 1 April - 30 June 2019

First quarter · Net sales increased by 22 percent and amounted to SEK 2,934 million (2,395). · Operating profit before amortisation of intangible non-current assets (EBITA) increased by 31 percent and amounted to SEK 341 million (260) corresponding to an EBITA-margin of 11.6 percent (10.9). · Operating profit increased by 32 percent and amounted to SEK 292 million (221) corresponding to an operating margin of 10.0 percent (9.2). · Profit after tax increased by 40 percent and amounted to SEK 226 million (162) and earnings per share before dilution amounted to SEK 3.35 (2.35). For the most recent 12-month period, earnings per share before dilution amounted to SEK 10.85 (7.95). · Return on working capital (P/WC) amounted to 54 percent (53). · Return on equity amounted to 31 percent (27). · The equity ratio amounted to 35 percent (39). · Cash flow from operating activities amounted to SEK 253 million (52). For the most recent 12-month period, cash flow per share from operating activities amounted to SEK 10.30 (7.55). · During the period, we have completed six acquisitions, of which one after the end of the period, with total annual sales of about SEK 540 million. Ceo's comments First quarter - a good start to the new yearOver all, the new financial year is off to a good start, particularly taking into account the strong comparison figures from the preceding year and this year’s Easter in April. Good organic growth of 12 percent generated excellent earnings growth and stronger margins. All of the business areas hold favourable positions and continue to experience good market conditions. In particular, we have succeeded to take good positions in segments with continuously very good growth. In some areas, however, we are now experiencing that the strong tailwind has abated. Market development – varying circumstancesThe business climate has been favourable in most customer segments and geographies, while the circumstances in the market have more clearly begun to vary. In particular, demand for production components for the mechanical industry has shown signs of evening out at a high level, as has demand in the special vehicles segment. A partial explanation for this is the long lead times previously occurring for certain components. These leadtimes were reduced in early 2019, resulting in decreased demand during the quarter, despite of continued high production rate. The marine segment has continued to grow strongly, and accounts for just over half of the Group’s organic growth in the first quarter. Demand for our products and services regarding environmental improvement solutions, has been very strong and is now expected to remain at this high level for at least the remainder of the financial year. From a geographical perspective, our best market situation was in Norway and Finland. Our sales in Sweden and Denmark were stable and our operations outside the Nordic region continued to perform well. However, our units in the UK continue to experience some uncertainty due to Brexit. AcquisitionsWe acquired five companies during the quarter, together contributing annual sales of about SEK 530 million. With our sound finances and strong pipeline with a favourable spread in terms of both on geography and segments, we see good opportunities for further acquisitions. Outlook – continued focus on development areasOur business model, with a mix of trade products, customised products and solutions and proprietary brands, represents a very important part of our success. This mix affords us flexibility with regard to customers’ needs and decreases our risks. In recent years, we have seen a shift in this mix. As shown in the model presented in our recently published annual report for the 2018/2019 financial year, our proprietary products and customised solutions now account for approximately 65 percent of our business, while 35 percent consists of trade products. Trade products will always be an important part of our business. At the same time, the trend confirms that we are really succeeding in adding increasing value for our customers and that our investments in proprietary products and brands have been successful. Looking ahead, we generally expect demand to persist, although evening out at a high level. External uncertainty affects us as it does everyone else, although, in the longer-term perspective, we still perceive many business opportunities within structurally driven areas of development such as the environment and climate, infrastructure and Industry 4.0. Stockholm, 12 July 2019 Niklas StenbergPresident and CEO This information is information that Addtech AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact persons set out below, at 8.15 a.m CET on 12 July 2019. For further information, please contact:Niklas Stenberg, President and CEO, +46 702 679 499Malin Enarson, CFO, +46 705 979 473 Addtech in briefAddtech is a technology trading group that provides technological and economic value added in the link between manufacturers and customers. Addtech operates in selected niches in the market for advanced technology products and solutions. Its customers primarily operate in the manufacturing industry and infrastructure. Addtech has about 2,900 employees in more than 130 subsidiaries that operate under their own brands. The Group has annual sales of more than SEK 10 billion. Addtech is listed on the Nasdaq Stockholm.

Interim report January to June 2019

Outlining the new TagMaster Second quarter · Net sales increased during the second quarter by 4,8 % to 53,2MSEK (50,7) · Result before depreciation (EBITDA) for the second quarter amounted to 0,0 MSEK (3,4), corresponding to a margin of 0,0% (6,7) · Net result after tax was -3,3 MSEK (0,8) · Result per share was -0,01 (0,00) · Cash flow from the business for the period was -0,2 MSEK (11,6) · The acquisition of Sensys Networks was completed on June 13. The purchase price was USD 16 million on a debt and cash free basis with adjustment of net working capital as of the closing date against normalized net working capital.  · Share capital increased by 5 534 530,50 SEK and the number of shares by 110 690 610 shares by a directed equity issue. An issue of equity with preferential rights for existing shareholders increased the share capital by 2 581 250 SEK by issuing 51 625 000 shares. First half year · Net sales increased during the period by 9,9% to 97,0 MSEK (107,7) · The result (EBITDA) was 4,3 MSEK (8,6), corresponding to a margin of 4,4% (8,0) · Result after tax was -2,8 MSEK (3,7) · Result per share was -0,01 (0,02) · Cash flow from the business was 3,2 MSEK (8,5) Comments by the CEO TagMaster has had a very exciting quarter, which has been much characterized by the acquisition of Sensys Networks, finalized on June 13. Through the acquisition we almost double our turnover and we also get a platform of our own in the US. We also receive a wider and deeper technology competence. Through the acquisition we achieve a higher organic growth potential and we become an even more interesting partner for building the smart cities of the future. Sensys Networks offer a wireless platform used in traffic and parking solutions. More specific it is an end to end solution composed by sensors, edge gateways and a sophisticated cloud-based data management system (SNAPS) installed in hundreds of cities around the world. The system addresses the need to let information control to offer more efficient traffic and parking solutions. Our total sales during the quarter has been higher than last year explained by that we include Sensys Networks’ figures for the last two weeks of the period. Adjusted for this, sales have been on the same level as last year, but with a higher gross margin. Costs have been temporarily higher for TagMaster as well as for Sensys Networks in connection with the acquisition, which ends up in a lower result. Our British businesses, CA Traffic and CitySync, have had a quarter in line with Q1, but with somewhat lower margins depending on unfavorable product mix. We will finish the integration work (a common structure) during the second half of the year and we continue to strengthen our sales and marketing resources. Our French businesses, Balogh, Magsys and Hikob have during the period altogether shown satisfactory results. Product deliveries of Baloghs new SIL 4 product platform have now started, but in a lower volume than planned. We have during the quarter had a somewhat higher cost level connected to the finalization of previous management changes. Also, in our French companies we bring the integration work one step further and merge legal units during the second half of the year. With an integrated business we look forward to a more powerful activity towards the exciting French market. In France we also continue recruitments to strengthen our sales and marketing resources. Our integration work, of previously acquired businesses, is getting to an end and our now cost-efficient units could from now on focus on increasing sales. The integration work with Sensys Networks has already started and we see in a first step close cooperation in the European sales work. Jonas Svensson CEO This as well as previous financial reports could be found at the company homepage www.tagmaster.com For further information, please contact Jonas Svensson, CEO, +46 8-6321950, jonas.svensson@tagmaster.com This information is information that TagMaster AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 8.30 a.m. CET on July 12, 2019. About TagMaster TagMaster is an application driven technology company that designs and markets advanced sensor systems and solutions based on radio & vision technology (RFID, Radar & ANPR) for demanding environments. Business areas include Traffic Solutions and Rail Solutions sold under the brands TagMaster, CitySync, Balogh, CA Traffic, Magsys and Sensys Networks with innovative mobility solutions in order to increase efficiency, security, convenience and to decrease environmental impact within Smart Cities. TagMaster has dedicated agencies in the US and in China and exports mainly to Europe, The Middle East, Asia and North America via a global network of partners and, systems integrators. TagMaster was founded in 1994 and has its headquarters in Stockholm. TagMaster is a public company and its shares are traded on First North stock exchange in Stockholm, Sweden. TagMasters certified advisor is Erik Penser Bank telephone +46 8 4638300, E-mail: certifiedadviser@penser.se 

Beijer Ref AB Q2-2019

Net sales increased by 14% in the second quarter compared to the same period last year and amounted to SEK 3,996 million (3,510). Organic growth was 4.4%. The operating profit for the quarter amounted to SEK 373 million (345), an increase of 8% compared with the same period last year. The operating margin was 9.3% (9.8%), of which 0.2% is a positive IFRS 16 effect. Profit for the period totalled SEK 265 million (255). Profit per share amounted to SEK 2.08 (1.98). The company's liquidity is good and unutilised credit amounts to SEK 1427 million (393). With effect from 1 January 2019, the company applies IFRS 16 with regard to the group's leasing agreements and all figures for 2019 include this change. The conversion affected operating profit positively by SEK 7 million and net profit by SEK 0.1 million. The equity ratio has decreased by 3.3 percentage points as a result of an increased balance sheet total. Comments by the CEO Environmentally-friendly refrigeration technology and air conditioning drive growth The market during the quarter was characterised by continuing strong demand and both sales and profit increased, both organically and through acquisitions. In total, net sales amounted to SEK 3,996 million (3,510), an increase of 14% of which 7% is acquired sales and more than 4% is organic growth. The operating margin, including the effect of IFRS 16, amounted to 9.3% (9.8%). The margin is slightly lower than in the previous year, mainly due to the price of refrigerants not being at the same high level as in 2018. One of the main features of the quarter is that our OEM and HVAC segments are moving forward strongly, especially in Europe. Both segments are driven by the EU's phasing-out programme for HFC gases, which are being gradually replaced by environmentally friendly alternatives. The OEM segment grew in total by 32% during the quarter and accounted for 10% of the group's sales. The warm summers of recent years in Europe have contributed to an increased interest in heat pumps, since these are also used for air conditioning. This, combined with a generally high demand, contributes to the strong development of the HVAC segment. Long-term partnerships with strong brands, such as Toshiba, Carrier and Mitsubishi Heavy Industries, give us a good market position. In total, sales in HVAC increased by 37% and now represent 41% of the group's sales. The quarter has tough comparative figures, since 2018 was a year when the price of refrigerants was at a historically high level. From autumn 2018 and during the first half of 2019, prices have gradually fallen, which affects the commercial refrigeration segment negatively, although volume sales did not decline at the same rate. The decline in sales is well offset by the growth of other segments, which means that the importance for the group of the price trend for refrigerants is declining. The assessment is that the price of refrigerants will stabilise during the autumn. The phasing-out period runs until 2030, with the next major reduction in import quotas in 2021. All of our geographical regions show growth apart from Eastern Europe, which has been most affected by the price trend for refrigerants. It is positive that the African market is showing growth after having previously been in recession, and we see potential for continuing improvement in earnings. In general, we can see how more and more countries outside Europe are committing to resolutions that involve phasing out HFC gases. Recently, for example, Cuba became the 73rd country to sign the Kigali agreement and more are being added on an ongoing basis. The agreement means that the consumption of HFC gases is to be reduced by more than 80% over the next 30 years. During the autumn, we will start a project to expand our production capacity in OEM in order to better meet the increasing demand for eco-friendly refrigeration technology. We will also invest in our own production line, which will handle natural, environmentally friendly refrigerants at the company's filling unit in Gothenburg. Our market is growing globally and we have much left to do. The group's liquidity is good, which opens up opportunities for new acquisitions. Overall, we are entering the third quarter in excellent shape. Per Bertland, CEO Second quarter of 2019 NET SALES  Beijer Ref increased its net sales by 14 per cent to SEK 3,996 million (3,510) in the second quarter of 2019, 7% of which is explained by the acquisitions made in 2018. Adjusted for exchange rate changes and acquisitions, organic growth in net sales was 4.4 per cent. All regions except Eastern Europe show sales growth. Commercial refrigeration represents 49% of the company's sales, 41% is air conditioning and OEM accounts for 10% of total sales. The latter two show a 20% increase in sales during the quarter, while dependence on refrigerants has decreased. A weakened Swedish krona resulted in positive currency effects of SEK 85 million (133), corresponding to 2.6% (5.8), since most of the company’s sales are in currencies other than Swedish kronor. PROFIT  The group’s operating profit totalled SEK 373 million (345) during the second quarter, an increase of 8 per cent. The operating margin was 9.3% (9.8%), the main explanation for which is lower prices for refrigerants and that companies acquired during 2018 have a slightly lower margin. Adjusted for IFRS 16 effect, the company's net financial items are in principle unchanged compared with the previous year despite increased borrowing. The pre-tax profit was SEK 359 million (342). Profit for the period was SEK 265 million (255). Profit per share amounted to SEK 2.08 (1.98). CASH FLOW  Cash flow from current operations before changes in working capital amounted to SEK 381 million in 2019, compared with SEK 286 million in 2018. The increase is due to improved profits during the quarter and a positive effect of SEK 74 million attributable to depreciation of usage rights assets arising from the transition to IFRS 16 (leasing). The corresponding amount of SEK 74 m is reported as a decrease in financing activities. Working capital increased by SEK 426 million during the quarter compared with SEK 275 million the previous year. This gives cash flow from operating activities of SEK -45 million, compared with SEK 11 million the previous year. The change in working capital from year to year is due primarily increasing capital build-up during the quarter. At the end of the period, the group had unutilised credit facilities totalling SEK 1,427 million (393). INVESTMENTS  The group’s investments in fixed assets including business combinations totalled SEK 40 million (626) during the quarter and refer primarily to investments in fixed assets. In the previous year, Kirby HVAC & Refrigeration Pty Ltd was acquired during the quarter. COMPANY ACQUISITIONS No major acquisitions were made during the quarter, but the company is continuously evaluating new opportunities for growth and complementary acquisitions. The group made a small asset acquisition in Switzerland of a distributor of insulation materials, Durissol, amounting to SEK 3.6 m, which gives the company exclusive rights to their products for five years. SIGNIFICANT EVENTS AFTER THE QUARTER   The group has made a minor supplementary acquisition after the quarter of the remaining shares in AC & Ref Parts CQ Patton Pty Ltd in Australia and now owns 100% of the company. The company has annual sales of approximately SEK 25 million through two sales branches. The company is included in its entirety in the consolidated accounts with effect from 1 July 2019. THE SHARE  Since 2 January 2019, Beijer Ref’s B share has been listed on Nasdaq OMX Stockholm's Large Cap list. The share capital in Beijer Ref totals SEK 371,685,513, made up of 127,434,690 shares, each with a quota value of SEK 2.92. There are two types of share, A shares and B shares, with ten and one vote respectively. Beijer Ref had 7,893 shareholders on 28 June 2019. At present there are 9,918,720 A shares and 117,515,970 B shares. RISK DESCRIPTION  The Beijer Ref Group’s operations are subject to a number of business environment factors, the effects of which on the Group’s operating profit can be controlled to varying degrees. The Group’s operations depend on general economic trends, primarily in Europe, which determine demand for Beijer Ref’s products and services. Acquisitions are normally associated with risks, for example loss of key employees. Other operating risks, such as agency and supplier agreements, product liability and delivery commitments, technical development, warranties, dependence on key individuals, etc., are analysed continually. Where necessary, measures are taken to reduce the Group’s risk exposure. In its operations, Beijer Ref is subject to financial risks such as currency risk, interest rate risk and liquidity risk. The Parent’s risk profile is the same as that of the Group. For further information, see the Group’s Annual Report. ACCOUNTING POLICIES  This interim report was prepared in accordance with IAS 34, the Swedish Annual Accounts Act and RFR 2. Beijer Ref continues to apply the same accounting policies and valuation methods as described in the most recent annual report. IFRS 16 Leases  IFRS 16 Leases, is applied from 1 January 2019. Beijer Ref has chosen to report the transition to the new standard using the simplified method. The relief rule not to create a comparative year has been applied. A discount rate has been defined per each country and are decided quarterly. Right of use agreements of less than 12 months are reported as short-term agreements and are therefore not included in the reported liabilities or rights of use. Right of use agreements with an acquisition value below USD 5,000 have been classified as low-value agreements and are not included in the reported liabilities or rights of use. The lease portfolio contains approximately 1,500 contracts and comprises primarily operational leases for offices, warehouses, company cars, forklift trucks and office equipment. Beijer Ref has identified many agreements, primarily relating to properties, with the right to extend. As a result of these considerations, many leases have been deemed to be longer. All leases relating to properties that fall due in 2019 have been extended by three years. Comparative information is not recalculated and is still reported in accordance with IAS 17 Leases and IFRIC 4 Determining whether an Agreement contains a Lease. Financial assets and liabilities by category and measurement level Financial assets and liabilities consist of financial assets valued at fair value and also financial assets and liabilities valued to discounted acquisition cost. Financial assets valued at fair value consist of two holding, one of which (SEK 22 million) refers to listed shares and is valued at market value on the balance sheet date (measurement level 1). The second holding (SEK 25 million) is an unlisted holding and is valued at estimated fair value (measurement level 3). Financial assets valued at discounted acquisition cost, such as accounts receivables including other receivables and liquid funds, amount to SEK 4 131 million on the balance sheet date and financial liabilities, such as trade creditor including other liabilities, borrowing and other long-term liabilities, amount to SEK 7 432 million. Financial interest-bearing liabilities such as borrowing linked to financing are valued at discounted acquisition cost and are considered representing a reasonable approximation of the fair value. WEB MEETING Q2 2019 The company invites investors, analysts and the media to attend a web meeting at which CEO Per Bertland and CFO Maria Rydén present the interim report for the second quarter of 2019. The presentation will be held in English and lasts for about 20 minutes. The meeting is on 12 July at 10.00 CET. Email your wish to participate at info@beijerref.com and a link will be distributed before the meeting. Internet connection is required. The presentation will be available on the company's website www.beijerref.com. For more information on this report: Per Bertland, CEO – switchboard, +46 (0)40-35 89 00 Maria Rydén, CFO – switchboard, +46 (0)40-35 89 00 This interim report has not been the subject of examination by the Company’s Auditors. The Board of Directors and the President assure that the six-month report is prepared in accordance with generally accepted accounting principles for listed companies. The information provided corresponds with the actual conditions in the operation and nothing of significant importance has been left out which could affect the picture of the Group and the parent company that has been created by the six-month report. Malmö, Sweden, 12 July 2019 Bernt Ingman Chairman Peter Jessen Jürgensen Board Member Frida Norrbom Sams Board Member William Striebe Board Member Chris Nelson Board Member Monica Gimre Board Member Joen Magnusson Board Member Per Bertland President This information is information that Beijer Ref AB is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact person set out above, at 08.30 CET on 12 July 2019. This document is a translation of the Swedish language version. In the event of any discrepancies between this translation and the original Swedish document, the latter shall be deemed correct. www.beijerref.com 

Triton to acquire Aleris

Stockholm (Sweden) 12 July 2019 – Funds advised by Triton (“Triton“) have signed an agreement to acquire the larger part of the company commonly referred to as Aleris (“Aleris”), through the legal entities Aleris Healthcare AB and Aleris Imaging AB.Aleris is one of the leading healthcare companies in the Nordics and a wholly-owned subsidiary of Patricia Industries, a part of Investor AB. Patricia Industries acquired Aleris in 2010. Tritons´ acquisition does not include the entity Doctor24.  The transaction is subject to regulatory approval. Patient care and daily operations of the company will continue as usual. Headquartered in Stockholm, Sweden and with more than 3,000 employees, Aleris is a provider of specialty care, healthcare and radiology with a strong footprint across Scandinavia. The company’s specialist care operations cover hospitals, outpatient clinics, radiology and labs through more than 100 units with approximately one million radiological examinations annually.   "We look forward to actively supporting Aleris talented management and employees in developing the company. Our strong Nordic healthcare expertise, gained through our investments in Ambea and Mehiläinen and strengthened by our senior industry experts, will contribute in taking the company to the next level.” said Peder Prahl, Director of the General Partner for the Triton funds.“Aleris is one of few private healthcare providers with scale in the Nordics and we believe that the market for high-quality healthcare services will play an even more important role in society in the future. We are impressed by the professionalism and commitment from Aleris employees and the company runs an attractive, quality focused business which is a market leader in several service areas and geographies. The Nordic healthcare services market is non-cyclical, and we see opportunities for further consolidation and digital transformation. Triton will be an active and responsible owner, supporting Aleris and it´s employees’ further development as leaders in this field, says Jan Pomoell, Investment Advisory Professional, sector leader for Healthcare and advisor to the Triton Funds.   About AlerisAleris is one of Scandinavia’s leading private healthcare providers with a versatile offering of specialist care and diagnostic services. Through approx. 100 facilities, Aleris aims to provide a person-oriented and seamless healthcare journey for all individuals seeking care – either physically or through its digital offering. About TritonSince its establishment in 1997, Triton has sponsored nine funds, focusing on businesses in the industrial, business services, consumer and health sectors. The Triton funds invest in and support the positive development of medium-sized businesses headquartered in Europe. Triton seeks to contribute to the building of better businesses for the longer term. Triton and its executives wish to be agents of positive change towards sustainable operational improvements and growth. The 38 companies currently in Triton's portfolio have combined sales of around €14.9 billion and around 73,000 employees. Press contacts TritonFredrik HazénPhone: +46 70 948 38 10

SKF extends sponsorship of Gothia Cup

Gothenburg, 12 July 2019: SKF has extended its sponsorship of Gothia Cup. SKF will continue as main partner for the world’s largest youth football tournament, which takes place every summer in Gothenburg. SKF has been involved with Gothia Cup since 2006, becoming main partner in 2007. The new sponsorship agreement means SKF will continue as main partner until 2022. In addition to being main partner, SKF will continue with its SKF Meet the World tournaments. Through local qualifying tournaments, SKF Meet the World gives children from different backgrounds the opportunity to travel to Sweden to participate in Gothia Cup. Since its inception, approximately 5000 children have been afforded this opportunity. Alrik Danielson, President and CEO, says: “Gothia Cup is one of the world’s largest sporting events and a great way for use to showcase our support for young people and the city of Gothenburg. We will continue to invest in this great event over the next three years and look forward to welcoming youngsters to Sweden.” Dennis Andersson, General Secretary of Gothia Cup, says: “SKF contributes with their genuine support which adds in spreading the Gothia Cup spirit about joyfulness and equality around the world in general, and in creating the world’s largest meeting place for youth in particular through the SKF Meet the World tournaments. We look forward to spending another three years together with SKF as our main partner.” This year’s Gothia Cup will take place from 14–20 July. Aktiebolaget SKF     (publ)

Q-linea strengthens management team

“I am pleased to welcome Tiziana Di Martino to the Q-linea-family. In her previous roles she has successfully managed clinical projects related to new product launches. Her experience will be a great benefit for Q-linea in our present position with our upcoming launches in Europe and the US.” said Jonas Jarvius, CEO of Q-linea.Tiziana Di Martino has more than 16 years’ experience in clinical practice, research and medical affairs positions in the microbial diagnostic industry. Her latest position was Head of Clinical Development EMEA at Accelerate Diagnostics. Tiziana Di Martino is a Medical Doctor from Università Cattolica del Sacro Cuore in Rome, has a Master’s degree (MSc) in Toxicology from the University of Surrey and also holds an MBA from London Business School. Tiziana Di Martino will be part of Q-linea’s management team as of July 2019.     For more information, please contact:Jonas Jarvius, CEO, Q-linea AB Jonas.Jarvius@qlinea.com,+46 (0)70-323 77 60Anders Lundin, CFO, Q-linea ABAnders.Lundin@qlinea.com +46 (0)70-600 15 20About Q-lineaQ-linea is an innovative research, development and manufacturing company that primarily develops instruments and disposables for rapid and reliable infection diagnostics. Q-linea’s vision is to help save lives by ensuring antibiotics continue to be an effective treatment for future generations. Q-linea develops and delivers preferred solutions for healthcare providers, enabling them to accurately diagnose and treat infectious disease in the shortest possible time. The company’s lead product ASTar™ is a fully automated instrument for antibiotic susceptibility testing (AST), giving a susceptibility profile within six hours directly from a positive blood culture. For more information, please visit www.qlinea.com.The information was submitted for publication, through the agency of the contact persons set out above, at 09:00 CET on July 12, 2019.

Significantly oversubscribed rights issue in Scandion Oncology

CEO Nils Brünner comments: “We are very grateful for the interest in our rights issue and I would like to thank both our existing shareholders for their trust and all interested parties who have chosen to invest in Scandion Oncology. With the capital that we are now provided through this share issue, we look forward to continuing the planned activities. Subscription and allotment in the rights issue The rights issue was subscribed to SEK 58,298,052 including pre-subscription commitment and excluding guarantee commitments, corresponding to a subscription rate of approx. 199 percent. 7,144,590 new shares and 2,381,530 warrants of series TO 1 will be issued and Scandion Oncology is thus now provided approx. SEK 29.3 million before issue costs, which are estimated to amount to approx. SEK 3.8 million (12.8% of the issue volume) of which approx. SEK 0.7 million refers to guarantee compensation. 2,214,691 units, corresponding to approx. 93 percent of the subscribed issue volume, were subscribed by shareholders with the support of unit rights. Due to the extensive interest, guarantee commitments are not activated. Allotment of units (shares and warrants) have been decided upon by the Board of Directors in accordance with the principles stated in the prospectus. Settlement notes are expected to be sent out today, July 12, 2019. Subscribers who are not allocated units will not receive settlement notes. Number of shares and share capital When the rights issue has been registered with the Danish Business Authority, the number of shares in Scandion Oncology will amount to 19,052,241 shares and the share capital will amount to DKK 1,400,339.7135. Trading in BTU (Paid-up for units) Trading in BTU will take place on Spotlight Stock Market until the Danish Business Authority has registered the rights issue. This registration is expected to take place late July 2019. Disclosure notice regarding Jan Stenvang Due to the rights issue, a requirement for a disclosure notice regarding Jan Stenvang (CSO in Scandion Oncology) occurs. As a result of dilution, Jan Stenvang’s ownership in Scandion Oncology is reduced from approx. 12.44% to approx. 7.77%. Financial adviser, issuing agent and legal adviser Sedermera Fondkommission is the financial advisor and issuing agent to Scandion Oncology in connection with the rights issue. Markets & Corporate Law acts as the legal advisor. For more information regarding Scandion, please contact: Nils Brünner, CEO Phone: +45 26 14 47 08 E-mail: nb@scandiononcology.com  www.scandiononcology.com This information is information that Scandion is obliged to publish in accordance to the EU Market Abuse Regulation. The information was provided by the contact person above for publication on July 12, 2019. Scandion Oncology A/S is a biotechnology company founded in 2017 for the purpose of addressing and tackling one of the greatest challenges in modern oncology – the effective treatment of cancer which contains drug resistant cells or which has developed resistance to a previously prescribed cancer-fighting drug. In preclinical animal studies, the company’s leading candidate drug, SCO-101, was found to significantly enhance the efficacy of certain standard cancer treatments when given in combination. In addition, SCO-101 restores chemotherapy sensitivity in in vitro grown resistant cancer cells. Scandion Oncology will in Q4 2019 initiate a clinical phase II study with SCO-101 in combination with chemotherapy. Scandion Oncology was listed on Spotlight, Sweden in November 2018.

Cimco Marine AB (publ) publishes convening notice for extraordinary general meeting and proposes issue authorisation for the board

The shareholders in the Company are hereby convened to the extraordinary general meeting on Tuesday 30 July 2019, at 2 pm, at Best Western Plus Hus 57, Östergatan 57 in Ängelholm. Notice etc. Shareholders who wish to participate at the general meeting must: -                   on Wednesday 24 July 2019, be registered in the share register kept by Euroclear Sweden AB (“Euroclear”); and -                   at the latest on Wednesday 24 July 2019 notify the intention to attend the general meeting by e-mail to cimcoEGM2019@lindahl.se or by post to Advokatfirman Lindahl KB, att. Alexandra Niemelä Ingvarsson, Box 11911, 404 39 Göteborg. Such notification shall include the shareholder’s name and should include personal identification number or corporate registration number (or similar), address and daytime telephone number, number of shares, details on advisors (no more than two), if any, and where applicable, details of representatives or proxies. Nominee-registered shares To be entitled to participate in the general meeting, shareholders whose shares are registered in the name of a nominee must temporarily re-register their shares in their own names in the share register maintained by Euroclear. Such registration must be duly effected (registered with Euroclear) in the share register on Wednesday 24 July 2019, and the shareholders must therefore advise their nominees well in advance of such date. Proxy Shareholders represented by proxy must submit a dated proxy. If the proxy is executed by a legal person, a copy of the registration certificate or equivalent must be attached. The proxy may not be valid for a period longer than five years from its issuance. The original proxy and certificate of registration should be submitted to Advokatfirman Lindahl KB by mail at the address mentioned above in due time prior to the general meeting. The Company provides a form of proxy at request and it is also available at the Company’s website, www.oxe-diesel.com. Proposed agenda 1. Opening of the general meeting and election of chairman of the general meeting 2. Preparation and approval of the voting list 3. Election of one or several persons to verify the minutes of the meeting 4. Determination of whether the meeting has been duly convened 5. Approval of the agenda 6. Resolution on authorisation for the board of directors to resolve on directed issues of new warrants to the European Investment Bank 7. Close of the general meeting Proposals to resolutions Item 6 – Resolution on authorisation for the board of directors to resolve on directed issues of new warrants to the European Investment Bank On 5 July 2019, the Company entered into a EUR 14 million credit facility agreement with the European Investment Bank (the “EIB”). The credit facility is split into three tranches. Drawdown under tranche A and tranche B respectively are amongst other things conditioned upon the Company issuing share warrants to the EIB without consideration, entitling the EIB to subscribe for shares in the Company corresponding to 7.5 percent of the fully-diluted share capital of the Company (i.e. up to a total of 15 percent calculated considering all issued share warrants and any convertibles in the Company from time to time). Should the Company utilize both tranche A and tranche B, the Company will have issued share warrants to the EIB entitling the EIB to a total of 15 percent ownership after full dilution. The Company and the EIB intend to enter into a separate warrant agreement regarding the Company’s issues of share warrants to the EIB. The credit facility agreement and the warrant agreement are hereinafter jointly referred to as the “Financing Agreements“. The board of directors of the Company proposes that the general meeting resolves to authorise the board to, with deviation from the shareholders’ pre-emption rights, at one or several occasions during the time up until the next annual general meeting, resolve on issuing the lowest number of new warrants without consideration required for the Company to fulfill the conditions for drawdown under tranches A and B of the Financing Agreements. The board shall have the right to set the terms and conditions for issues under this authorisation. The reason for the deviation from the shareholders’ pre-emption rights is for the Company to fulfil the conditions for drawdown under tranches A and B of the Financing Agreements. The CEO, or a person appointed by the board of directors, shall be entitled to make any minor amendments that may be required in connection with registering the resolution with the Swedish Companies Registration Office and/or Euroclear. Majority requirement Resolution under item 6 above requires, for its validity, that a minimum of two thirds of the votes cast and the shares represented support the resolution. Documentation The board of directors’ complete proposal, as well as other documents according to the Swedish Companies Act will be held available at the Company’s office with address Metallgatan 17 B in Ängelholm and on the Company’s website not later than two weeks before the general meeting, i.e. not later than 16 July 2019. The documents will also be sent, without charge, to shareholders who so request and inform the Company of their postal address. The documents will also be available and presented at the general meeting. Processing of personal data For information on the Company’s processing of personal data in connection with the general meeting, please refer to https://www.euroclear.com/dam/ESw/Legal/Privacy-notice-bolagsstammor-engelska.pdf. Ängelholm in July 2019 Cimco Marine AB (publ) The board of directors

Interim Report Q2, January-June 2019

April – June 2019 · Net sales decreased to SEK 507 million (543) · Operating profit before depreciation decreased to SEK 19 million (21) · Operating profit decreased to SEK -3 million (10) · Earnings after tax amounted to SEK -16 million (-17) · Earnings per share amounted to SEK -0.08 (-0.08) · Cash flow after investing activities amounted to SEK -11 million (-48) January – June 2019 ·  Net sales decreased to SEK 1,078 million (1,081) ·  Operating profit before depreciation increased to SEK 56 million (44) ·  Operating profit decreased to SEK 12 million (22) ·  Earnings after tax amounted to SEK -14 million (-21) ·  Earnings per share amounted to SEK -0.07 (-0.11) ·  Cash flow after investing activities amounted to SEK 31 million (-46) Bong is one of the leading providers of envelope products in Europe that also offers solutions for distribution and packaging of information, advertising materials and lightweight goods. Important growth areas in the Group are packaging within retail and e-commerce and the envelope market within Eastern Europe. The Group has annual sales of approximately SEK 2.2 billion and about 1,400 employees in 12 countries. Bong has strong market positions in most of the important markets in Europe and the Group sees interesting possibilities for continued development. Bong is a public limited company and its shares are listed on Nasdaq Stockholm (Small Cap). For further information, please contact Kai Steigleder, CEO for Bong AB.  Tel (switchboard) 46 44-20 70 00   This is information that Bong AB is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact person set out above, at 12:00 CET on July 12th 2019. 

Interim report January-June 2019: Continued positive progress, and acquisition of Swiss tech company

Second quarter · Order intake amounted to 377 MSEK (371). · Net sales increased by 6% to 381 MSEK (361). · EBIT up to 21.5 MSEK (18.0). · Profit after tax amounted to 13.7 MSEK (10.5). · Earnings per share increased to 0.48 SEK (0.36). · Acquisition of Neratec in Switzerland after the end of the reporting period. First half-year · Order intake amounted to 745 MSEK (769). · Net sales increased by 8% to 752 MSEK (698). · EBIT up to 51.6 MSEK (36.0). · Profit after tax amounted to 33.7 MSEK (20.1). · Earnings per share increased to 1.18 SEK (0.70). · Continued positive progress, and acquisition of Swiss tech company COMMENTS FROM CEO PER SAMUELSSON “BEIJER GROUP kept heading in a positive direction in the second quarter, largely following the strategic plan we set a few years ago. However, viewed in a longer perspective, the second quarter marked something of a pause in the Group’s continued expansion and aim to achieve long-term targets. Combined with increased costs resulting from our focused initiatives, growth somewhat below plan meant a limited pay-off in earnings. The continued improvement of gross margins was positive. Higher overheads worked in the opposite direction, and the EBIT increase was held at just below 20%. The positive growth trend continued in the Westermo business entity, with increased order intake and sales. Since the quarter had no major orders, its core business achieved good organic growth. Meanwhile, overheads increased, due to continued production capacity expansion and initiatives in network solutions for the power distribution and rail infrastructure segments. The business entity was also charged with non-recurring expenses for the acquisition of Neratec. Overall, this meant earnings gains in the quarter were modest. The Beijer Electronics business entity posted continued earnings and margin gains despite sales being unchanged. But we can also conclude that the numbers were lower than desired. As stated in the previous quarterly report, the phase-out of previous product families has created some irregularity between quarters, and that it’s now clear that exceptional large orders customers placed for products in phase-out before year-end did slow order placing and sales in the second quarter. These effects will gradually taper off. We have also seen a somewhat slower transition to new products in the US. Consequently, the business entity implemented a new organizational structure, appointing some new executives in the US to accelerate growth. Basically, the Korenix business entity progressed as planned, with somewhat higher sales and improved earnings, and is thus nearing break-even. Korenix is focusing on regenerating its product range and achieving profitability in 2019. I can see that where the business cycle is heading is still uncertain, but for us, the underlying trend remains positive, and we haven’t seen any signs of a slowdown in customer activity. Our business entities are executing a number of major projects, which with positive outcomes, will make a good contribution to growth. Westermo’s acquisition of Neratec in Switzerland is another step in our long-term strategic plan. Neratec is a complementary acquisition that is a good fit with, and enhances, Westermo’s product offering. It also contributes to increasing already healthy organic growth. The acquisition also marks the Group achieving a stability that enables resources to be freed up to increase expansion. Our priority remains organic growth, but this can be supplemented by further acquisitions when the opportunity arises. For the full year 2019, we reiterate our view that BEIJER GROUP will be able to increase sales and earnings compared to the figures for 2018.” INVITATION TO CONFERENCE CALL Today, a conference call will be held for press and analysts, where President and CEO Per Samuelsson and EVP and CFO Joakim Laurén present the company and comment on the report. Time:  Friday July 12, at 14.00 CEST To participate in the conference please dial: From SE: +46850558359From UK: +443333009274 To access the presentation please use this link: https://www.anywhereconference.com?Conference=301292644&PIN=33176776&UserAudioMode=DATA  The report and the presentation will be available at the company’s website www.beijergroup.com . A recording of the conference call will also be available here after the event. Welcome!  

Sandvik acquires stake in leading Additive Manufacturing service provider

Sandvik has acquired a 30% stake in privately owned Italian company Beam IT, a leading provider of metal Additive Manufacturing (AM) services and advanced end-use components. “The investment in Beam IT will complement our existing offer in Additive Manufacturing. It is also in line with Sandvik’s strategic ambition to become a leading solution provider for the wider component manufacturing industry,” says Lars Bergström, President of Sandvik Machining Solutions. Beam IT is a trusted supplier of metal AM end-components to demanding industries, including automotive, energy and aerospace, and holds several relevant quality certifications to serve these industries. The company has more than 20 years of experience within Additive Manufacturing (AM) and has more than 20 Powder Bed Fusion printers installed. “The AM sector is developing fast and there is a need for AM-specialist-partners with the advanced skills and resources required to help industrial customers develop and launch their AM programs. With this investment we provide our customers with the opportunity to access the complementary and combined power of Sandvik and Beam IT, says Kristian Egeberg, President of the Additive Manufacturing division in Sandvik. In 2018, Beam IT generated revenues of about 70 million SEK, with its 38 employees. Sandvik has the right to further increase its stake over time. The parties have agreed not to disclose the purchase price. Stockholm, 12 July 2019 Sandvik AB For further information, contact Ann-Sofie Nordh, Vice President Investor Relations, phone: +46 8 456 14 94 or Martin Blomgren, Press and Media Relations Manager, phone: +46 70 577 0549.

Elekta to demonstrate leadership in Precision Radiation Medicine at AAPM with launch of new QA portfolio

SAN ANTONIO – At the 61st American Association of Physicists in Medicine (AAPM) Annual Meeting & Exhibition, July 14 - 18 in San Antonio, Elekta (EKTA-B.ST) will feature advanced quality assurance (QA) and treatment planning solutions that simplify the delivery of radiation therapy techniques. “As the complexity of radiation therapy increases, the need to achieve stringent safety, efficacy and efficiency requirements places additional demands on clinics,” said Ferhan Bulca, Elekta’s Vice President QA solutions. “Elekta is committed to providing our customers with a smarter way to achieve real-time QA. Partnerships with iRT, DOSIsoft and RTsafe will enable us to provide clinicians with a suite of advanced solutions, enabling fast QA through automated, integrated and adaptive workflows that ensure safety before, during and after treatment. These solutions give providers the confidence necessary to support advanced treatments – such as SRS and SRT – and make data-driven decisions essential for optimizing patient outcomes. The ability to keep the QA process simple is essential, especially as treatment paradigms become more complex and access to resources more difficult.” Elekta QA demonstrations at AAPM include: ·  A complete suite of easy-to-use, web-based QA tools that enable safe, standardized and efficient delivery of radiation therapy treatments while reducing administrative and non-treatment machine time. ·  Best-in-class QA products that provide ease of use for machine, plan and patient QA. ·  New solutions that bring real time online verification, as well as end-to-end SRS assurance. ·  Vendor neutral and scalable solutions that ensure patients are treated safely, regardless of department size or existing equipment. Elekta Unity abstracts add to growing body of data At AAPM, Elekta’s clinical collaborators will present 24 abstracts supporting the technical applications of Elekta Unity, a state-of-the-art MR-linac that is redefining a new standard for personalized radiation therapy based on real-time, high-resolution anatomical and biological MRI at the point-of-care. With the potential to preserve more healthy tissue than ever before, the system enables the use of radiation therapy in hard-to-treat cancers, going beyond anatomy with biological MRI to assess tumor responses early in treatment. Across the globe, nine leading cancer centers with Unity have treated twelve different cancer indications and more than 250 patients have been treated. Visitors to Elekta booth 216 also will have an opportunity to learn about Monaco® HD treatment planning system, the gold standard for delivering fast, accurate treatment plans. With Smart Sequencing and true multicriterial optimization, Monaco HD achieves superior plan quality with short delivery time. MOSAIQ® Plaza, Elekta’s newest software solution for the delivery of complex precision radiation medicine treatment regimens is also available for demonstration. MOSAIQ Plaza is a patient-centric, integrative ecosystem, designed to manage a connected workflow for every moment of each patient’s journey. For real-time updates from our educational events and the AAPM show floor, follow @Elekta  on Twitter. To learn more about Elekta at AAPM, visit www.elekta.com/AAPM. Elekta Unity has CE mark and 510(k) clearance but is not available in all markets. MOSAIQ Plaza is not available in all markets. # # # For further information, please contact:Oskar Bosson, Global EVP Corporate Communications and Investor RelationsTel: +46 70 410 7180, e-mail: Oskar.Bosson@elekta.comTime zone: CET: Central European Time Raven Canzeri, Global Public Relations ManagerTel: +1 770 670 2524, e-mail: raven.canzeri@elekta.comTime zone: ET: Eastern Time

Lifco acquires Ergopack Deutschland GmbH

Lifco  has signed an agreement to acquire the majority of the German company Ergopack.  The company is the leading manufacturer of ergonomic and mobile pallet strapping systems that are used in many different industries globally.  In 2018, the acquired operation reported net sales of approximately 22 MEUR. The business is based in Lauingen, Germany and employs around 85 people. The operation will be consolidated in Business Area Systems Solutions, division Environmental Technology. The acquisition is subject to anti-trust clearance from German authorities. The acquisition will not have any significant effect on Lifco’s earnings or financial position in current financial year. Please visit www.ergopack.de for more information. For more information please contact: Per Waldemarson CEO and President Lifco E-mail per.waldemarson@lifco.se Åse Lindskog  Media and investor relations managerPhone +46 730 244 872, e-mail ir@lifco.se  About Lifco Lifco offers a safe haven for small and medium-sized businesses. Lifco’s business concept is to acquire and develop market-leading niche businesses with the potential to deliver sustainable earnings growth and robust cash flows. Lifco is guided by a clear philosophy implying that the company has a long-term view on its holdings, a focus on profitability and a strongly decentralised organisation. The Group has three business areas: Dental, Demolition & Tools and Systems Solutions. At the end of 2018 the Lifco Group consisted of 146 operating companies in 29 countries. In 2018 Lifco reported EBITA of SEK 2,168 million on net sales of SEK 12.0 billion. The EBITA margin was 18.1 per cent. Read more at www.lifco.se.

Dow Jones signs two year renewal agreement with Cxense

Oslo, Norway – 15 July 2019 – Cxense ASA (OSE: CXENSE), the AI-powered data management and intelligent personalization company that drives revenue for publishers and brands, today announces that Dow Jones & Company, Inc. (Dow Jones), a global leader in news and business intelligence and owner of The Wall Street Journal, has renewed its agreement with Cxense for two years with an option to extend for a third year.  Since the start of the partnership with Cxense in 2013, Dow Jones has successfully leveraged Cxense technology and know-how to grow digital revenue for its flagship publication, The Wall Street Journal.  Over the past years, Dow Jones, a pioneer in applying a data- and reader-led approach to subscription growth, and Cxense have strengthened their partnership and reached several important milestones. As early as 2016, The Wall Street Journal and Cxense were among the first to implement a machine learning-powered dynamic paywall. A dynamic paywall works by determining automatically and in real time, when, why and how a reader is asked to pay based on the information a publisher has on that reader. This enabled The Wall Street Journal to prove the value of their journalism to more potential subscribers and increase conversions significantly. In addition, a propensity model was introduced that predicts with up to 90% accuracy whether a reader will subscribe.  These innovative approaches have since been incorporated into Conversion Engine, Cxense’s all-in-one solution for dynamic paywalls and personalized customer journeys, and have been adopted by other leading publishers across the globe.  Speaking about the partnership, Christian Printzell Halvorsen, CEO of Cxense said: “In light of Dow Jones’ recent announcement that The Wall Street Journal has reached a record high of almost 1.8 million digital subscribers, today’s renewal confirms the trust in the partnership as well as in Cxense technology and know-how. We are proud to work with the Dow Jones team to enable them to provide their readers with personalised access to great journalism at each stage of the customer journey and take their subscription business to new heights.”  About Dow Jones:Dow Jones is a global provider of news and business information, delivering content to consumers and organizations around the world across multiple formats, including print, digital, mobile and live events. Dow Jones has produced unrivaled quality content for more than 125 years and today has one of the world’s largest news gathering operations globally. It produces leading publications and products including the flagship The Wall Street Journal, America’s largest newspaper by paid circulation; Factiva, Barron’s, MarketWatch, Financial News, DJX, Dow Jones Risk & Compliance, Dow Jones Newswires, and Dow Jones VentureSource.  For more information visit www.dowjones.com. About Cxense: Cxense is an AI-powered Data Management and Intelligent Personalization platform that helps 190 leading publishers and marketers around the globe deliver personalized experiences that grow subscription revenue and boost targeted advertising. Our technology organizes first, second, and third party data into powerful custom segments and 1:1 user profiles before applying machine learning to understand and predict customer behavior and intent. As a result, our clients are able to deliver unique and relevant content and offers to customers in real time, driving more subscriptions, sales, advertising revenue, and higher customer lifetime value. The Cxense platform creates 15 billion personalized touchpoints for 2 billion user profiles each quarter. Cxense works with global brands such as The Wall Street Journal, Singapore Press Holdings, Mediahuis and The Mainichi Newspapers. We are listed on the Oslo Stock Exchange and have offices in Norway, the US, Japan, Russia, Germany, and Argentina. Investor Relations Contact: Jørgen Evjen, Chief Financial Officer Email: ir@cxense.com Mobile: +47 928 04 014 Media contact:Tobias Arns, Head of Marketing and CommunicationsEmail: tobias.arns@cxense.comMobile: +47 920 24 305

Miss Group makes second acquisition in two weeks

ProfesionalHosting (which trades as Soluciones Web On Line S.L.), was founded in 2002 with the objective of offering web hosting and domain registration services. With a commitment to progressive growth, and innovation, the company has expanded its internet services, infrastructure and technology, reaching the variety offered today.  The business allows corporate, professional and private users to build an effective presence online with its full range of services. ProfesionalHosting has offices in Madrid and Almeria, Spain. Mattias Kaneteg CEO and founder of Miss Group said: "The acquisition of Profesional Hosting gives Miss Group the perfect platform to build on in Spain and replicate the success we have had in Scandinavia over the past five years. We will focus on both organic growth and our buy and build strategy in Spanish speaking markets. We have ambitious growth plans for Miss Group so this is an important market for us to grow in.”David Garcia, CEO and founder of ProfesionalHosting said: “We’ve admired Miss Group as a company and watched the growth journey to date. We are looking forward to joining forces with such an impressive business and taking the combined organisation to a new level." In August 2018, Miss Group received a £6.4m investment from BGF and in June 2019 another £13m investment to accelerate its international expansion strategy. BGF is the UK and Ireland’s most active investor. The funding has allowed the business to build further scale through driving organic growth and acquiring web hosting companies in new and existing markets. Prior to BGF investment Miss Group have received funding from Harbert European Growth Capital. About ProfesionalHosting:ProfesionalHosting was founded in 2002 and offer everything from Web Hosting, Domain Registration, VPS, Dedicated Servers, Site builders and just about anything a corporate, professional or private user could require building an effective presence online. The company has offices in Madrid and Almeria, Spain. About Miss Group:Founded in 2014, Miss Group is an International Web Hosting Group that offers a range of Hosting related services at favorable prices such as Web Hosting, Domain Registration, VPS, Dedicated Servers, Sitebuilder, SSL-Certificate, SEO Tools, Web Security and Domain Management. Miss Hosting is also an ICANN-accredited Domain Name registrar via NameISP. The company is headquartered in Manchester, UK.

IRLAB reports top line results from Phase IIa study with IRL790

Analysis of UDysRS, the primary efficacy variable, showed no statistical difference between IRL790 and placebo in the per protocol analysis set (PPAS) or full analysis set (FAS). The other two prespecified assessments indicated that IRL790 reduced dyskinesias. Dyskinesia assessment using MDS-UPDRS (question 4.1+4.2) showed an improvement by IRL790 treatment (p=0.03 PPAS, p=0.07 FAS) as compared to placebo. Also, the patient reported diaries showed that IRL790 treatment, compared to placebo, significantly reduced the daily time with troublesome dyskinesias in ON state (p=0.03 PPAS, p=0.03 FAS). IRL790 was well tolerated in the study. The mean dose of IRL790 at end of treatment was 16.2 mg daily. Three patients prematurely discontinued treatment, two due to adverse events, one treated with IRL790 and one with placebo, and one IRL790 treated patient due to withdrawal of consent. Any adverse event was reported by 78 % of placebo treated patients and 74% of IRL790 treated patients. The most common adverse events reported by system organ class (SOC) were nervous system disorders reported by 42% of placebo treated patients and 49% of IRL790 treated patients. There were 3 Serious Adverse Events (SAEs), none related to IRL790 treatment, 2 occurred during the screening period before randomization and 1 was reported for a patient treated with placebo. Cardiovascular assessments including blood pressure, heart rate, and ECG, showed no clinically relevant changes due to IRL790 treatment. Assessment of other motor symptoms of Parkinson’s disease using MDS-UPDRS part II+III, MDS-UPDRS off-time assessment as well as 24-hour diaries showed that patients treated with IRL790 maintained their general motor functions and had no increase in OFF time. Joakim Tedroff, CMO at IRLAB, commented “Dyskinesia is a burdensome symptom for patients with Parkinson’s disease as it is affecting their everyday lives and limits optimization of L-Dopa treatment. The patient reported outcome in this study suggest that adding IRL790 to their otherwise stable anti-parkinsonian treatment can improve the quality of daily motor function by reducing troublesome dyskinesias. This outcome was also independently reflected in the UPDRS ratings but not in the UDysRS ratings. This discrepancy needs to be investigated further. Importantly, the excellent safety and tolerability profile observed for IRL790 treatment in this study provides additional reassurance that IRL790 is safe to use in this vulnerable patient population and supports a careful assessment of the continued clinical development of IRL790.” Nicholas Waters, CEO at IRLAB, commented “We are pleased that the study is completed. Given the ambiguity between UDysRS and the other two methods used to assess dyskinesias, further analyses aiming to clarify the underlying reasons will be prioritized to optimize the clinical path forward. Next planned clinical study with IRL790 is in psychosis associated with Parkinson’s disease, PD-P, while continuing CMC development and long-term toxicological studies”. The company will continue and complete analysis of the current Phase II study data. The full results of the study will be published in an international scientific journal. About the study IRL790C003 (ClinicalTrials.gov Identifier: NCT03368170) The Phase IIa study was randomized, double-blind, placebo-controlled and run at 16 sites in the UK and 4 sites in Sweden. 106 patients with Parkinson’s disease and dyskinesia (involuntary movements) were screened for participation in the study and 75 patients, fulfilling inclusion criteria, were randomized to four weeks of treatment, 39 patients with IRL790 and 36 patients with placebo. 42 patients were male and 33 female and the mean age of the patients in the study was 66.6 years. Average duration of Parkinson’s disease was 10.7 years. IRL790 was taken twice daily (b.i.d.) as adjunctive treatment to the patients’ regular and stable antiparkinsonian medication. The first two weeks of treatment comprised titration of placebo or IRL790 (10 to 20 mg daily) to the individually preferred and tolerated dose then used for the remaining two weeks. Tolerability and safety were continuously monitored. About FAS and PPAS The Full Analysis Set (FAS) consisted of all randomised and treated patients who received one or more doses and who provided post baseline data. The Per Protocol Set (PPS) consisted of patients from the FAS but excluded those with major protocol violations. About IRL790 IRL790 is under development for the treatment of levodopa (L-dopa) induced dyskinesias (PD-LIDs), and psychosis in Parkinson’s disease (PD-P). Dyskinesias are involuntary movements that often follows treatment with L-dopa. In pre-clinical studies, IRL790 reduces involuntary movements that occurs after a period of treatment with L-dopa. Additionally, in pre-clinical studies, IRL790 has shown antipsychotic properties. The company believes that IRL790 thus has the potential to simultaneously treat both dyskinesias and psychosis in Parkinson’s disease. About Unified Dyskinesia Rating Scale (UDysRS) The Unified Dyskinesia Ratings Scale (UDysRS) evaluates the involuntary movements that can be associated with long-term treatment with dopaminergic medication. The UDysRS has four parts:          I.            Historical Disability (patient perceptions) of ON-Dyskinesia impact        II.            Historical Disability (patient perceptions) of OFF-Dystonia impact       III.            Objective Impairment (dyskinesia severity, anatomical distribution over seven body regions, and type (choreic or dystonic) based on four activities observed or video-recorded      IV.            Objective disability based on Part III activities About Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) Unified Parkinson's Disease Rating Scale (MDS-UPDRS) is a standardized and validated estimation scale developed for assessment of symptoms in Parkinson's disease. The instrument has been tested for good reliability and validity and consists of the following four parts: Part I – Non-Motor Aspects of Experiences of Daily Living Part II – Motor Aspects of Experiences of Daily Living Part III – Motor Examination Part IV – Motor complications of therapy Each section has questions that rate the symptoms from 0 to 4 where higher values indicate more severe symptoms. About patient completed 24-hour diaries Clinical diaries are a standardized method for patients to assess their health status. Patients log their motor status every 30 minutes for 24 hours. Patients record whether their motor status is “OFF”, “ON" or “ON with troublesome dyskinesias”. “OFF” denotes stiffness, marked decrease of mobility or immobility. “ON” denotes good or practically normal mobility, “ON with troublesome dyskinesias” is when the patient is troubled by involuntary twisting and turning movements. Additionally, sleep time is recorded. In this study patients completed two 24-hour diaries before randomization and two 24-hour diaries during the last week of the four-week treatment period.

Interim report January - June 2019

New sales record and increased profit Second quarter April – June 2019 · Net sales amounted to 282.1 MSEK (236.1), which is an increase by 19.5 percent compared to the corresponding quarter last year. At comparable exchange rates[1] and adjusted for acquisitions, sales increased by 5.8 percent. · Operating profit increased by 12.1 percent to 56.1 MSEK (50.0). · Result after tax increased by 5.4 percent to 54.2 MSEK (51.4). · Earnings per share amounted to 0.83 SEK (0.79) before and after dilution. · The cash flow from operating activities increased to 43.2 MSEK (24.6). · Dividends to the shareholders were paid to the amount of 97.8 MSEK (90.6). · Net debt[1] at June 30 amounted to 192.3 MSEK (-13.5). Cash and cash equivalents amounted to 108.1 MSEK (95.8). Liabilities to credit institutions amounted to 149.9 MSEK (109.3). · On May 24 the Board of Directors announced that Tomas Blomquist has been appointed as new CEO for Biotage effective November 6. Six months January - June 2019 · Net sales amounted to 530.1 MSEK (444.1), an increase by 19.4 percent compared to the corresponding period last year. At comparable exchange rates1) and adjusted for acquisitions, net sales increased by 7.2 percent. · Operating profit increased by 15.6 percent to 105.9 MSEK (91.6). · Result after tax increased by 5.6 percent to 101.7 MSEK (96.3). · Earnings per share amounted to 1.56 MSEK (1.49). · The cash flow from operating activities amounted to 55.7 MSEK (52.7).  · The acquisition of PhyNexus Inc. was completed on January 15. The purchase price amounted to approx. 21.3 MUSD (approx. 190.6 MSEK[2]), of this sum approx. 4.8 MUSD (approx. 43.2 MSEK) in cash payment and approx. 6.6 MUSD (approx. 58.6 MSEK) in newly issued shares in Biotage was paid in connection with closing. The remaining approx. 10.0 MUSD (approx. 89.3 MSEK) is expected future additional purchase price payments based on future results. · The issue of consideration shares for the acquisition increased the number of shares in Biotage from 64,714,447 to 65,201,784, which has resulted in a dilution of 0.7 percent for existing shareholders.  [1] See definition on pp. 18-20[2] Based on an exchange rate SEK/USD of 8,93 Comments by CEO Torben Jörgensen Biotage follows up the strong first quarter with yet another record quarter concerning sales and earnings. The reported sales increased by no less than 19.5 percent compared with the second quarter 2018. At comparable exchange rates and adjusted for acquisitions, sales increased by 5.8 percent in the quarter isolated, while the corresponding figure for organic growth reaches 7.2 percent for the first six months. This means that Biotage is approaching its financial target; an average annual organic sales growth of 8 percent measured over a three year period. The increased sales have effect on profitability and Biotage is growing with increased profitability. The gross margin for the quarter as well as for the six months period exceeds our strategic goal of 60 percent. For the quarter the gross margin increased to 62.3 percent. The operations in Asia continue to show strong growth. Biotage’s initiative with direct sales in India is so far very successful with a sales increase of over 30 percent compared with the corresponding quarter last year. We have been successful especially in organic chemistry and we now have the three largest local Indian contract research organizations in our line of business as our customers. Also the operations in China are growing beyond expectations and here we are especially pleased that the sales of our products in analytical chemistry are gaining momentum. During the quarter we entered into an OEM collaboration with Shandong Yingsheng Biotechnology Co., Ltd. and the first deliveries of systems and consumables for analytical chemistry within the framework of this collaboration were made at the end of the quarter. The Americas is still our single biggest geographical market and after a period with lower sales than expected in the US it is satisfying to see that in the second quarter sales are back on track. Sales in the Americas region, including the US, Canada and Latin America, increased by almost 30 percent compared to the preceding quarter this year. This is partly due to the improved situation concerning recruitment of sales staff in the US, at the end of the quarter we for the first time in a long time no longer had any vacancies in this sales force. The sales in the EU and EMEA decreased by 5 percent adjusted for acquisitions compared to the corresponding quarter last year, which is not at all up to our expectations, but over the first six months of the year the EU and EMEA still grew by a little over 6 percent. The operating margin (EBIT) is rounded to 20 percent both for the quarter and for the six months period and now amounts to 18.1 percent on a rolling average for the last three years, to be compared with Biotage’s profitability target of an average of 20 percent over a three year period. During the latter part of the quarter we carried out launches of new products primarily for environmental applications, developed at our new unit in Salem, New Hampshire, where we are also working intensely with production transfers of other Biotage products, including products gained in the acquisition of PhyNexus in January. The integration of PhyNexus proceeds according to plan and currently beta testing of a new instrument generation for automated purification of plasmids is in progress, estimated to be launched later this year. During the quarter Biotage has also launched software updates for the flash purification system Biotage® Selekt that further strength the competitive advantages of this system and the associated consumables Biotage® Sfär. The sales of Biotage® Selekt are gaining momentum and we are seeing an increased use of our systems not least in the US pharma industry. The demand for our systems is increasing also in the area of industrial products, where we see a broad increase all the way from pilot to production scale. As previously announced Biotage’s Board of Directors has recruited a replacement for me and I am very pleased with the selection of Tomas Blomquist as new CEO of Biotage AB. Blomquist takes up his duties on November 6, 2019 and then takes over the responsibility for the Group. He has recently served as Vice President EMEA Cardiometabolic at Abbott. I look forward to the second half of 2019 with confidence. Coming financial reports The interim report for the third quarter 2019 will be published on Nov 5, 2019.The year-end report for 2019 will be published on February 7, 2020. All reports are available at Biotage’s website from the above dates.  This report has not been reviewed by the company’s auditor.   Uppsala July 16, 2019   Torben JörgensenPresident and CEO   For further information, please contact: Torben Jörgensen, President and CEO, phone: +46 707 49 05 84Erika Söderberg Johnson, CFO, phone: +46 707 20 48 20   This information is information that Biotage AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact persons set out above, at 08.30 CET on July 16, 2019. About BiotageBiotage offers efficient separation technologies from analysis to industrial scale and high quality solutions for analytical chemistry from research to commercial analysis laboratories. Biotage’s products are used by government authorities, academic institutions, contract research and contract manufacturing companies, pharmaceutical and food companies, among others. The company is headquartered in Uppsala and has offices in the US, UK, China, Japan, South Korea and India. Biotage has approx. 440 employees and had sales of 911 MSEK in 2018. Biotage is listed on NASDAQ Stockholm. Website: www.biotage.com

STENOCARE to establish the world’s first hybrid, in-door cultivation facility for production of premium medical cannabis at scale

Raising the bar: For more than a year, STENOCARE has been pursuing innovative ways to combine the benefits of scale from green-house cultivation of medical cannabis with the advantages of highly controlled production. In pursuit of this, STENOCARE has selected a global leader in its field, Havecon Horticultural Projects (Netherlands) to co-develop a unique technology/facility that meets extreme demands for control of light, climate and 100% pesticide free in-door cultivation, at scale. This includes 24/7 environmental control through application of “pharma-standard” technology involving air filtration, active climate control with positive pressurized rooms, water treatment and continuous monitoring of all relevant quality parameters and processes. Ready in Q1-2020: The project is now ready to commence. Therefore, STENOCARE has today entered into a turnkey construction contract with Havecon to build the first such facility in the world. The commercial terms and technical specifications remain undisclosed for competitive reasons, yet the parties announce that the construction will commence shortly, and the facility is expected to be ready for cultivation in Q1-2020. In the meantime, STENOCARE will continue its already initiated initial cultivation in order to secure the ability to produce with consistency. Cultivation is developed in close cooperation with and based upon intense tech-/knowledge transfer from our partner and shareholder, CannTrust in order to set new standards for best-of-breed cultivation. Independent Premium Brand: The decision to establish premium manufacturing at scale is a natural consequence of STENOCARE’s recent announcement that it has commenced its cultivation of medical cannabis on Danish grounds and marks the next step towards establishing STENOCARE as a frontrunner and global premium brand in medical cannabis. Funding: STENOCARE has decided to establish a 15mDKK unsecured debt facility with 1,5% in monthly interest (accrued, no compound interest) which along with cash at hand will finance the contract. The loan is provided by a consortium of not closely related private individuals and can be repaid or converted, depending upon STENOCARE’s future decisions in relation to funding of its further growth and expansion. Thomas Schnegelsberg, CEO of STENOCARE, comments: “Our Production Director, Søren Kjær, has been working intensively with the specialists at our partner, Havecon Horticultural Projects to arrive at today’s important announcement that we will establish a highly innovative and industry leading cultivation facility. This will play an important role in establishing STENOCARE as a leader in premium medical cannabis”. Henk Verbakel, CEO of Havecon, comments: “We were impressed and excited from our first contact with STENOCARE. We have established over 10 projects for medicinal/medical cannabis cultivation worldwide but have never before seen such ambition to create a hybrid that lives up to the benefits of scale from traditional greenhouses while maintaining the benefits of quality from cleanroom type manufacturing. Together with STENOCARE, we have developed just that. I am very proud”. This information is information that STENOCARE A/S is obliged to publish in accordance with the EU Market Abuse Regulation. The information was provided by the contact person above for publication on July 16, 2019.

Turkcell adopts DOCOMO Digital’s AI-driven solutions to drive further growth in its digital services business

Turkcell, Turkey’s dominant telecom carrier has partnered with DOCOMO Digital, the preeminent mobile commerce enabler to bring the power of artificial intelligence to further fuel the growth of its digital services business. Turkcell and DOCOMO Digital have been working closely for the past five years to ensure that nearly 34 million mobile subscribers, both pre and post-paid, can pay for popular apps and digital content in a secure and convenient way through their monthly phone bills or top-ups. Now with DOCOMO Digital’s AI-powered “Billing Risk Manager”, Turkcell can dynamically forecast, manage and mitigate direct carrier billing-related bad debt. The tool enables Turkcell to adjust user spending and subscriptions based on real-time monitoring of user behavior. The tool’s simulator model continually learns and adjusts bad debt thresholds based on transactions data and Turkcell policies, thereby helping Turkcell plug revenue leakage from its OTT business. "Turkcell has always been a frontrunner in the adoption of leading-edge technology, and our latest partnership with DOCOMO Digital once again demonstrates our ability to bring the best of digital services to our subscribers, underpinned by robust risk management. This will further accelerate the uptake of apps and digital content.”, said Onur Güven, Director of Customer & Product Management at Turkcell Payment Services or Paycell. “DOCOMO Digital is committed to removing friction from mobile commerce for our partners like Turkcell and we believe Billing Risk Manager will help bolster Turkcell’s digital business with more robust risk management in the direct carrier billing area.”, said Dheeraj Soni, President of DOCOMO Digital’s Payments business. About Turkcell Turkcell is a converged telecommunication and technology services provider, founded and headquartered in Turkey. It serves its customers with voice, data, TV and value-added consumer and enterprise services on mobile and fixed networks. With more than 33 million subscribers and 20,000 employs, Turkey’s dominant telecom operator has rapidly been expanding in the region with strategic partnerships. Turkcell's shares have been traded on the Borsa Istanbul (BIST) and New York Stock Exchanges (NYSE) since July 11, 2000, and it is the only Turkish company to be listed on the latter exchange. For more information, visit https://www.turkcell.com.tr/